,date,information,related
0,2022-09-23,"Headline: Got $1,000? 2 Stocks That Could Be Bargain Buys For 2022 and Beyond, source:Yahoo, summary: Let's look at two biotech stocks that look attractive at current levels: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD).  AbbVie is one of the largest pharmaceutical companies around.  Like other drugmakers, AbbVie benefits from the fact that doctors do not stop prescribing lifesaving drugs even during challenging economic times, nor do patients stop taking them., Headline: 4 Questions With Dr. Javier Cortes: The Importance of Scientific Exchange To Advance Breast Cancer, source:Yahoo, summary: NORTHAMPTON, MA / ACCESSWIRE / September 23, 2022 / Gilead Sciences For Dr. Javier Cortes, being a breast cancer researcher isn't just a profession - it's a calling. As the head of the International Breast Cancer Center (IBCC) in Madrid and Barcelona, ..., Headline: Gilead Sciences Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 1.43% to $62.86 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",GILD
1,2022-09-24,"Headline: Institutional owners may take dramatic actions as Gilead Sciences, Inc.'s (NASDAQ:GILD) recent 4.2% drop adds to one-year losses, source:Yahoo, summary: A look at the shareholders of Gilead Sciences, Inc. ( NASDAQ:GILD ) can tell us which group is most powerful. We can..., Headline: Dividend Champion, Contender, And Challenger Highlights: Week Of September 25, source:SeekingAlpha, summary: Weekly summary of dividend activity for Dividend Champions, Contenders, Challengers. Click here to see companies with upcoming ex-dividend dates and pay dates.",GILD
2,2022-09-26,"Headline: Guild Esports shares rocket on global sponsorship deal with Sky, source:Alliance News, summary: No summary, Headline: Gilead Sciences Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 0.83% to $62.34 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",GILD
3,2022-09-27,"Headline: The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market, source:InvestorPlace, summary: Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market., Headline: IN BRIEF: Guild Esports renegotiates agreement with David Beckham, source:Alliance News, summary: No summary, Headline: I-Mab: Another CD47 Inhibitor Biotech With Great Potential, source:SeekingAlpha, summary: I-Mab expects to have three BLAs file in China over the next few years. Read why IMAB is a great speculative biotech play., Headline: Gilead Sciences Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.47% higher to $62.63 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with..., Headline: Gilead Sciences (GILD) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed the most recent trading day at $62.63, moving +0.47% from the previous trading session., Headline: Gilead Sciences (GILD) Shares Cross Above 200 DMA, source:Dividend Channel, summary: dividend channel,GILD,",GILD
4,2022-09-28,"Headline: Blue Star Capital shares rise on conclusion of portfolio review, source:Alliance News, summary: No summary, Headline: Cantor Fitzgerald healthcare analysts to hold KOL luncheon panel, source:Thefly.com, summary: In conjunction with Canto... AZN, AMGN, MRTX, GILD, IMAB, NVS, SURF, PFE, ALXO, RHHBY, MRK, Headline: In the wake of Gilead Sciences, Inc.'s (NASDAQ:GILD) latest US$2.4b market cap drop, institutional owners may be forced to take severe actions, source:Yahoo, summary: To get a sense of who is truly in control of Gilead Sciences, Inc. ( NASDAQ:GILD ), it is important to understand the..., Headline: Gilead Sciences: WHO Expands Recommendation for Veklury® (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline, source:Finnhub, summary: Veklury is Now Recommended by the WHO for Use in Both Non-Severe COVID-19 Patients at the Highest Risk of Hospitalization and Patients with Severe COVID-19FOSTER CITY, Calif. - Gilead Sciences, Inc.... | September 28, 2022, Headline: Gilead Sciences Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. advanced 2.08% to $63.93 Wednesday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: Gilead Sciences: WHO Expands Recommendation for Veklury(R) (Remdesivir) to Patients With Severe Disease in Latest Update to COVID-19 Guideline, source:Yahoo, summary: Gilead Sciences, Inc. (Nasdaq:GILD) today announced updates to the World Health Organization's (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury® (remdesivir) for the treatment of patients with severe COVID-19 and continues to conditionally recommend Veklury in those with non-severe COVID-19 at the highest risk of hospitalization., Headline: Gilead widens battle against alleged counterfeit HIV drug ring, source:Reuters, summary: A federal judge in New York has frozen the assets of dozens of people and entities accused of operating a massive nationwide scheme to distribute counterfeit bottles of Gilead Sciences Inc HIV drugs, including two alleged ""kingpins."", Headline: nan, source:TipRanks, summary: nan, Headline: 3 Biotech Stocks to Sell in October, source:InvestorPlace, summary: These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market.",GILD
5,2022-09-29,"Headline: 7 Monthly Dividend Stocks to Buy for Safety, source:Yahoo, summary: The best safe monthly dividend stocks are remarkably compelling during the current market downturn. However, many top dividend stocks have also taken a sizeable hit in value over the past several months. The pull-back presents an incredible opportunity to load up on dividend stocks and generate regular income. Dividend stocks usually belong to companies with stable businesses with robust earnings that can be reinvested for the benefit of their shareholders. During the current bear run, it can he, Headline: Gilead's Investigation Reveals Two Kingpins Directly Associated With Fake HIV Medications Scheme, source:Yahoo, summary: U.S. District Judge Ann Donnelly has ordered to freeze several assets related to people and entities accused of operating a U.S. supply chain that distributes counterfeit bottles of Gilead Sciences Inc's (NASDAQ: GILD) HIV drugs. In a statement, Gilead has identified and named as defendants two individuals responsible for leading and orchestrating the counterfeit scheme. The company initiated this litigation in July 2021 to halt the distribution of counterfeits. A court filing uncovered an opera, Headline: Gilead Sciences Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 1.35% to $63.07 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",GILD
6,2022-09-30,"Headline: Unusually active option classes on open September 30th, source:Thefly.com, summary: Unusual total active opti... QUAD, WSM, INDA, AMLX, AVCT, NCLH, GILD, LULU, LI, APRN, Headline: Gilead Sciences: Mother of Three Shares Her CAR T-Cell Therapy Journey: Kelly's Story, source:Yahoo, summary: Kelly was getting ready to leave on a trip to celebrate her 25th wedding anniversary when she started experiencing pain in her abdomen and discovered a lump on her neck. When the pain progressed to the point where it got worse when she laid down, she asked her husband, an emergency room doctor, what he thought., Headline: Gilead Sciences Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 2.19% to $61.69 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",GILD
7,2022-10-02,"Headline: Gilead Sciences, Inc. (NASDAQ:GILD) is a favorite amongst institutional investors who own 81%, source:Yahoo, summary: A look at the shareholders of Gilead Sciences, Inc. ( NASDAQ:GILD ) can tell us which group is most powerful. And the..., Headline: 2 Top Biotech Stocks to Buy for the Long Haul, source:Yahoo, summary: The healthcare industry is a great place to start.  Let's examine two biotechs that seem to be able to do that: Gilead Sciences (NASDAQ: GILD) and CRISPR Therapeutics (NASDAQ: CRSP).  Gilead Sciences is a leader in the market for HIV drugs although the company has recently faced some headwinds in this space.",GILD
8,2022-10-03,"Headline: Large Cap Biopharmaceuticals: Core Holdings For Your Portfolio , source:TalkMarkets, summary: Now that some clarity is apparent for drug pricing legislation you should have a few large-cap biopharmaceutical stocks in your portfolio., Headline: Gilead Sciences: Becoming A Cure, source:SeekingAlpha, summary: Gilead Sciences remains a solid Covid-19 hedge and some bolt-on deal making adds to the potential. Click here for a full investment analysis of GILD stock., Headline: Kite announces FDA approval of RVV manufacturing facility in California, source:Thefly.com, summary: Kite, a Gilead company, a... GILD, Headline: Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product, source:Yahoo, summary: SANTA MONICA, Calif., October 03, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production. Viral vectors are key components needed to manufacture Kite’s cell therapies to treat certain blood cancers. Kite is the only cell therapy company with in-house commercial and clinical trial viral vector manufacturing capabilities, au, Headline: Gilead Sciences Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rose 1.02% to $62.32 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P..., Headline: Gilead Sciences (GILD) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed at $62.32 in the latest trading session, marking a +1.02% move from the prior day., Headline: What You Missed On Wall Street On Tuesday, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. TSLA, TWTR, POSH, MU, F, DXC, PARA, PARAA, DPZ, GILD, AMZN, UBER, COMM, SSNLF, TCEHY, BABA, BA, AAPL, INBX, RIVN, CORZ, KALV, MRVI, HAS, AXTI, AYI, REBN, AEP",GILD
9,2022-10-04,"Headline: Home - The Fly, source:Thefly.com, summary: The Fly is a leading digital publisher of real-time financial news. The Fly team scours all sources of company news and delivers short-form stories consisting of only market moving content., Headline: Gilead upgraded to Overweight from Neutral at JPMorgan, source:Thefly.com, summary: JPMorgan analyst Chris Sc... GILD, Headline: GLOBAL BROKER RATINGS: RBC raises Severn Trent; BofA likes B&M, source:Alliance News, summary: No summary, Headline: Rivian, Poshmark, Tesla Rise Premarket; Kalvista Pharmceuticals Falls, source:Yahoo, summary: By Peter Nurse, Headline: Gilead Company - Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product, source:Finnhub, summary: SANTA MONICA - Kite, a Gilead Company , today announced the U.S. Food and Drug Administration has approved the company's retroviral vector manufacturing facility in Oceanside, California, for... | October 4, 2022, Headline: Stocks making the biggest moves premarket: Rivian, Credit Suisse, Poshmark and more, source:CNBC, summary: These are the stocks posting the largest moves in premarket trading. , Headline: Gilead Has Growth Potential in HIV and Oncology Franchises, Analyst Says, source:MarketWatch, summary: A JPMorgan analyst upgraded shares of Gilead to Overweight from Neutral., Headline: Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: Domino's Pizza upgrade, Paramount downgrade and TD Synnex initiation among today's top calls on Wall Street GILD, DPZ, ILMN, COMM, BK, PARA, SRAD, MCG, MTB, WLK, AGTC, SNX, GKOS, DHX, LFG, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: Five top five lists with the news and calls moving stocks, powered by The Fly. TWTR, TSLA, POSH, MU, BA, F, PARA, DPZ, GILD, AMZN, UBER, COMM, HNHPF, AAPL, BABA, TCEHY, BBBY, INBX, RIVN, CORZ, KALV, MRVI, HAS, AXTI, AYI, REBN, AEP, Headline: Gilead stock rallies after J.P. Morgan turns bullish, citing HIV and undervalued oncology businesses, source:Yahoo, summary: Shares of Gilead Sciences Inc. rallied 3.2% in premarket trading Tuesday, after the biopharmaceutical company was upgraded at J.P. Morgan, which cited greater clarity on the human immunodeficiency virus (HIV) IV franchise and an emerging and undervalued oncology, or cancer treatment franchise. Analyst Christopher Schott raised his rating to overweight, after being at neutral for at least the past 2 1/2 years, while raising his stock price target to $80 from $72. ""At current levels, we see GILD's, Headline: Stocks making the biggest moves midday: Twitter, Poshmark, Rivian and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Gilead Sciences Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rose 4.80% to $65.31 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500..., Headline: How to Trade Gilead Sciences as Charts Get More Positive, source:Yahoo, summary: Biopharmaceutical company Gilead Sciences  was raised to an ""overweight (buy)"" rating by a sell-side firm Tuesday.  In the daily bar chart of GILD, below, we can see that the shares have been working on a bottom pattern since February.  Trading volume has been improving since June., Headline: Assembly Biosciences CEO John McHutchison to retire, Jason Okazaki to succeed, source:Thefly.com, summary: Assembly Biosciences (ASM... ASMB, GILD",GILD
10,2022-10-05,"Headline: 10 Healthcare Stocks to Watch in Light of Biden’s ‘60 Minutes’ Interview, source:Yahoo, summary: In this article, we will be taking a look at the 10 healthcare stocks to watch in light of Biden’s 60 Minutes interview. To skip our detailed analysis of these stocks and Biden’s insights, you can go directly to see the 5 Healthcare Stocks to Watch in Light of Biden’s 60 Minutes Interview. On September […], Headline: Assembly Biosciences CEO John McHutchison to Retire, Succeeded by Jason Okazaki, source:MarketWatch, summary: By Kathryn Hardison Assembly Biosciences Inc. said Chief Executive Officer John McHutchison is retiring and will be succeeded by Jason Okazaki, the company's..., Headline: Gilead Sciences Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.21% higher to $65.45 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with...",GILD
11,2022-10-06,"Headline: Gilead Sciences, Inc. (NASDAQ:GILD) Looks Just Right, source:Yahoo, summary: With a price-to-earnings (or ""P/E"") ratio of 19.8x Gilead Sciences, Inc. ( NASDAQ:GILD ) may be sending bearish signals..., Headline: Kingmakers of Oakland Aims to Improve the Lives of Young Black Men, source:Yahoo, summary: Growing up in Oakland, Alonzo Henderson didn't have a lot of teachers that looked like him. As a young Black man, he says he felt isolated and thought the educators around him didn't understand his experiences or interests., Headline: Top 20 Drug Companies in the World in 2022, source:Yahoo, summary: In this article, we will be taking a look at the top 20 drug companies in the world in 2022. To skip our detailed analysis, you can go directly to see the top 5 drug companies in the world in 2022. While major pharmaceutical companies have always been derided for considering profits over the well-being […], Headline: Gilead Sciences Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 0.76% to $64.95 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...",GILD
12,2022-10-07,"Headline: Gilead Sciences Inc. stock falls Friday, still outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 1.02% to $64.29 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500..., Headline: Chipotle Stock Could Heat Up. Here Comes a Speedy Robo Burrito Maker., source:Yahoo, summary: Analysts also report on Gilead Sciences, Airbnb, CME Group, L3Harris Technologies, and Petco Health.",GILD
13,2022-10-10,"Headline: Great week for Gilead Sciences, Inc. (NASDAQ:GILD) institutional investors after losing 1.0% over the previous year, source:Yahoo, summary: To get a sense of who is truly in control of Gilead Sciences, Inc. ( NASDAQ:GILD ), it is important to understand the..., Headline: How to Find Stocks That Rise 10x, source:InvestorPlace, summary: Investors looking for 10X stocks should prioritize companies in high-growth areas that demonstrate high earnings quality., Headline: Gilead (GILD) Up 2.6% in 3 Months: Will the Momentum Continue?, source:Yahoo, summary: Gilead (GILD) is having a good run despite the volatility on a string of positive updates., Headline: Gilead Sciences (GILD) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed at $64.46 in the latest trading session, marking a +0.26% move from the prior day.",GILD
14,2022-10-11,"Headline: Arcus Biosciences initiated with an Overweight at Morgan Stanley, source:Thefly.com, summary: Morgan Stanley analyst Te... RCUS, GILD, RHHBY, Headline: FDA gives Gilead priority review for Trodelvy sBLA  for breast cancer treatment, source:Thefly.com, summary: Gilead Sciences, announce... GILD, Headline: Gilead's Trodelvy granted priority review by FDA, says Piper Sandler, source:Thefly.com, summary: Piper Sandler analyst Do ... GILD, Headline: Gilead Gets FDA Priority Review for Trodelvy in HR+/HER2- Metastatic Breast Cancer, source:MarketWatch, summary: By Colin Kellaher Gilead Sciences Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review to its application for expanded use of..., Headline: U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Gilead’s Trodelvy® for Pre-Treated HR+/HER2- Metastatic Breast Cancer, source:Yahoo, summary: FOSTER CITY, Calif., October 11, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have receiv, Headline: 12 Best Ethical Stocks To Buy Now, source:Yahoo, summary: In this article, we will take a look at 12 best ethical stocks to buy now. If you want to see some more of the best ethical stocks to buy, go directly to 5 Best Ethical Stocks To Buy Now. Sometimes investing is more than about just making money. Investing can also be used to […], Headline: Gilead's Trodelvy Under FDA Review For Pre-Treated HR+/HER2- Metastatic Breast Cancer, source:Yahoo, summary: The FDA has accepted for review Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan-hziy) for unresectable locally advanced or metastatic hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer. The supplemental application covers patients who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. The target action date of the Prescription Drug User Fee Act (PDUFA) is February",GILD
15,2022-10-12,"Headline: Gilead price target raised to $60 from $56 at Barclays, source:Thefly.com, summary: Barclays analyst Carter G... GILD, Headline: 4 Biotech Stocks With Huge Incoming Catalysts, source:Yahoo, summary: All four of these drugmakers are expecting important FDA approval decisions over the next few months., Headline: Want to Collect 4% in Dividends Every Month? Buy These 3 Stocks, source:Yahoo, summary: These stocks pay at different intervals and collectively can ensure you're collecting a dividend payment each month., Headline: Gilead Sciences: Gilead's Rashad Burgess Is Advancing Health and Equity in LGBTQ Communities of Color (The Reckoning), source:Yahoo, summary: Before Rashad Burgess held the professional title of Vice President of Advancing Health and Equity at Gilead Sciences or the personal identification of husband and father, he witnessed the devastating effects of HIV in the early nineties as a gay teenager growing up on the south side of Chicago., Headline: Gilead (GILD) Trodelvy Label Expansion sBLA Gets Priority Review, source:Yahoo, summary: Gilead's (GILD) efforts to expand Trodelvy's label progress, as the FDA accepts sBLA for the same and grants Priority Review., Headline: These 2 Growth Stocks Have Potential Catalysts on the Way, source:Yahoo, summary: Both drugmakers have been outperforming the market -- which may continue if they earn important regulatory approvals soon., Headline: Gilead Sciences Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slipped 0.43% to $65.39 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P..., Headline: Gilead Stock Delivers Stable Dividend In Hot Biotech Sector, source:Yahoo, summary: The established nature of Gilead's business allows the company to pay out a strong dividend, currently yielding 4.2%.",GILD
16,2022-10-13,"Headline: Dividend Income Update September 2022, source:TalkMarkets, summary: With the start of the final quarter of 2022, it’s time to take a look back at my previous month of dividend income., Headline: Cornell Pochily Investment Adv - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know, source:Yahoo, summary: No summary, Headline: Gilead Sciences Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rallied 1.64% to $66.46 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: Gilead Sciences to Release Third Quarter 2022 Financial Results on Thursday, October 27, 2022, source:Yahoo, summary: FOSTER CITY, Calif., October 13, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2022 financial results will be released on Thursday, October 27 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2022 financial results and will provide a business update., Headline: Gilead looks to shift 250,000 square feet in Peninsula campus master plan from office to lab, source:Yahoo, summary: The change represents Gilead's focus on research, now concentrated on the south section of its 72-acre Foster City campus., Headline: Gilead Sciences (GILD) Gains But Lags Market: What You Should Know, source:Yahoo, summary: In the latest trading session, Gilead Sciences (GILD) closed at $66.46, marking a +1.64% move from the previous day.",GILD
17,2022-10-14,"Headline: Top 5 3rd Quarter Trades of GR - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Gilead's Quality And Growth Potential Are Underappreciated, source:SeekingAlpha, summary: Gilead Sciences is a high-quality pharma company with a protected market position. Read why we think that GILD is an attractive investment., Headline: My Dividend Stock Portfolio: New September Record, source:SeekingAlpha, summary: September has been one of the worst months for stocks with all 3 major indices dropping at least 5%. Check out how my dividend stock portfolio performed in Sept., Headline: Why Cash-Rich Companies And #ETFs Are Beating The Market?, source:TalkMarkets, summary: Investors believe that “cash is king” in the current environment of surging inflation, rising rates, and a potential economic downturn. ETFs that hold cash-rich companies have seen a lot of interest from investors lately., Headline: Gilead Sciences Inc. stock falls Friday, still outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slipped 0.44% to $66.17 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",GILD
18,2022-10-15,"Headline: Why We're Not Concerned About Gilead Sciences, Inc.'s (NASDAQ:GILD) Share Price, source:Yahoo, summary: Gilead Sciences, Inc.'s ( NASDAQ:GILD ) price-to-earnings (or ""P/E"") ratio of 20x might make it look like a sell right...",GILD
19,2022-10-16,"Headline: 3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off, source:Yahoo, summary: Medical stocks don't generally have high dividends, but Abbvie (NYSE: ABBV), Pfizer (NYSE: PFE), and Gilead Sciences (NASDAQ: GILD) all have dividends with yields of 3.5% or more, and these pharmaceuticals stocks serve as a great hedge against inflation because their business models are largely resistant to recessions.  A high-yielding dividend without sound fundamentals can easily become a dividend trap, but all three of these companies have pipelines with great potential and a strong history of increasing revenue -- and none appear to be overpriced yet.  AbbVie is a new Dividend King., Headline: Kite says EC granted approval for use of Yescarta, source:Thefly.com, summary: Kite, a Gilead Company, a... GILD",GILD
20,2022-10-17,"Headline: Gilead, MacroGenics announce MGD024 option and collaboration agreement, source:Thefly.com, summary: Gilead (GILD) and MacroGe... GILD, MGNX, Headline: MacroGenics in Collaboration Agreement With Gilead Sciences for MGD024, source:MarketWatch, summary: By Chris Wack Gilead Sciences Inc. and MacroGenics Inc. have entered into an exclusive option and collaboration agreement to develop MGD024, a potential..., Headline: MacroGenics Teams up with Gilead, source:TipRanks, summary: Biopharmaceutical company MacroGenics’ (NASDAQ:MGNX) stock is soaring today after it announced a collaboration with Gilead Sciences (NASDAQ:GILD) for the developmen..., Headline: Gilead and MacroGenics Announce Oncology Collaboration to Develop Bispecific Antibodies, source:Yahoo, summary: FOSTER CITY, Calif. & ROCKVILLE, Md., October 17, 2022--Gilead Sciences, Inc. (NASDAQ: GILD) and MacroGenics (NASDAQ: MGNX) today announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART® platform, and two additional bispecific research programs. The collaboration agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid, Headline: MacroGenics Shares Jump On Gilead Licensing Pact For Blood Cancer Candidates, source:Yahoo, summary: Gilead Sciences Inc (NASDAQ: GILD) and MacroGenics Inc (NASDAQ: MGNX) announced an exclusive option and collaboration agreement to develop MGD024 and two additional bispecific research programs. MGD024 is an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics' DART platform. The collaboration agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid leukemia and myelodysplastic syndromes. Also Read:, Headline: Gilead Sciences Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.32% higher to $66.38 Monday, on what proved to be an all-around great trading session for the stock market, with the..., Headline: MacroGenics strikes deal with Gilead potentially worth more than $1.7B, source:Yahoo, summary: Rockville’s MacroGenics Inc. just struck a deal with a major U.S. pharmaceutical company that could mean more than $1.7 billion for the local biotech.  MacroGenics (NASDAQ: MGNX) said Monday it has formed a collaboration agreement with Foster City, California-based Gilead Sciences Inc. (NASDAQ: GILD) — giving Gilead the green light to develop and exclusively license MacroGenics’ blood cancer treatment candidate, called MGD024., Headline: IN BRIEF: Gilead Sciences gets EU marketing authorisation for Yescarta, source:Alliance News, summary: No summary, Headline: Kite’s Yescarta First CAR T-cell Therapy to Receive European Marketing Authorization for Use in Second-Line Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma, source:Yahoo, summary: SANTA MONICA, Calif., October 17, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Commission (EC) has granted approval for the use of Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. The approval is based on results from the pivotal Phase 3 ZUMA-7 study, the larg",GILD
21,2022-10-18,"Headline: Gilead gives new data from HIV R&D programs at at HIV Glasgow 2022, source:Thefly.com, summary: Gilead Sciences announced... GILD, Headline: RNC CAPITAL MANAGEMENT LLC Buy - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Gilead Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022, source:Yahoo, summary: FOSTER CITY, Calif., October 18, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company’s upcoming new data from its HIV research and development programs to be presented at the 30th International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2022) in Glasgow, Scotland and virtually from October 23-26, 2022. Gilead will present data supporting its current and pipeline innovations in HIV treatment and the latest research from its ongoing cure development program, reflecti, Headline: Europe Approves First CAR T-Cell Therapy For B-Cell Lymphoma In 30 Years to Improve Upon Standard of Care, source:Yahoo, summary: The European Commission approved Kite Pharma's, a Gilead Sciences Inc (NASDAQ: GILD) Yescarta (axicabtagene ciloleucel) for diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL). The approval covers patients who relapse within 12 months of completion or are refractory to first-line chemoimmunotherapy. The approval is based on results from the pivotal Phase 3 ZUMA-7 study, the largest and longest trial of a CAR T-cell therapy versus SOC in this patient population. Also Read:, Headline: Gilead's (GILD) Yescarta Gets EC Nod for New Cancer Indication, source:Yahoo, summary: The European Commission approves Gilead's (GILD) CAR T-cell therapy, Yescarta, for treating adult patients with second-line diffuse large b-cell lymphoma and high-grade b-cell lymphoma., Headline: Gilead Sciences Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.74% higher to $66.87 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with...",GILD
22,2022-10-19,"Headline: Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), UnitedHealth (UNH) and MacroGenics (MGNX), source:TipRanks, summary: Companies in the  Healthcare sector have received a lot of coverage today as analysts  weigh in on Gilead Sciences (<span class='tr-stock-ticker' style='color:blue;..., Headline: A Note On Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE and Debt To Equity, source:Yahoo, summary: While some investors are already well versed in financial metrics (hat tip), this article is for those who would like..., Headline: 15 Best Drug Stocks to Buy Now, source:Yahoo, summary: In this article, we discuss the 15 best drug stocks to buy now. If you want to read about some more stocks, go to 5 Best Drug Stocks to Buy Now. According to the International Federation of Pharmaceuticals Manufacturers & Associations, the global pharmaceutical sector or the drug industry is expected to post annual revenues […], Headline: Gilead Foundation Awards $20 Million to Organizations Working to Advance Health Through Education Equity, source:Yahoo, summary: Gilead Sciences, Inc. (Nasdaq:GILD) recently announced that the Gilead Foundation's Creating Possible Fund™ will provide a total of $20 million to 13 inaugural grantees. The Creating Possible Fund was launched to support creative and high-impact strategies that advance health through education equity, with a main focus on building a pipeline of Black health leaders., Headline: Gilead Sciences Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slipped 1.02% to $66.19 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P..., Headline: Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed the most recent trading day at $66.19, moving -1.02% from the previous trading session., Headline: Boston Common Asset Management - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: ",GILD
23,2022-10-20,"Headline: HQH: A Dividend Paymaster That Fails To Register Price Growth, source:SeekingAlpha, summary: Tekla Healthcare Investors is able to generate steady yield and currently trades at a good discount to its NAV. Read more to see why HQH is a Buy., Headline: Kite, Refuge announce exclusive cancer immunotherapy license agreement, source:Thefly.com, summary: Kite, a Gilead (GILD) com... GILD, Headline: Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers, source:Yahoo, summary: SANTA MONICA, Calif. & MENLO PARK, Calif., October 20, 2022--Kite, a Gilead Company (Nasdaq: GILD) and Refuge Biotechnologies, Inc. (""Refuge""), today announced that Kite has entered into an exclusive, worldwide license agreement with Refuge, a synthetic biology company for cancer immunotherapy, for exclusive rights to utilize Refuge’s proprietary gene expression platform to develop potential treatments for blood cancers., Headline: Analysts Estimate Gilead Sciences (GILD) to Report a Decline in Earnings: What to Look Out for, source:Yahoo, summary: Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Gilead Sciences Inc. stock falls Thursday, still outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slipped 0.05% to $66.16 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P...",GILD
24,2022-10-21,"Headline: Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers, source:Yahoo, summary: Gilead (GILD) signs a license agreement with Refuge Biotechnologies to use the latter's gene expression platform to develop treatments for blood cancers.",GILD
25,2022-10-23,"Headline: Tekla Life Sciences Investors: 10% Yield And Trading 10.5% Below NAV, source:SeekingAlpha, summary: Tekla Life Sciences currently has a high 10% yield. The CEF is currently trading 10.5% below NAV. Read why investors are getting HQL at an attractive valuation., Headline: Investors Interested In Gilead Sciences, Inc.'s (NASDAQ:GILD) Earnings, source:Yahoo, summary: When close to half the companies in the United States have price-to-earnings ratios (or ""P/E's"") below 14x, you may...",GILD
26,2022-10-24,"Headline: MATRIX ASSET ADVISORS INC/NY B - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities, source:Yahoo, summary: FOSTER CITY, Calif., October 24, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of real-world results from the BICSTaR study, highlighting Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a generally well tolerated and efficacious regimen regardless of prior treatment and comorbidity status in people with HIV. The latest five-year data from two Phase 3 studies (Study 1489 and Study 1490) provide evidence of the long-t, Headline: Top 5 3rd Quarter Trades of Tw - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: ",GILD
27,2022-10-25,"Headline: Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release, source:Yahoo, summary: Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Gilead Sciences Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.87% higher to $69.60 Tuesday, on what proved to be an all-around great trading session for the stock market, with the...",GILD
28,2022-10-26,"Headline: Bristol Myers Squibb: Looking Down A Patent Cliff, source:SeekingAlpha, summary: Bristol Myers Squibb stock looks cheap and the dividends will likely be increased when the company reduces its debt leverage. Click here to see why BMY is a Hold., Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rallied 1.75% to $70.82 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow..., Headline: Gilead raises FY22 adjusted EPS view to $6.95-$7.15 from $6.35-$6.75, source:Thefly.com, summary: Consensus $6.54. Sees Tot... GILD",GILD
29,2022-10-27,"Headline: Gilead Sciences (GILD) Receives a Buy from Mizuho Securities, source:TipRanks, summary: Mizuho Securities analyst Salim Syed maintained a Buy rating on Gilead Sciences (GILD &#8211; Research Report) today and set a price target of $75.00. The company&#..., Headline: Notable companies reporting after market close, source:Thefly.com, summary: Notable companies reporti... AAPL, AMZN, TMUS, INTC, GILD, VRTX, EW, DXCM, COF, PINS, ZEN, FSLR, TXRH, Headline: Gilead Sciences Announces Third Quarter 2022 Financial Results, source:Business Wire, summary: No summary, Headline: Gilead Sciences 3Q Profit Fell as Sales of Covid-19 Drug Declined, source:MarketWatch, summary: By Jeffrey T. Lewis Gilead Sciences Inc.'s profit fell in the third quarter after sales of antiviral medicine Veklury declined. The Foster City, Calif.-based..., Headline: Gilead stock rises on more upbeat forecasts, while COVID drug sales slide, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rose after the drugmaker reported third-quarter results that topped expectations and boosted its full-year profit and sales..., Headline: Gilead Sciences Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 0.88% to $70.20 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow..., Headline: Gilead Science sees revenue and profit drop on lower Veklury sales, source:Alliance News, summary: No summary, Headline: Gilead Sciences, Inc. (GILD) Q3 2022 Earnings Call Transcript, source:SeekingAlpha, summary: Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Q3 2022 Results Conference Call October 27, 2022 04:30 PM ET Company Participants Jacquie Ross - VP, IR Daniel OâDay - Chairman and CEO Johanna..., Headline: American Association for Cancer Research to hold a symposium, source:Thefly.com, summary: EORTC-NCI-AACR Molecular ... CYCC, OLMA, MRUS, VERU, GILD, NVCT, CYT, KRON, CLLS, MAIA, AADI, TYRA",GILD
30,2022-10-28,"Headline: Gilead upgraded to Buy from Hold at Truist, source:Thefly.com, summary: Truist analyst Robyn Karn... GILD, Headline: Needham Reaffirms Their Hold Rating on Gilead Sciences (GILD), source:TipRanks, summary: In a report released today, Joseph Stringer from Needham maintained a Hold rating on Gilead Sciences (GILD &#8211; Research Report). The company&#8217;s shares clos..., Headline: Gilead upgraded to Buy at Truist on oncology assets and COVID drugs, source:Thefly.com, summary: Truist analyst Robyn Karn... GILD, Headline: Gilead price target raised to $80 from $75 at Cowen, source:Thefly.com, summary: Cowen analyst Tyler Van B... GILD, Headline: Wells Fargo Keeps Their Hold Rating on Gilead Sciences (GILD), source:TipRanks, summary: In a report released today, Mohit Bansal from Wells Fargo maintained a Hold rating on Gilead Sciences (GILD &#8211; Research Report), with a price target of $75.00...., Headline: Gilead price target raised to $72 from $63 at BMO Capital, source:Thefly.com, summary: BMO Capital analyst Evan ... GILD, Headline: Bristol-Myers Squibb And Gilead - Still A Buy After Strong Q3?, source:SeekingAlpha, summary: Both Bristol-Myers Squibb (BMY) and Gilead (GILD) reported solid Q3 results. Check out whether I am still a buyer despite the outperformance of both stocks., Headline: Early notable gainers among liquid option names on October 28th, source:Thefly.com, summary: Notable gainers among liq... DXCM, INTC, VRSN, GILD, TMUS, Headline: WHO panel says no evidence yet that new omicron subvariants are more dangerous than others that are circulating, source:MarketWatch, summary: The omicron sublineages named BQ.1 and XBB do not appear to have immune escape mutations that warrant their being designated as variants of concern, Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Dexcom (DXCM), Gilead Sciences (GILD) and Laboratory (LH), source:TipRanks, summary: Companies in the  Healthcare sector have received a lot of coverage today as analysts  weigh in on Dexcom (<span class='tr-stock-ticker' style='color:blue; font-wei..., Headline: Gilead Stock Jumps as 2 Analysts Turn Upbeat, source:MarketWatch, summary: Truist's Robyn Karnauskas and Piper Sandler's Do Kim lifted their ratings to Buy and Overweight, respectively, from the equivalent of Hold., Headline: Notable Friday Option Activity: GILD, DVA, ALGN, source:Stock Options Channel, summary: Staff article entitled Notable Friday Option Activity: GILD, DVA, ALGN, about stock options, from Stock Options Channel., Headline: Stocks making the biggest moves midday: Apple, Amazon, Intel and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Intel, Gilead Sciences rise; Amazon, DaVita fall, source:Associated Press, The, summary: No summary, Headline: How major US stock indexes fared Friday 10/28/2022, source:Associated Press, The, summary: No summary, Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. jumped 12.92% to $79.27 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P..., Headline: Gilead (GILD) Q3 Earnings & Sales Top, Guidance Raised, source:Yahoo, summary: Gilead (GILD) Q3 earnings and sales beat on strong HIV and oncology business. The company also raises its annual guidance., Headline: Top 10 Gainers on Friday, source:Yahoo, summary: In this article, we will take a look at the top 10 gainers on Friday. If you want to see some more stocks rallying today, go directly to Top 5 Gainers on Friday. All three key U.S. indices jumped this morning, thanks to better-than-expected earnings of giants like Apple Inc. (NASDAQ:AAPL), Intel Corporation (NASDAQ:INTC) and […], Headline: Gilead Sciences stock surges amid earnings beat and analyst upgrades, source:Yahoo, summary: Shares of Gilead Sciences are getting a boost thanks to strong earnings for its third quarter., Headline: Gilead Breaks Out In Bullish Volume As Its Cancer Drug Sales Nearly Double, source:Yahoo, summary: Gilead Sciences reported 79% growth for its cancer drugs, helping beat expectations. On Friday, GILD stock broke out., Headline: FDA rejects Gilead hepatitis delta virus drug already greenlighted in Europe, source:Yahoo, summary: The company said it will resubmit the drug to the FDA for approval. There are no FDA-approved therapies for hepatitis D, or HDV., Headline: These 2 Stock Winners Topped Apple's Big Gains Friday, source:Yahoo, summary: The stock market soared on Friday, ignoring one high-profile earnings miss among the largest companies in the market and instead focusing on the relatively solid performance from Apple (NASDAQ: AAPL).",GILD
31,2022-10-29,"Headline: $10K to $100K in 10 Years? Build Your Own ETF with Undervalued Dividend Stocks, source:TipRanks, summary: Exchange-traded funds, or ETFs, are a fast and convenient way to own a group of stocks with something in common. There&#8217;s nothing inherently wrong with taking ...",GILD
32,2022-10-30,"Headline: Under-the-radar trend shows tech investors remain loyal despite major losses this year, source:CNBC, summary: The widely held ARK Innovation ETF and the Technology Select Sector SPDR Fund aren't showing meaningful outflows so far this year., Headline: Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), Gilead Sciences (GILD) and InMode (INMD), source:TipRanks, summary: Companies in the  Healthcare sector have received a lot of coverage today as analysts  weigh in on Argenx Se (<span class='tr-stock-ticker' style='color:blue; font-..., Headline: SVB Securities Reaffirms Their Hold Rating on Gilead Sciences (GILD), source:TipRanks, summary: SVB Securities analyst David Risinger maintained a Hold rating on Gilead Sciences (GILD &#8211; Research Report) on October 27 and set a price target of $112.00. Th..., Headline: Stocks slip, but still end up with big gains for October, source:Associated Press, The, summary: No summary",GILD
33,2022-10-31,"Headline: Gilead Sciences Reaches Analyst Target Price, source:ETF Channel, summary: Staff article entitled Gilead Sciences Reaches Analyst Target Price, about ETFs, from ETF Channel., Headline: Gilead price target raised to $92 from $84 at Maxim, source:Thefly.com, summary: Maxim analyst Jason McCar... GILD, Headline: Peak Gilead, source:SeekingAlpha, summary: Gilead's future will be sprinkled with important new revenue drivers. Click here to see why GILD stock can well afford to pay a nice dividend and keep its debt in check., Headline: GLOBAL BROKER RATINGS: Jefferies raises Reckitt; DB likes BASF, source:Alliance News, summary: No summary, Headline: Can Biotech Stocks Continue Rallying In This Bear Market? , source:TalkMarkets, summary: Despite a vicious bear market in 2022 biotech stocks have come back in October recovering with the XBI up 3.72% to $83.76 on Friday., Headline: Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It, source:Yahoo, summary: No summary, Headline: Institutional investors are Gilead Sciences, Inc.'s (NASDAQ:GILD) biggest bettors and were rewarded after last week's US$14b market cap gain, source:Yahoo, summary: To get a sense of who is truly in control of Gilead Sciences, Inc. ( NASDAQ:GILD ), it is important to understand the..., Headline: Biogen: Super-Strong Momentum In A Defensive Sector, source:SeekingAlpha, summary: Biogen remains a financially cheap, unloved Big Pharma name with a number of promising drugs under development. See why I would reenter a position in BIIB stock., Headline: Gilead Sciences Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 1.02% to $78.46 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",GILD
34,2022-11-01,"Headline: AnaptysBio upgraded to Buy at Guggenheim on checkpoint agonist opportunity, source:Thefly.com, summary: Guggenheim analyst Yatin ... ANAB, GILD, Headline: SVB Securities Keeps Their Hold Rating on Gilead Sciences (GILD), source:TipRanks, summary: SVB Securities analyst David Risinger maintained a Hold rating on Gilead Sciences (GILD &#8211; Research Report) today and set a price target of $81.00. The company..., Headline: Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease, source:Yahoo, summary: FOSTER CITY, Calif., November 01, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that clinical and real-world data from more than 70 abstracts will be presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place from Nov. 4-8, 2022. Key presentations include Week 48 integrated efficacy and safety analyses from Phase 2 and Phase 3 studies of Hepcludex® (bulevirtide), Gilead’s first-in-class investigational treatment for chronic hepatit, Headline: 15 Best NASDAQ Dividend Stocks To Buy, source:Yahoo, summary: In this article we present the list of 15 Best NASDAQ Dividend Stocks To Buy. Click to skip ahead and see the 5 Best NASDAQ Dividend Stocks To Buy. Starbucks Corporation (NASDAQ:SBUX), Gilead Sciences, Inc. (NASDAQ:GILD), and Intel Corporation (NASDAQ:INTC) are just a handful of the best NASDAQ dividend stocks to buy, which we’ll examine in […], Headline: Lilly (LLY) Beats on Q3 Earnings & Sales, Lowers '22 View, source:Yahoo, summary: Eli Lilly's (LLY) earnings and sales surpass third-quarter estimates. The company lowers 2022 financial view for the third time this year. The stock falls in pre-market trading., Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rose 1.12% to $79.34 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500..., Headline: 6 Stocks With Healthy Dividends and Solid Returns, source:MarketWatch, summary: AbbVie, Gilead Sciences, Cardinal Health, Merck, Bristol Myers, and Amgen are large-cap healthcare companies that have the capacity to grow their dividends.",GILD
35,2022-11-02,"Headline: FDA approves Gilead sNDA  for Vemlidy to treat pediatric hepatitis B virus, source:Thefly.com, summary: Gilead Sciences, announce... GILD, Headline: Jounce earns clinical milestone payment under agreement with Gilead, source:Thefly.com, summary: Jounce Therapeutics (JNCE... JNCE, GILD, Headline: Unusually active option classes on open November 2nd, source:Thefly.com, summary: Unusual total active opti... THO, GOOS, BEKE, GSK, CVS, UNG, UAL, GILD, HYG, FUBO, Headline: Top 5 3rd Quarter Trades of HO - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients, source:Yahoo, summary: FOSTER CITY, Calif., November 02, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B virus (HBV) infection in pediatric patients 12 years of age and older with compensated liver disease., Headline: Jounce Therapeutics earns clinical milestone payment under the CCR8 exclusive license agreement with Gilead Sciences, Inc., source:Yahoo, summary: CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today earning a $15.0 million clinical milestone payment from Gilead Sciences, Inc. (NASDAQ: GILD) under the exclusive license agreement for GS-1811, an anti-CCR8 antibody for which Gilead has exclusive rights to develop and commercialize. GS-1811 (formerly JTX-1811) is, Headline: Gilead's Path to Equitable Global COVID-19 Treatment Access, source:Yahoo, summary: NORTHAMPTON, MA / ACCESSWIRE / November 2, 2022 / Gilead Sciences Since the beginning of the COVID-19 pandemic, Gilead's first-in-class antiviral was made available to more than 11 million patients globally- over 65% of whom live in low-and lower-middle-income ..., Headline: G1 Therapeutics Says Its Lead Candidate May Cut Adverse Events Of Gilead's Breast Cancer Drug, source:Yahoo, summary: G1 Therapeutics Inc (NASDAQ: GTHX) described safety data from the first 18 patients enrolled in its ongoing Phase 2 study of trilaciclib administered before sacituzumab govitecan-hziy in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC). Sacituzumab govitecan is marketed as trodelvy by Gilead Sciences Inc (NASDAQ: GILD). ""We believe we are seeing on-target effects of trilaciclib in the expected reduction in the rate of myelosuppression and the rates o, Headline: Gilead Sciences Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 1.84% to $77.88 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P..., Headline: Esperion (ESPR) Q3 Earnings Beat Estimates, Revenues Miss, source:Yahoo, summary: Esperion Therapeutics (ESPR) reports mixed third-quarter results, beating earnings estimates but missing out on sales.",GILD
36,2022-11-03,"Headline: Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022, source:Yahoo, summary: FOSTER CITY, Calif. & SANTA MONICA, Calif., November 03, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will support 30 data presentations, including seven oral presentations in large B-cell lymphoma (LBCL), and two oral presentations on investigator-sponsored studies in acute myeloid leukemia (AML) during the 64th Annual American Society of Hematology (ASH) Annual Meeting (December 10-13)., Headline: Gilead Sciences Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rose 2.03% to $79.46 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500..., Headline: Allogene (ALLO) Reports Narrower-Than-Expected Loss in Q3, source:Yahoo, summary: Allogene's (ALLO) third-quarter earnings beat estimates, but sales miss the mark. ALLO will host an R&D showcase later this month and discuss updated clinical data on its pipeline candidates., Headline: Sarepta (SRPT) Q3 Loss Wider-Than-Expected, Sales Lag Estimates, source:Yahoo, summary: Sarepta's (SRPT) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales. Shares decline in after-market trading post the announcement., Headline: Moderna's (MRNA) Lags on Q3 Earnings, Lowers '22 Sales Outlook, source:Yahoo, summary: Moderna's (MRNA) third-quarter earnings miss expectations, while sales narrowly beat the mark. Shares declined in pre-market trading after management announced a guidance cut in COVID vaccine sales.",GILD
37,2022-11-04,"Headline: Is There An Opportunity With Gilead Sciences, Inc.'s (NASDAQ:GILD) 46% Undervaluation?, source:Yahoo, summary: Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Gilead Sciences, Inc..., Headline: TEVA Misses on Q3 Earnings, Cuts 2022 Sales View, Stock Down, source:Yahoo, summary: TEVA reports dismal Q3 results, missing estimates for both earnings and sales. It slightly lowers its sales expectations for 2022 while keeping the adjusted earnings per share guidance intact., Headline: Puma Biotech (PBYI) Q3 Earnings Top, Nerlynx Sales View Up, source:Yahoo, summary: Puma Biotech (PBYI) beats earnings and revenue estimates for third-quarter 2022. It increases product revenue guidance for full-year 2022 to reflect improving demand trends for Nerlynx in the United States., Headline: Karuna Therapeutics (KRTX) Posts Wider-Than-Expected Q3 Loss, source:Yahoo, summary: Karuna Therapeutics (KRTX) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales., Headline: Nektar's (NKTR) Q3 Earnings and Revenues Beat Estimates, source:Yahoo, summary: Nektar (NKTR) reports encouraging third-quarter 2022 results. The narrower-than-expected loss is on account of lower operating expenses incurred during the quarter., Headline: Gilead Sciences Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. advanced 1.11% to $80.34 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...",GILD
38,2022-11-05,"Headline: 3 No-Brainer Dividend Stocks to Buy in November, source:Yahoo, summary: Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ).  This FUD relates to concerns about how the impending loss of exclusivity (LOE) in the U.S. for Humira will impact AbbVie.  The blockbuster drug generated more than 37% of the company's total sales in the third quarter.",GILD
39,2022-11-07,"Headline: U.S. Supreme Court rejects Bristol Myers cancer-drug patent fight with Gilead, source:Reuters, summary: The U.S. Supreme Court on Monday rebuffed a bid by Bristol Myers Squibb Co's Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with Gilead Sciences Inc subsidiary Kite Pharma Inc over a lymphoma drug., Headline: Gilead Sciences Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rose 1.39% to $81.46 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P..., Headline: Gilead, Kite in process of pausing Twitter advertising, source:Reuters, summary: Gilead Sciences Inc said on Monday the company and its unit Kite were in the ""process of pausing advertising"" on Twitter, after Elon Musk completed his takeover of the social media company., Headline: UPDATE 1-Gilead, Kite in process of pausing Twitter advertising, source:Yahoo, summary: Gilead Sciences Inc said on Monday the company and its unit Kite were in the ""process of pausing advertising"" on Twitter, after Elon Musk completed his takeover of the social media company.  In a statement to Reuters, Gilead said it was monitoring its advertising spend and waiting to better understand how community standards and content moderation will be handled on Twitter now.  Gilead joins a growing list of U.S. companies, including General Motors and General Mills, who have either paused or are in the process of re-evaluating advertising on the social media platform., Headline: US Supreme Court Throws Out Bristol Myers Appeal On Cancer-Drug Related Patent With Gilead, source:Yahoo, summary: The U.S. Supreme Court turned away an appeal made by rebuffed efforts made by Bristol Myers Squibb Co's (NYSE: BMY) Juno Therapeutics Inc to reinstate a $1.2 billion award it won in its patent fight with Gilead Sciences Inc's (NASDAQ: GILD) Kite Pharma Inc over Yescarts, a lymphoma drug. Juno and Sloan Kettering Institute for Cancer Research sued Kite in 2017 in a federal court in Los Angeles, accusing it of copying technology the institute licenses to Juno. A jury awarded the plaintiffs $778 mi, Headline: American Association for Study of Liver Diseases to hold a meeting, source:Thefly.com, summary: AASLD 2022: The Liver Mee... WXXWY, VIR, SRZN, LGND, LLY, EXEL, EXAS, BAYRY, BD, BMRN, BMY, CALT, ALBO, ALGS, ALIM, ALNY, ALT, ALXN, ASMB, AXLA, JNJ, KMDA, IPSEY, IVA, SLP, SMMNY, SIEGY, RARE, PKI, NVO, GSK, GLTO, GILD",GILD
40,2022-11-08,"Headline: Gilead price target raised to $88 from $75 at Mizuho, source:Thefly.com, summary: Mizuho analyst Salim Syed... GILD, Headline: Gilead Sciences Third Quarter 2022 Earnings: Beats Expectations, source:Yahoo, summary: Gilead Sciences ( NASDAQ:GILD ) Third Quarter 2022 Results Key Financial Results Revenue: US$7.04b (down 5.1% from 3Q..., Headline: Why Shares of Gilead Sciences Rose 27.20% in October, source:Yahoo, summary: Gilead Sciences (NASDAQ: GILD) saw its shares rise 27.20% in October, according to data from S&P Global Intelligence.  The biotech stock ended September at $61.69.  Gilead, a biopharmaceutical company that focuses on oncology and HIV therapies, showed it has a strong future even as sales of its COVID-19 therapy, Veklury (remdesivir), have begun to ebb., Headline: Perrigo (PRGO) Lags on Q3 Earnings & Sales, Lowers '22 EPS View, source:Yahoo, summary: Perrigo (PRGO) reports dismal third-quarter 2022 results. Unfavorable currency movements force management to lower earnings outlook for 2022. Shares down., Headline: Gilead Sciences Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.95% higher to $82.23 Tuesday, on what proved to be an all-around great trading session for the stock market, with the..., Headline: Goldman Sachs’ Cheap Dividend Stocks, source:Yahoo, summary: In this article, we will discuss Goldman Sachs’ cheap dividend stocks. You can skip our detailed analysis of dividend investing and the firm’s outlook on dividend stocks, and go directly to read Goldman Sachs’ 5 Cheap Dividend Stocks. Growth tech stocks have dominated the market for years due to their innovative products and services. However, […], Headline: Here's My Formula for Investing in Gilead Sciences, source:Yahoo, summary: We reviewed the charts of Gilead Sciences on Oct. 4 and wrote that we ""like the current look of the charts and indicators. Traders could go long GILD on strength above $68 and above $72. Our price target is $81 for now.",GILD
41,2022-11-09,"Headline: See Which Of The Latest 13F Filers Holds Gilead Sciences, source:Preferred Stock Channel, summary: Staff article entitled See Which Of The Latest 13F Filers Holds Gilead Sciences, about stock options, from Holdings Channel., Headline: My Dividend Stock Portfolio: New October Record - 103 Holdings With 27 Buys, source:SeekingAlpha, summary: My dividend income amounted to a new October record of $566, which is up 63% Y/Y. Read more to know the details of my dividend stock portfolio for October., Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.11% higher to $82.32 Wednesday, on what proved to be an all-around grim trading session for the stock market, with...",GILD
42,2022-11-10,"Headline: AlloVir: Solid Data, But Market Isn't Paying Attention, source:SeekingAlpha, summary: AlloVir has some solid data in an area of unmet need. The company is well-capitalized. Read why this could be a buying opportunity for ALVR stock., Headline: Has This Hot Stock Run Out of Steam?, source:Yahoo, summary: One of the hottest healthcare stocks on the markets of late has been HIV-focused drugmaker Gilead Sciences (NASDAQ: GILD).  Shares of Gilead are up a whopping 33% over just the past three months, dwarfing the S&P 500 and its 8% losses during that stretch.  Here's a closer look at what's been behind Gilead's recent rally and whether or not its shares could still go higher., Headline: Gilead Sciences: A Career Rooted in Championing Diversity and Inclusion: Jesse's Story, source:Yahoo, summary: NORHAMPTON, MA / ACCESSWIRE / November 10, 2022 / Gilead Sciences While Jesse Garcia was growing up in Chicago's inner city, his parents didn't immediately turn to a doctor when someone in the family got sick. ""We relied on traditional Latino ..., Headline: Jazz's (JAZZ) Q3 Earnings Beat Estimates, New Drugs Drive Sales, source:Yahoo, summary: Jazz's Q3 earnings and sales beat expectations on strong demand for new drugs and drugs added with the GW Pharmaceuticals acquisition. The company raises the mid-point of its 2022 sales guidance., Headline: Big Pharma Stocks Are Breaking Out. Here Are Some Winners., source:MarketWatch, summary: Drug stocks have been outperforming the market all year since their sales are unaffected by changes in economic demand.",GILD
43,2022-11-11,"Headline: Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know, source:Yahoo, summary: No summary",GILD
44,2022-11-12,"Headline: 2 Top Biotech Stocks to Buy in November, source:Yahoo, summary: Biotech giants Regeneron Pharmaceuticals (NASDAQ: REGN) and Gilead Sciences (NASDAQ: GILD) are among them.  Eylea could lose patent protection as early as next year.  Why is Regeneron beating the market this year despite these issues?",GILD
45,2022-11-13,"Headline: Those who invested in Gilead Sciences (NASDAQ:GILD) three years ago are up 43%, source:Yahoo, summary: You can receive the average market return by buying a low-cost index fund. But you can make superior returns by picking..., Headline: Vertex: High Growth For Years Ahead, source:SeekingAlpha, summary: Vertex is the market leader company for Cystic Fibrosis disease. The company reports unexpected sales and earnings growth in recent quarters Q3.",GILD
46,2022-11-14,"Headline: Tango Therapeutics: Behind The Recent Momentum, source:SeekingAlpha, summary: Shares of early clinical-stage biotech Tango Therapeutics, Inc. (TNGX) are down ~50% since going public in August 2021 â primarily victimized by a lack of catalysts and a tough market., Headline: Gilead Sciences: A Range Trader's Dream Stock (Technical Analysis), source:SeekingAlpha, summary: Gilead has been range bound for several years and is now testing the upper range that has been established. A sell or short at the current price around $80 could net positive returns., Headline: Gilead Sciences Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rallied 1.26% to $82.85 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P..., Headline: SHELTON CAPITAL MANAGEMENT Buy - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: GLOBEFLEX CAPITAL L P Buys 4,  - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: ",GILD
47,2022-11-15,"Headline: Weaver C. Barksdale & Associat - GuruFocus.com, source:GuruFocus, summary: GuruFocus Article or News written by insider and the topic is about: , Headline: Gilead Sciences Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.18% higher to $83.00 Tuesday, on what proved to be an all-around positive trading session for the stock market, with..., Headline: Gilead Sciences to Present at Upcoming Investor Conferences, source:Yahoo, summary: FOSTER CITY, Calif., November 15, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:",GILD
48,2022-11-16,"Headline: IDNA: Healthcare Dashboard For November, source:SeekingAlpha, summary: The pharmaceutical and biotechnology subsector is undervalued by about 17% relative to 11-year averages. Read how this ties into the IDNA healthcare ETF., Headline: Gilead Sciences Inc. stock falls Wednesday, still outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 0.14% to $82.88 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",GILD
49,2022-11-17,"Headline: Gilead Sciences: Dr. Amelie Ramirez Seeks To End Disparities in Latino Cancer Care, source:Yahoo, summary: For nearly 30 years, Dr. Amelie Ramirez has sought to move the needle on health disparities in the Latino community through a mix of education, research and community-based care., Headline: Is There An Opportunity With Gilead Sciences, Inc.'s (NASDAQ:GILD) 44% Undervaluation?, source:Yahoo, summary: Does the November share price for Gilead Sciences, Inc. ( NASDAQ:GILD ) reflect what it's really worth? Today, we will..., Headline: Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?, source:Yahoo, summary: Here is how Gilead Sciences (GILD) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year., Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.89% higher to $83.62 Thursday, on what proved to be an all-around dismal trading session for the stock market, with...",GILD
50,2022-11-18,"Headline: Gilead Sciences Inc. stock remains steady Friday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. were unchanged Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500..., Headline: Gilead (GILD) Outperforms YTD: Will It Retain the Momentum?, source:Yahoo, summary: Biotech giant Gilead (GILD) outperforms the industry and the S&P 500 Index as its core business maintains momentum despite volatility., Headline: Top Analyst Reports for Lowe's, Gilead Sciences & Intuitive Surgical, source:Yahoo, summary: Today's Research Daily features new research reports on 16 major stocks, including Lowe's Companies, Inc. (LOW), Gilead Sciences, Inc. (GILD) and Intuitive Surgical, Inc. (ISRG)., Headline: Billionaire Cliff Asness’ Top 10 Dividend Stocks, source:Yahoo, summary: In this article, we will take a look at billionaire Cliff Asness’ top 10 dividend stocks. If you want to see more of billionaire Cliff Asness’ dividend stocks, go directly to Billionaire Cliff Asness’ Top 5 Dividend Stocks. Billionaire Cliff Asness is the founder of AQR Capital Management, one of the largest hedge funds in […], Headline: Rockville’s MacroGenics scores $60M from Provention Bio’s FDA approval, source:Yahoo, summary: Rockville’s MacroGenics Inc. (NASDAQ: MGNX) just had its second big win within a month, after inking a major deal with a U.S. pharmaceutical company in October.  MacroGenics said late Thursday the Food and Drug Administration has approved teplizumab, a Type 1 diabetes treatment candidate that Provention Bio Inc. bought from MacroGenics in 2018.  As part of that deal, Red Bank, New Jersey's Provention agreed to pay $60 million to Macrogenics upon receiving the agency’s green light to take the drug to market.",GILD
51,2022-11-21,"Headline: Is There An Opportunity With Gilead Sciences, Inc.'s (NASDAQ:GILD) 44% Undervaluation?, source:Yahoo, summary: Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Gilead Sciences, Inc..., Headline: The Zacks Analyst Blog Highlights Lowe's, Gilead Sciences, Intuitive Surgical, Valero Energy and MercadoLibre, source:Yahoo, summary: Lowe's, Gilead Sciences, Intuitive Surgical, Valero Energy and MercadoLibre are part of the Zacks top Analyst Blog., Headline: SDOG: Dividend ETF Not To Be Confused With 'Dogs Of The Dow', source:SeekingAlpha, summary: SDOG ETF applies the Dogs of the Dow theory on a sector-by-sector basis using the S&P 500 as the starting point. Read if it is a good dividend income opportunity., Headline: Investing In Minimum Volatility Stocks Can Backfire, source:SeekingAlpha, summary: The minimum volatility factor outperformed last week and is also outperforming for the year. See why low-volatility trade often turns into a higher-risk trade.",GILD
52,2022-11-22,"Headline: Puma Biotechnology, Inc. (PBYI) Hits Fresh High: Is There Still Room to Run?, source:Yahoo, summary: Puma Biotech (PBYI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues., Headline: We still think there's more room for biotech to go higher, says Jefferies' Yee, source:CNBC, summary: Michael Yee, Jefferies managing director, joins 'Power Lunch' to discuss what's behind the general move higher in biotech stocks, why biotech stocks were under-owned not long ago and if it's too late to 'nibble' on stocks in the sector., Headline: GILD vs. HALO: Which Stock Is the Better Value Option?, source:Yahoo, summary: GILD vs. HALO: Which Stock Is the Better Value Option?, Headline: Buy this Medical Sector Pioneer Stock, source:Yahoo, summary: Gilead Sciences (GILD) is up roughly 20% since its Q3 release in October, let's take a look at what could continue propelling GILD stock., Headline: Gilead Sciences: Best Near-Term Biopharma Cap Gain Bet Say Market-Makers, source:SeekingAlpha, summary: This articleâs focus is on earning capital gain from stock investment in Gilead Sciences, Inc. Read more to see what makes GILD stock a buy at this time.",GILD
53,2022-11-23,"Headline: See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch, source:Yahoo, summary: Gilead Sciences' first-in-class cancer drug and GILD stock are finally hitting their stride. The oncology business is growing bullishly., Headline: Gilead Sciences: Staying Positive While Facing Metastatic Triple-Negative Breast Cancer: Jacquie's Story, source:Yahoo, summary: Jacquie's journey with cancer began with non-Hodgkin lymphoma when she was just 15 years old., Headline: Is Most-Watched Stock Gilead Sciences, Inc. (GILD) Worth Betting on Now?, source:Yahoo, summary: No summary, Headline: Gilead Sciences Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.22% higher to $85.42 Wednesday, on what proved to be an all-around favorable trading session for the stock market,...",GILD
54,2022-11-25,"Headline: Investing in Gilead Sciences (NASDAQ:GILD) three years ago would have delivered you a 45% gain, source:Yahoo, summary: Thanks in no small measure to Vanguard founder Jack Bogle, it's easy buy a low cost index fund, which should provide...",GILD
55,2022-11-28,"Headline: Retirement Stock Portfolio: 11 Safe Dividend Stocks to Consider, source:Yahoo, summary: In this article, we discuss the 11 safe dividend stocks for a retirement stock portfolio. If you want to read about some more dividend stocks, go directly to Retirement Stock Portfolio: 5 Safe Dividend Stocks to Consider. Across the world, investors have been scrambling to find ways to strengthen their portfolios and reduce risk as […], Headline: Retirement Stock Portfolio: 11 Safe Tech Stocks to Consider, source:Yahoo, summary: In this article, we discuss the 11 safe tech stocks for a retirement stock portfolio. If you want to read about some more tech stocks, go directly to Retirement Stock Portfolio: 5 Safe Tech Stocks to Consider. There is broad-based consensus among finance professionals that the traditional definitions of growth and value stocks do hold-up […], Headline: Gilead and Arcus Biosciences Announce Positive Update on Joint TIGIT Program From Interim Analysis of ARC-7 Study in Non-Small Cell Lung Cancer, source:Yahoo, summary: FOSTER CITY, Calif. & HAYWARD, Calif., November 28, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences (NYSE: RCUS) today announced a positive update from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations. ARC-7 is evaluating the combinations of a, Headline: Gilead-Arcus Biosciences Partnered Lung Cancer Therapy Shows Continuous Positive Efficacy Measures, source:Yahoo, summary: Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences (NASDAQ: RCUS) announced an update from the fourth interim analysis of Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations. ARC-7 is evaluating the combinations of anti-TIGIT antibody domvanalimab plus zimberelimab (doublet) and domvanalimab plus zimberelimab and, Headline: Gilead Sciences Inc. stock falls Monday, still outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 1.22% to $85.21 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500..., Headline: Gilead's Cancer Program Notches Another Win, But It's Arcus Stock That Surges, source:Yahoo, summary: Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher.",GILD
56,2022-11-29,"Headline: Overdone Selloff? Fed Talking Heads, Trading Gilead, Iger's Magic Disney Words, source:Yahoo, summary: What happened on Monday, was largely profit-taking, pin action related to a couple of large names, and defensive selling., Headline: European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations, source:Yahoo, summary: FOSTER CITY, Calif., November 29, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has authorized a new low-dose tablet dosage form of Biktarvy® (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) and an extension of the indication for Biktarvy to treat HIV infection in virologically suppressed children who are at least two years of age and weigh at least 14 kg. The European Marketing Authorization is the first pediatric approv, Headline: Investors in Gilead Sciences (NASDAQ:GILD) have made a notable return of 46% over the past three years, source:Yahoo, summary: Thanks in no small measure to Vanguard founder Jack Bogle, it's easy buy a low cost index fund, which should provide..., Headline: Gilead (GILD), RCUS Announce Positive Data From NSCLC Study, source:Yahoo, summary: Gilead (GILD) and RCUS release encouraging data from the fourth interim analysis of the phase II ARC-2 study in patients with first-line metastatic non-small cell lung cancer (NSCLC)., Headline: Gilead Sciences Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.65% higher to $85.76 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the..., Headline: Gilead Sciences, Inc. (GILD) 2022 5th Annual Evercore ISI HealthCONx Conference(Transcript), source:SeekingAlpha, summary: Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) 2022 5th Annual Evercore ISI HealthCONx Conference Call November 29, 2022 13:00 ET Company Participants Andrew Dickinson - Executive Vice...",GILD
57,2022-11-30,"Headline: These 3 Stocks Are Rallying While the Rest of the Market Plunges, source:Yahoo, summary: Sometimes an organization's growth -- and growth story -- is strong enough to overcome marketwide headwinds., Headline: Gilead (GILD) Gets EC Approval for Biktarvy Label Expansion, source:Yahoo, summary: Gilead (GILD) gets EC authorization for Biktarvy for the treatment of HIV in pediatric populations., Headline: 2 Reasons This Stock Could Outperform in 2023, source:Yahoo, summary: Biotech giant Gilead Sciences (NASDAQ: GILD) is a member of this elite club, having seen its shares rise by 15% year to date.  Let's consider two reasons why Gilead Sciences is worth serious consideration heading into the new year.  Gilead Sciences' most important unit by some margin remains its HIV business., Headline: Gilead Sciences, Inc. (GILD) Management presents at Piper Sandler Healthcare Conference (Transcript), source:SeekingAlpha, summary: Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Piper Sandler Healthcare Conference November 30, 2022 11:30 AM Company Participants Merdad Parsey - Chief Medical Officer Conference Call...",GILD
58,2022-12-01,"Headline: The Top Healthcare Stocks to Buy With $100, source:Yahoo, summary: Although hard, it's not impossible, there are healthcare companies with solid earnings and dividend growth that can be had for less than a bill with Ben Franklin's picture on it.  Gilead Sciences (NASDAQ: GILD) and Bristol Myers Squibb (NYSE: BMY) have posted triple-digit percentage gains over the past 10 years in revenue, earnings per share (EPS), and total return price.  On top of that, shares of Gilead and Bristol can both be bought for less than $90 a share, at least for the time being., Headline: Gilead Sciences: All Stars Project Empowers Youth Through Performance, source:Yahoo, summary: Dancing has always been a part of Shadae McDaniel's life., Headline: Why Is Exelixis (EXEL) Up 0.4% Since Last Earnings Report?, source:Yahoo, summary: Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",GILD
59,2022-12-02,"Headline: Here's how one hedge fund is going aginst the grain and beating the markets, source:MarketWatch, summary: This fund is crushing it. Here are its top 5 stock picks, Headline: BBH: Portfolio Of Large-Cap Biotechnology Stocks Has Delivered Strong Returns, source:SeekingAlpha, summary: BBH has an asset base of $520 million, posted strong growth over the past 6 months, and is trading much higher than its pre-pandemic price range. Click here to learn more., Headline: Allogene Therapeutics (ALLO) Down 1.6% Since Last Earnings Report: Can It Rebound?, source:Yahoo, summary: Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",GILD
60,2022-12-03,"Headline: Finally, We're Less Fed Up With The Fed, source:SeekingAlpha, summary: It feels like markets are moving in the investorsâ favor. Check out what's working and what's not this week., Headline: Gilead Sciences, Inc. (NASDAQ:GILD) Delivered A Weaker ROE Than Its Industry, source:Yahoo, summary: While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...",GILD
61,2022-12-05,"Headline: Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?, source:Yahoo, summary: Here is how Gilead Sciences (GILD) and HealthEquity (HQY) have performed compared to their sector so far this year., Headline: Adaptive Biotechnologies Isn't Quite Your Portfolio's Immune Booster, source:SeekingAlpha, summary: Adaptive is, in my opinion, still too early in its development cycle to warrant a buy recommendation. Click here to read my analysis of ADPT stock.",GILD
62,2022-12-06,"Headline: Should You Consider Adding Gilead Sciences (GILD) to Your Portfolio?, source:Yahoo, summary: Ariel Investments, an investment management company, released its “Ariel Global Fund” third-quarter investor letter. A copy of the same can be downloaded here. In the third quarter, the fund declined -10.05%, underperforming the MSCI ACWI Index and the MSCI ACWI Value Index, which returned -6.82% and -7.66%, respectively. Multiple headwinds from all over the world affected […], Headline: 5 Dividend Stocks to Allay Fears of a More-Aggressive Fed, source:Yahoo, summary: As U.S. stocks stumble on concerns of further rate hikes, investing in dividend players like Exxon Mobil (XOM), Gilead Sciences (GILD) and Conagra Brands (CAG) for a steady stream of income seems prudent., Headline: New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer, source:Yahoo, summary: FOSTER CITY, Calif., December 06, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from a post-hoc analysis from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy; SG) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- metastatic breast cancer who progressed on endocrine-based therapies and at least two chemotherapies. In the analysis, Trodelvy improved progression-free survival (PFS), overall surviva",GILD
63,2022-12-07,"Headline: The Zacks Analyst Blog Highlights Exxon Mobil, WesBanco, S&T Bancorp, Gilead Sciences and Conagra Brands, source:Yahoo, summary: Exxon Mobil, WesBanco, S&T Bancorp, Gilead Sciences and Conagra Brands are included in this Analyst Blog., Headline: Should Gilead Sciences, Inc. (NASDAQ:GILD) Focus On Improving This Fundamental Metric?, source:Yahoo, summary: Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is..., Headline: Gilead Sciences, Inc. (GILD) Presents at NASDAQ 47th Investor Conference (Transcript), source:SeekingAlpha, summary: Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) NASDAQ 47th Investor Conference December 07, 2022, 08:00 AM ET Company Participants Dan O'Day - Chairman and CEO Conference Call Participants..., Headline: Wall Street Bulls Look Optimistic About Gilead (GILD): Should You Buy?, source:Yahoo, summary: The average brokerage recommendation (ABR) for Gilead (GILD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?, Headline: Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan, source:Yahoo, summary: SANTA MONICA, Calif. & TOKYO, December 08, 2022--Kite Pharma, Inc., a Gilead Company, (hereafter Kite) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) today jointly announced the revision of their 2017 partnership agreement, which gave Daiichi Sankyo exclusive rights to develop, manufacture and commercialize Yescarta (axicabtagene ciloleucel) in Japan. Kite was acquired by Gilead Sciences, Inc. later in 2017 after the Daiichi Sankyo partnership agreement. Daiichi Sankyo and Kite have no",GILD
64,2022-12-08,"Headline: Will Big Pharma Stocks Stronghold Endure In 2023, Or Is It Time To Sell?, source:SeekingAlpha, summary: Most Big Pharma stocks have performed very well in 2022, which is hardly surprising given the late stage of the cycle we are in. See is it time to sell them., Headline: Is Gilead Sciences Stock Still a Buy After Soaring in 2022?, source:Yahoo, summary: Gilead faces some challenges. But there are several reasons to think the stock could keep the momentum going., Headline: Gilead Sciences: U.S. Military Veteran Battles Lymphoma With Car T-Cell Therapy: Marcus' Story, source:Yahoo, summary: Marcus arrived home to Mississippi from his military assignment overseas, excited to see his 20-month-old son, when he realized something was wrong., Headline: Is Gilead Sciences a Buy?, source:Yahoo, summary: Gilead Sciences (NASDAQ: GILD) is a top healthcare company that generates the bulk of its revenue from medicine that treats HIV.  Lenacapavir is an HIV treatment that would require patients to receive an injection just twice a year.  It's a significant change from the daily pills many HIV patients are accustomed to taking today.",GILD
65,2022-12-09,"Headline: Arcellx, Gilead Ink Multiple Myeloma Collaboration >ACLX GILD, source:MarketWatch, summary: By Colin Kellaher Arcellx Inc. and Gilead Sciences Inc. on Friday said they agreed to co-develop and co-commercialize Arcellx's lead late-stage product..., Headline: Arcellx Stock Surges on Multiple Myeloma Treatment Collaboration With Gilead, source:MarketWatch, summary: The deal involves an upfront cash payment of $225 million to Arcellx and a $100 million equity investment from Gilead's Kite Pharma., Headline: Arcellx Shares Reach New Heights on Gilead Collaboration >ACLX, source:MarketWatch, summary: By Colin Kellaher Shares of Arcellx Inc. hit an all-time high on Friday after the clinical-stage biotechnology inked a lucrative agreement with Gilead..., Headline: Don't Race Out To Buy Gilead Sciences, Inc. (NASDAQ:GILD) Just Because It's Going Ex-Dividend, source:Yahoo, summary: It looks like Gilead Sciences, Inc. ( NASDAQ:GILD ) is about to go ex-dividend in the next four days. The ex-dividend..., Headline: Arcellx and Kite Announce Strategic Collaboration to Co-Develop and Co-Commercialize Late-Stage Clinical CART-ddBCMA in Multiple Myeloma, source:Yahoo, summary: Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx's lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe, and broadly accessible therapies., Headline: Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma, source:Yahoo, summary: SANTA MONICA, Calif. & REDWOOD CITY, Calif., December 09, 2022--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, safe, and broadly accessible therapies., Headline: Gilead to co-develop Arcellx's multiple myeloma drug, source:Yahoo, summary: Gilead Sciences Inc. said Friday that it will co-develop and co-commercialize Arcellx Inc.'s multiple myeloma treatment candidate, which is currently in Phase 2 clinical trials. Gilead will pay Arcellx $225 million upfront, plus make a $100 million equity investment in the company. The deal, which will reduce Gilead's GAAP and non-GAAP earnings per share next year by 16 cents, is expected to close in the first quarter. Gilead's stock is up 37.0% over the past three months, while Arcellx shares h, Headline: Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences, source:Yahoo, summary: Recent initial public offering Arcellx forged a $325 million cancer deal with Gilead Sciences on Friday, and the IPO stock broke out., Headline: Kodiak Sciences Inc. (KOD) Up 1% Since Last Earnings Report: Can It Continue?, source:Yahoo, summary: Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",GILD
66,2022-12-10,"Headline: Dividend Champion, Contender, And Challenger Highlights: Week Of December 11, source:SeekingAlpha, summary: Weekly summary of dividend activity for Dividend Champions, Contenders, Challengers. Read more to see companies with upcoming ex-dividend dates and pay dates.",GILD
67,2022-12-11,"Headline: Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis, source:Yahoo, summary: SANTA MONICA, Calif., December 11, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announced results from one of the largest real-world analyses of patients who received CAR T-cell therapy assessing the impact of time from leukapheresis to infusion (""vein-to-vein"" time) for Yescarta® (axicabtagene ciloleucel) in adult patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). The analysis reported shorter vein-to-vein times associated with improved outcomes in patients treated w, Headline: Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite’s Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma, source:Yahoo, summary: SANTA MONICA, Calif., December 11, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announced findings from two new analyses of the landmark ZUMA-7 trial of Yescarta® (axicabtagene ciloleucel), the largest and longest follow-up of a CAR T-cell therapy versus standard of care (SOC) in patients with relapsed or refractory large B-cell lymphoma (r/r LBCL). These results include an analysis of outcomes for patients who received subsequent treatment for their lymphoma following second-line Yescarta",GILD
68,2022-12-12,"Headline: Pfizer: The Best Long-Term Investment Setup Since 2009, source:SeekingAlpha, summary: Pfizer has a history of performing well during recessions and bear markets on Wall Street. COVID-19 sales may remain high. Read more on PFE stock here., Headline: SPYD, SPHD: Dividend Gives S&P 500 Wings, source:SeekingAlpha, summary: The S&P 500 nearly moved from bear-market to bull-market in a matter of weeks. However, read why we aren't backing off from our defensive approach., Headline: 4 Stocks With Impressive Interest Coverage Ratio to Snap Up, source:Yahoo, summary: A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Sprouts Farmers (SFM), Fortinet (FTNT), O'Reilly Automotive (ORLY) and Gilead Sciences (GILD) are strong enough to meet financial obligations., Headline: New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response, source:Yahoo, summary: SANTA MONICA, Calif., December 12, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announced findings from follow-up analyses of two pivotal studies (ZUMA-2 and ZUMA-3) of the CAR T-cell therapy Tecartus® (brexucabtagene autoleucel). A comparison of two-year follow-up from ZUMA-3 and SCHOLAR-3, a retrospective historical control study, evaluating Tecartus versus standard of care (SOC) in adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), was presented i, Headline: Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months, source:Yahoo, summary: SANTA MONICA, Calif., December 12, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announced three-year follow-up data from the pivotal ZUMA-5 study for Yescarta® (axicabtagene ciloleucel) in relapsed or refractory (r/r) indolent non-Hodgkin lymphoma (iNHL), showing continued response in 52% of all enrolled patients, and prolonged duration of progression-free survival (PFS) in the Phase 2 study, presented at the 2022 American Society of Hematology (ASH) Annual Meeting & Exposition (Abstract #, Headline: Beat the Dow Jones With This Unstoppable Dividend Stock, source:Yahoo, summary: The Dow Jones Industrial Average is an index of 30 of the largest companies in the U.S. and it serves as a popular (if somewhat flawed) indicator of how the broader stock market is doing, and it has averaged an annual return of 8% since the 1980s.  Pharmaceutical company Gilead Sciences (NASDAQ: GILD) is one possible answer.  The company pays a solid dividend and could have the growth prospects to deliver market-beating returns over the next several years., Headline: Gilead Sciences Again Named to Dow Jones Sustainability World Index, source:Yahoo, summary: FOSTER CITY, Calif., December 12, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World). This ranking is based on an in-depth analysis of Gilead’s sustainability performance and highlights the company’s longstanding sustainable business practices and transparency on environmental, social and governance (ESG) issues., Headline: Gilead Sciences Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.65% higher to $88.54 Monday, on what proved to be an all-around great trading session for the stock market, with the...",GILD
69,2022-12-13,"Headline: With 83% ownership, Gilead Sciences, Inc. (NASDAQ:GILD) boasts of strong institutional backing, source:Yahoo, summary: A look at the shareholders of Gilead Sciences, Inc. ( NASDAQ:GILD ) can tell us which group is most powerful. With 83..., Headline: My Dividend Stock Portfolio: New November Record - 100 Holdings With 24 Buys, 1 Sale, source:SeekingAlpha, summary: Inflation and (expected) actions by the Federal Reserve continue to dominate market movements. Check out my dividend income for November., Headline: 22 Most Charitable Companies in 2022, source:Yahoo, summary: In this article, we discuss the 22 most charitable companies in 2022. If you want to skip the details about corporate and individual charitable practices and global charity statistics, go directly to the 5 Most Charitable Companies in 2022. According to the Charities Aid Foundation World Giving Index 2022, 40% of the global population took […], Headline: Gilead Sciences Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.24% higher to $88.75 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with...",GILD
70,2022-12-14,"Headline: Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More, source:Yahoo, summary: Acquisitions news from HZNP and AMGN form the key highlights from the biotech sector during the past week., Headline: Gilead Sciences Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.43% higher to $88.40 Wednesday, on what proved to be an all-around grim trading session for the stock market, with..., Headline: Gilead Sciences (GILD) Stock Moves -0.39%: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed at $88.40 in the latest trading session, marking a -0.39% move from the prior day.",GILD
71,2022-12-15,"Headline: Gilead Sciences: Latinas Contra Cancer Empowers Patients To Advocate for Change, source:Yahoo, summary: When Darcie Green's dad got sick, she thought she was prepared to help him navigate the healthcare system. She'd spent her entire career in healthcare policy., Headline: Gilead Sciences Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 2.06% to $86.58 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500..., Headline: Shionogi's Xocova Potentially Better Than Pfizer And Merck's Antivirals, source:SeekingAlpha, summary: Shionogi's Xocava is set to outcompete far less effective COVID antivirals by Pfizer and Merck. Read why I think an investment in Shionogi is worth consideration., Headline: Gilead: Downgrade To Hold, source:SeekingAlpha, summary: Gilead's return profile has weakened substantially given the valuation risks and fundamental uncertainties. Read why GILD is a Hold.",GILD
72,2022-12-16,"Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.21% higher to $86.76 Friday, on what proved to be an all-around rough trading session for the stock market, with the...",GILD
73,2022-12-17,"Headline: With 82% ownership, Gilead Sciences, Inc. (NASDAQ:GILD) boasts of strong institutional backing, source:Yahoo, summary: Every investor in Gilead Sciences, Inc. ( NASDAQ:GILD ) should be aware of the most powerful shareholder groups. The...",GILD
74,2022-12-18,"Headline: IBBQ: Healthcare Dashboard For December, source:SeekingAlpha, summary: The pharmaceuticals/biotechnology subsector has good value and quality scores. Click here to read more about IBBQ ETF.",GILD
75,2022-12-19,"Headline: Schrodinger: Upgrading My Rating Post The Recent Nimbus Deal, source:SeekingAlpha, summary: Schrodinger shares have rallied ~25% since the Nimbus Takeda deal announcement. See why I believe SDGR stock is a good buy for long-term investors., Headline: Gilead Sciences Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 0.39% to $86.42 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500..., Headline: Anti-TIGIT Domvanalimab-Containing Study Arms Improve Progression-Free Survival Compared to Anti-PD1 Alone in Phase 2 Non-Small Cell Lung Cancer Study, source:Yahoo, summary: FOSTER CITY, Calif. & HAYWARD, Calif., December 19, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced positive results from the fourth interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase (EGFR/ALK) mutations. ARC-7 is a Phase 2, multicenter, three-arm, randomized, open-label, Headline: Unusual Options Activity in Apple, Home Depot and 8 Other Stocks, source:Fintel, summary: nan, Headline: Tuesday Talk: Where is Santa?, source:TalkMarkets, summary: No summary, Headline: Gilead: A Phoenix Has Risen From Its Ashes, source:SeekingAlpha, summary: Gilead Sciences is committed to growing its dividend and repurchasing its own shares, to at least make sure the stock is not diluted. Read why I am not selling GILD stock.",GILD
76,2022-12-20,"Headline: Kite to acquire Tmunity, terms undisclosed, source:Thefly.com, summary: No summary, Headline: Gilead expects Tmunity acquisition to reduce FY23 EPS by 18c-22c, source:Thefly.com, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Staar Surgical (STAA) and Cocrystal Pharma (COCP), source:TipRanks, summary: No summary, Headline: Gilead`s Kite unit to acquire CAR T therapy developer Tmunity Therapeutics, source:Seeking Alpha, summary: No summary, Headline: Gilead's Kite Unit to Buy Tmunity Therapeutics, source:MarketWatch, summary: By Dean Seal The Gilead Sciences Inc. subsidiary Kite has signed a deal to acquire the biotech company Tmunity Therapeutics. Kite said Tuesday that Tmunity,..., Headline: Video: S&P 500 Movers: GILD, NEM, source:Market News Video, summary: No summary, Headline: Video: Nasdaq 100 Movers: GILD, LCID, source:Market News Video, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Amicus (FOLD), Gilead Sciences (GILD) and Staar Surgical (STAA), source:TipRanks, summary: No summary, Headline: Stocks making the biggest moves midday: Gilead Sciences, Moderna, Tesla and more, source:CNBC, summary: These are the stocks posting the largest moves midday., Headline: Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer, source:Yahoo, summary: SANTA MONICA, Calif. & PHILADELPHIA, December 20, 2022--Kite, a Gilead Company (Nasdaq: GILD), and Tmunity Therapeutics (Tmunity), today announced that the companies have signed an agreement in which Kite will acquire Tmunity, a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies. The acquisition of Tmunity complements Kite’s existing in-house cell therapy research capabilities by adding additional pipeline assets, platform capabilities, and a stra, Headline: Gilead Data Raise New Questions About Cancer Therapy, source:MarketWatch, summary: New data on a cancer drug trial from Gilead Sciences and Arcus Biosciences are resurfacing debate around the class of cancer drugs known as anti-TIGITs., Headline: Arcus Biosciences, Gilead shares are down after sharing data about new lung cancer drug, source:Yahoo, summary: Shares of Arcus Biosciences Inc. were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatment for metastatic non-small cell lung cancer that it's developing with Gilead Sciences Inc. improved progression-free survival and overall response rate [ORR] in a Phase 2 clinical study. ""The data clearly show that the program is viable, keeping hope alive for active building blocks within the large lung cancer space, but numerical ORR may be disappointing to, Headline: bluebird's (BLUE) SCD Studies Clinical Hold Lifted by the FDA, source:Yahoo, summary: bluebird (BLUE) announces that the partial clinical hold on studies evaluating lovo-cel for sickle cell disease (SCD) for patients under the age of 18 has now been lifted., Headline: Gilead-Arcus Partnered Domvanalimab Combo Study Show Improved Progression-Free Survival In Lung Cancer Patients, source:Yahoo, summary: Gilead Sciences Inc (NASDAQ: GILD) and Arcus Biosciences Inc (NASDAQ: RCUS) announced results from the fourth interim analysis of the ARC-7 Phase 2 study for metastatic non-small cell lung cancer with PD-L1 tumor proportion score ≥50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations. The study evaluates the combinations of domvanalimab + zimberelimab (doublet) and domvanalimab + zimberelimab + etrumadenant (triplet) versus zimberelimab monotherapy. Related: Gilead, Headline: Arcus, Gilead Disappoint As Lung-Cancer Regimen Lags Rival Roche, source:Yahoo, summary: Gilead and Arcus toppled Tuesday after their lung-cancer regimen trailed a rival concoction from Roche. RCUS stock skidded more than 20%., Headline: Gilead unit to buy Carl June-founded Penn cell therapy spinout, source:Yahoo, summary: The Philadelphia cell therapy developer suffered a major setback last year when two patients died in a clinical trial testing the company's prostate cancer cell therapy., Headline: FuelCell, Wells Fargo fall; Steelcase, Blucora rise, source:Associated Press, The, summary: No summary, Headline: Gilead Sciences Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 1.91% to $84.77 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P..., Headline: Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed at $84.77 in the latest trading session, marking a -1.91% move from the prior day.",GILD
77,2022-12-21,"Headline: Madrigal: Next Steps After `Wow` Data In NASH, source:Seeking Alpha, summary: No summary, Headline: Madrigal: Next Steps After 'Wow' Data In NASH, source:SeekingAlpha, summary: On Monday, Madrigal Pharmaceuticals announced a best-case dataset from its phase 3 trial in NASH. Click here to read why I think his opens up a Huge market for MDGL., Headline: XBI: Attractive Value In Diversified Biotech Growth, source:SeekingAlpha, summary: Valuations on biotechnology stocks have moderated substantially since the pandemic peak in 2021. Click to read my analysis of the SPDR S&P Biotech ETF (XBI)., Headline: Is Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE Of 16% Concerning?, source:Yahoo, summary: One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will..., Headline: Gilead Sciences: Tatiana Williams Leads the Way With the Transinclusive Group, source:Yahoo, summary: When Tatiana Williams was growing up as a young Trans woman in Florida, she faced many challenges and hardships - but she didn't find many resources available to her., Headline: Are Medical Stocks Lagging  Gilead Sciences (GILD) This Year?, source:Yahoo, summary: Here is how Gilead Sciences (GILD) and HealthEquity (HQY) have performed compared to their sector so far this year., Headline: Gilead Sciences Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.59% higher to $85.27 Wednesday, on what proved to be an all-around great trading session for the stock market, with..., Headline: Kite says Yescarta now approved in Japan for initial treatment, source:Thefly.com, summary: No summary, Headline: Gilead`s Yescarta approved in Japan for initial treatment of B-cell lymphomas, source:Seeking Alpha, summary: No summary",GILD
78,2022-12-22,"Headline: Gilead announces Sunlenca granted FDA approval in multidrug resistant HIV, source:Thefly.com, summary: No summary, Headline: Gilead wins U.S. approval for twice yearly HIV med, source:Seeking Alpha, summary: No summary, Headline: Gilead wins U.S. approval for twice yearly HIV med lenacapavir, source:Seeking Alpha, summary: No summary, Headline: Gilead Sciences Gets FDA Approval for Sunlenca to Treat HIV-1, source:MarketWatch, summary: By Chris Wack Gilead Sciences Inc. said Thursday that Sunlenca lenacapavir, in combination with other antiretrovirals, has been granted approval by the U.S...., Headline: Gilead`s Sunlenca could expand into broader HIV, says Piper Sandler, source:Thefly.com, summary: No summary, Headline: Gilead says Sunlenca treatment for HIV-1 patients gets US FDA approval, source:Alliance News, summary: No summary, Headline: Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV, source:Yahoo, summary: FOSTER CITY, Calif., December 22, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Sunlenca® (lenacapavir), in combination with other antiretroviral(s) (ARV), has been granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection. Sunlenca has a multi-stage mechanism of action distinguishable from other currently approved classes of antiviral agents, Headline: UPDATE 2-U.S. FDA approves Gilead's long-acting HIV drug Sunlenca, source:Yahoo, summary: The U.S. Food and Drug Administration (FDA) on Thursday approved Gilead Sciences Inc's Sunlenca therapy for HIV infections, paving the way for a drug that requires less frequent dosing than existing treatments.  Treatment of HIV infections typically involves daily administration of a combination of drugs - such as Gilead's Biktarvy and ViiV Healthcare's Triumeq - that suppress replication of the virus.  The initial doses of Sunlenca, whose chemical name is lenacapavir, are given as oral tablets and injections to get the drug up to therapeutic levels quickly, followed by injections every six months to sustain the treatment., Headline: U.S. FDA approves Gilead's long-acting HIV drug Sunlenca, source:Reuters, summary: The U.S. Food and Drug Administration (FDA) on Thursday approved Gilead Sciences Inc's Sunlenca therapy for HIV infections, paving the way for a drug that requires less frequent dosing than existing treatments., Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.01% higher to $85.28 Thursday, on what proved to be an all-around grim trading session for the stock market, with the..., Headline: FDA Approves Gilead's New HIV Treatment For Heavily Treated With Multi-Drug Resistant Patients, source:Yahoo, summary: The FDA has approved Gilead Sciences Inc's (NASDAQ: GILD) Sunlenca (lenacapavir), in combination with another antiretroviral (s) (ARV), for HIV-1 infection in heavily treatment-experienced (HTE) adults with multi-drug resistant (MDR) HIV-1 infection. The approval comes almost a week before the PDUFA date of December 27. The company says that Sunlenca offers a new, twice-yearly treatment option for adults with HIV that is not adequately controlled by their current treatment regimen. In August, th, Headline: Gilead's twice-a-year HIV drug Sunlenca approved by FDA, source:Yahoo, summary: The drug will cost $42,250 as therapy is initiated — a combination of tablets, an injection just under the skin and antiretroviral drugs — and $39,000 a year for maintenance therapy., Headline: Gilead Sciences Snags FDA Approval For Twice-Yearly HIV Shot, source:Yahoo, summary: Gilead won Food and Drug Administration approval for a twice-a-year HIV treatment called Sunlenca on Thursday., Headline: Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma, source:Yahoo, summary: SANTA MONICA, Calif. & TOKYO, December 22, 2022--Kite Pharma, Inc., a Gilead Company, (hereafter, Kite) (NASDAQ: GILD) and Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) (TSE: 4568) today jointly announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has approved Yescarta (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, for the initial treatment of patients with relapsed/refractory large B-cell lymphoma ( R/R LBCL): diffuse large B-cell lymphoma,, Headline: Gilead's treatment for large B-cell lymphoma gets approval in Japan, source:Alliance News, summary: No summary",GILD
79,2022-12-23,"Headline: 3 Nasdaq Stocks That Are Up 25% in 3 Months, source:Yahoo, summary: The Nasdaq Composite has plummeted 33% this year, but there are signs that for at least some stocks, brighter days could be on the horizon.  Entering this week, three Nasdaq stocks were up 25% in just the past three months.  Among the hottest buys of late are chipmaker Nvidia (NASDAQ: NVDA), and healthcare companies Biogen (NASDAQ: BIIB) and Gilead Sciences (NASDAQ: GILD)., Headline: Gilead Sciences Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 0.62% to $84.75 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500..., Headline: Gilead (GILD) Gets FDA Nod for Twice-Yearly HIV Treatment, source:Yahoo, summary: Gilead'ls (GILD) HIV franchise gets a boost with FDA's approval of twice-yearly HIV treatment Sunlenca for the treatment of HIV-1 infection in heavily treatment-experienced adults with multi-drug resistance., Headline: Gilead Sciences to Present at Upcoming Investor Conference, source:Yahoo, summary: FOSTER CITY, Calif., December 23, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:",GILD
80,2022-12-24,"Headline: HQH: 50 Big-Yield Healthcare Stocks, These 3 Worth Considering, source:SeekingAlpha, summary: We share data on over 50 big-yield healthcare investments, including individual stocks, REITs, closed-end funds (CEFs) and bonds. Learn about our 3 top picks here.",GILD
81,2022-12-25,"Headline: Gilead Sciences, Inc. (NASDAQ:GILD) Shares Could Be 40% Below Their Intrinsic Value Estimate, source:Yahoo, summary: Today we will run through one way of estimating the intrinsic value of Gilead Sciences, Inc. ( NASDAQ:GILD ) by taking..., Headline: Dividend Champion, Contender, And Challenger Highlights: Week Of December 25, source:Seeking Alpha, summary: No summary, Headline: 3 Stocks That Could Soar in a Santa Claus Rally, source:Yahoo, summary: Years ago, investors observed that a phenomenon dubbed the Santa Claus rally often occurred during the year-end holidays.  Three Motley Fool contributors identified stocks they think could soar in a Santa Claus rally.  Here's why they picked Gilead Sciences (NASDAQ: GILD), NovoCure (NASDAQ: NVCR), and Pfizer (NYSE: PFE).",GILD
82,2022-12-26,"Headline: Gilead to buy remaining rights for GS-1811 from Jounce Therapeutics for $67M, source:Thefly.com, summary: No summary",GILD
83,2022-12-27,"Headline: Tracking John Rogers` Ariel Investments Portfolio - Q3 2022 Update, source:Seeking Alpha, summary: No summary, Headline: Gilead To Acquire All Remaining Rights To Potential First-In-Class Immunotherapy GS-1811 From Jounce Therapeutics, source:GlobeNewswire, summary: No summary, Headline: Gilead buys out remaining rights for oncology asset GS-1811, source:Alliance News, summary: No summary, Headline: Gilead Sciences to Acquire Remaining Rights to GS-1811 from Jounce Therapeutics, source:MarketWatch, summary: By Denny Jacob Gilead Sciences Inc. on Tuesday said it will acquire all outstanding rights of Jounce Therapeutics Inc. to GS-1811 following an amended..., Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.31% higher to $85.01 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the..., Headline: Stocks to Watch: Kala Pharmaceuticals, Clene, Jounce Therapeutics, source:MarketWatch, summary: By Denny Jacob Kala Pharmaceuticals Inc. said the Food and Drug Administration accepted its investigational new drug application for the treatment of an eye..., Headline: Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics, source:Yahoo, summary: FOSTER CITY, Calif. & CAMBRIDGE, Mass., December 27, 2022--Gilead Acquires All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 from Jounce Therapeutics, Headline: Jounce stock bounces more than 70% after Gilead acquires immunotherapy drug, source:Yahoo, summary: Jounce Therapeutics Inc.  (JNCE)  shares jumped more than 70% in after-hours trading Tuesday, following an announcement that Gilead Sciences Inc.  (GILD)  would completely acquire rights to an immunotherapy drug from Jounce.  Gilead said it would buy out its remaining obligations under a licensing agreement executed in 2020 between the two companies and acquire intellectual property and rights to the cancer treatment, known as GS-1811.  “It was important for Jounce at this time to bolster our cash resources, given challenges in capital markets for biotech companies,” Jounce Chief Executive Richard Murray said in a statement., Headline: UPDATE 1-Gilead buys out rights to cancer therapy from Jounce for $67 mln, source:Yahoo, summary: Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday.  The amended licensing deal will bolster Jounce's cash resources in a challenging market for biotech companies.  Shares of Jounce more than doubled to $1.68, while Gilead's shares fell marginally in after market trading., Headline: Gilead buys remaining rights to cancer immunotherapy drug from East Coast partner, source:Yahoo, summary: Gilead Sciences Inc. will pay $67 million for the remaining rights to a cancer immunotherapy drug from partner Jounce Therapeutics Inc., a move to strengthen the Foster City-based drug maker's pipeline of potential cancer drugs.  Gilead (NASDAQ: GILD) said Tuesday that it and Cambridge, Massachusetts-based Jounce (NASDAQ: JNCE) amended a licensing agreement for a drug named JTX-1811 — now GS-1811 — that enables Gilead to buy out all remaining contingent payments.  The deal comes more than two years after Gilead and Jounce disclosed a potential $805 million deal — including a $35 million equity investment in Jounce — that was part of a push by Gilead to beef up the number of potential cancer drugs., Headline: Tracking John Rogers' Ariel Investments Portfolio - Q3 2022 Update, source:SeekingAlpha, summary: Ariel Investmentsâ 13F portfolio value decreased from $10.02B to $9.11B this quarter. Read more to for an update on the portfolio's trades for Q3 2022., Headline: Gilead Sciences (GILD) Gains As Market Dips: What You Should Know, source:Yahoo, summary: In the latest trading session, Gilead Sciences (GILD) closed at $85.01, marking a +0.31% move from the previous day., Headline: Gilead buys out rights to cancer therapy from Jounce for $67 million, source:Reuters, summary: Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday., Headline: What You Missed On Wall Street On Wednesday, source:Thefly.com, summary: No summary",GILD
84,2022-12-28,"Headline: Gilead Sciences buys sole rights to cancer therapy for USD67 million, source:Alliance News, summary: No summary, Headline: Why Is Jounce Therapeutics (JNCE) Stock Up 70% Today?, source:InvestorPlace, summary: No summary, Headline: Fly Intel: Pre-market Movers, source:Thefly.com, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Zacks Industry Outlook Highlights Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals, source:Yahoo, summary: Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals are part of the Zacks Screen of the Week article., Headline: Gilead Sciences Acquires Jounce Therapeutics Cancer Immunotherapy Program, source:Yahoo, summary: Gilead Sciences Inc (NASDAQ: GILD) and Jounce Therapeutics Inc (NASDAQ: JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buyout remaining contingent payments potentially due under the license agreement executed in August 2020. GS-1811, an immunotherapy, is designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory cells in the tumor microenvironment. It is currently in Phase 1 development for solid tumors. Jounce will recei, Headline: Gilead (GILD) To Get Full Rights for Jounce's Immunotherapy, source:Yahoo, summary: Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from Jounce Therapeutics., Headline: Gilead Sciences Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. sank 0.52% to $84.57 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P..., Headline: Biotech: 3 Profitable Bios Worth Owning, source:Yahoo, summary: The biotechnology space can be a difficult area to generate profits. Drugs take years to develop and often fail FDA approval. Today we will look at three top biotech stocks that are very profitable and have attractive future prospects.",GILD
85,2022-12-29,"Headline: Are Investors Undervaluing Gilead Sciences, Inc. (NASDAQ:GILD) By 40%?, source:Yahoo, summary: Does the December share price for Gilead Sciences, Inc. ( NASDAQ:GILD ) reflect what it's really worth? Today, we will..., Headline: 3 High-Yielding Dividend Stocks That Could See Hikes in January, source:Yahoo, summary: As long as a company is doing well and an increase to the dividend looks probable, the timing of the announcement often will come at around the same time as it did in the previous year.  Three stocks that I expect will announce increases to their dividend payments in January are Gilead Sciences (NASDAQ: GILD), Viatris (NASDAQ: VTRS), and Kimberly-Clark (NYSE: KMB).  Gilead Sciences is a healthcare company that makes a wide range of medicines focused on treating HIV, hepatitis, and cancer., Headline: This New Drug Could Be Gilead Sciences' Growth Catalyst, source:Yahoo, summary: Gilead Sciences (NASDAQ: GILD) has been a top stock to own this year, with its shares rising 17% and dwarfing the S&P 500 and its 21% loss over the same stretch.  Health officials have given the green light on another one of its HIV treatments, which promises to improve lives and potentially generate billions in revenue for the business.  Is now the time to load up on Gilead's stock?, Headline: Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More, source:Yahoo, summary: Updates from Gilead Sciences (GILD) and ProQR (PRQR) are the key highlights from the biotech sector during the past week., Headline: Gilead Sciences Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.82% higher to $85.26 Thursday, on what proved to be an all-around positive trading session for the stock market, with..., Headline: A promising new Covid pill shows key advantages over Paxlovid in trial, source:CNBC, summary: A Chinese antiviral pill was found to be as effective as Paxlovid in a Phase 3 trial, and it appeared to cause fewer side effects, NBC News reports., Headline: Gilead Sciences (GILD) Gains But Lags Market: What You Should Know, source:Yahoo, summary: In the latest trading session, Gilead Sciences (GILD) closed at $85.26, marking a +0.82% move from the previous day.",GILD
86,2022-12-30,"Headline: Opco reveals three biotech stocks that will outperform in 2023, source:Thefly.com, summary: No summary, Headline: Biotech Alert: Searches spiking for these stocks today, source:Thefly.com, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: Gilead Sciences Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.69% higher to $85.85 Friday, on what proved to be an all-around rough trading session for the stock market, with the..., Headline: Galapagos: Slow Transformation, But Led By An Expert, source:SeekingAlpha, summary: Galapagos is setting up to transform its business after a slew of failures. Read more to see why I think GLPG will be successful in its transformation plans.",GILD
87,2022-12-31,"Headline: Jim Simons Stock Portfolio: 10 Biggest Healthcare Stocks, source:Yahoo, summary: In this article we take a look at Jim Simons Stock Portfolio: 10 Biggest Healthcare Stocks. Click to skip ahead and see Jim Simons Stock Portfolio: 5 Biggest Healthcare Stocks. Gilead Sciences, Inc. (NASDAQ:GILD), Novo Nordisk A/S (NYSE:NVO), and Molina Healthcare, Inc. (NYSE:MOH) are three of the healthcare companies that Jim Simons’ quant fund has identified as […]",GILD
88,2023-01-02,"Headline: Piper Sandler keeps Overweight on Jounce Therapeutics, lowers price target to $5, source:Thefly.com, summary: No summary, Headline: Why Investors Shouldn't Be Surprised By Gilead Sciences, Inc.'s (NASDAQ:GILD) P/E, source:Yahoo, summary: With a price-to-earnings (or ""P/E"") ratio of 32.3x Gilead Sciences, Inc. ( NASDAQ:GILD ) may be sending very bearish..., Headline: Better Large-Cap Buy: Roche Holding or Gilead Sciences Stock?, source:Yahoo, summary: Roche Holding (OTC: RHHBY) and Gilead Sciences (NASDAQ: GILD) both saw increased sales during the pandemic, due in part to their COVID-19 products.  For Gilead, it was its COVD-19 antiviral, Veklury, and for Roche, its revenue was boosted mostly by coronavirus tests.  Gilead's shares have glittered in 2022, with the stock up more than 16%, while Roche's have fallen more than 23% so far this year., Headline: Gilead downgraded to Sector Perform from Outperform at RBC Capital, source:Thefly.com, summary: No summary",GILD
89,2023-01-03,"Headline: RBC downgrades Gilead, says drivers need time to play out, source:Thefly.com, summary: No summary, Headline: Gilead downgraded at RBC Capital Markets after recent rally, source:Seeking Alpha, summary: No summary, Headline: EVOQ to potentially receive $658.5M in Gilead collaboration on immunotherapies, source:Thefly.com, summary: No summary, Headline: Gilead to license technology from EVOQ to develop RA, lupus immunotherapies, source:Seeking Alpha, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Intra-Cellular Therapies (ITCI), source:TipRanks, summary: No summary, Headline: Gilead Teams with EVOQ on Lupus, Rheumatoid Arthritis Treatment, source:MarketWatch, summary: By Dean Seal Gilead Sciences Inc. and EVOQ Therapeutics Inc. said Tuesday that they are teaming up to advance the latter company's proprietary technology for..., Headline: EMA approves change to marketing authorization for Gilead`s breast cancer drug Trodelvy, source:Seeking Alpha, summary: No summary, Headline: Allogene ends winning streak as R&D chief departs, source:Seeking Alpha, summary: No summary, Headline: Gilead to collaborate with EVOQ on autoimmune treatments, source:Alliance News, summary: No summary, Headline: Truist biotech analyst to hold an industry dinner meeting, source:Thefly.com, summary: No summary, Headline: Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies, source:Yahoo, summary: FOSTER CITY, Calif. & ANN ARBOR, Mich., January 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and EVOQ Therapeutics, Inc. (EVOQ) today announced a collaboration and licensing agreement to advance EVOQ’s proprietary technology for the treatment of rheumatoid arthritis (RA) and lupus. EVOQ’s NanoDisc technology is designed to enable lymph-targeted delivery of disease-specific antigens and has the potential to change the paradigm for the treatment of autoimmune diseases. Under the agreement, Gilea, Headline: European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer, source:Yahoo, summary: FOSTER CITY, Calif., January 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Medicines Agency (EMA) has validated a Type II variation Marketing Authorization Application (MAA) for Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and, Headline: Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 0.54% to $85.39 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",GILD
90,2023-01-04,"Headline: Hookipa Pharma achieves $5M milestone payment from Gilead, source:Thefly.com, summary: No summary, Headline: Hookipa Pharma Gets $5M Milestone Payment From Gilead Sciences, source:MarketWatch, summary: By Chris Wack Hookipa Pharma Inc. said Wednesday that it has achieved a $5 million non-dilutive milestone payment under its collaboration agreement with..., Headline: First Week of GILD August 18th Options Trading, source:Stock Options Channel, summary: No summary, Headline: HOOKIPA Pharma achieves $5M milestone payment under collaboration with Gilead, source:Seeking Alpha, summary: No summary, Headline: Gilead Sciences: Connecting Breast Cancer Education to Community: Equal Hope, source:Yahoo, summary: NORTHAMPTON, MA / ACCESSWIRE / January 4, 2023 / Gilead Sciences On any given day on the west side of Chicago, you might encounter something unexpected. Outside a retail store or hair salon, there may be a table providing breast cancer education ..., Headline: Gilead's (GILD) Application for Trodelvy Gets EMA Validation, source:Yahoo, summary: Gilead Sciences (GILD) gets EMA validation for its application for breast cancer drug Trodelvy in the European Union., Headline: Gilead Sciences Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.13% higher to $85.50 Wednesday, on what proved to be an all-around positive trading session for the stock market,..., Headline: Gilead Sciences (GILD) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed at $85.50 in the latest trading session, marking a +0.13% move from the prior day.",GILD
91,2023-01-05,"Headline: My Dividend Stock Portfolio: New December Record - 96 Holdings With 24 Buys, 6 Sales, source:SeekingAlpha, summary: Inflation and (expected) actions by the Fed continue to dominate market movements. Learn more about the holdings for December in my dividend income portfolio., Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.41% higher to $85.85 Thursday, on what proved to be an all-around poor trading session for the stock market, with the..., Headline: Gilead Sciences Again Named to Dow Jones Sustainability World Index, source:Yahoo, summary: Gilead Sciences, Inc. (Nasdaq:GILD) announced the company has once again been recognized as one of the most sustainable pharmaceutical companies according to the Dow Jones Sustainability World Index (DJSI World).",GILD
92,2023-01-06,"Headline: Johnson & Johnson Vs. AbbVie: The Better Dividend Aristocrat Buy Might Shock You, source:SeekingAlpha, summary: Johnson & Johnson and AbbVie Inc. historically fall 70% to 80% less than the S&P 500 Index during bear markets since 1985. Click here to find out which is the better dividend aristocrat., Headline: AstraZeneca And Daiichi Sankyo's Zauberkugel (Magic Bullet), source:SeekingAlpha, summary: AstraZeneca, Daiichi Sankyo to market HER-2 cancer domain targeting therapy Enhertu. See why I consider accumulating DSKYF stock for Enhertu momentum play., Headline: Does Gilead Sciences (NASDAQ:GILD) Have A Healthy Balance Sheet?, source:Yahoo, summary: Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that..., Headline: Economic Forecast 2023: New challenges in biotech's 'valley of death', source:Yahoo, summary: The disappearance of investors and their cash is giving biotechs with drugs in development a vexing problem., Headline: Gilead Sciences Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rose 2.60% to $88.08 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500...",GILD
93,2023-01-09,"Headline: Gilead Sciences Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 3.38% to $85.10 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",GILD
94,2023-01-10,"Headline: Gilead Sciences Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rallied 2.40% to $87.14 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P...",GILD
95,2023-01-11,"Headline: Ranking The 10 Largest Biotechs By Pipeline, source:SeekingAlpha, summary: The pipeline is the heart of all drug discovery companies, leading to all growth in the future. Here we rank biotechs by pipeline, click to see the list., Headline: 2 Unstoppable Stocks That Could Beat the Market Again In 2023, source:Yahoo, summary: Biotech giant Gilead Sciences (NASDAQ: GILD) and payment technology specialist Visa (NYSE: V) were among them.  Gilead Sciences ended 2022 on a positive note.  On Dec. 22, the drugmaker announced that the U.S. Food and Drug Administration (FDA) had approved Sunlenca, a long-acting HIV treatment option., Headline: Top Dividend Stock: Gilead Sciences Nears Buy Point Ahead of Earnings, source:Yahoo, summary: This biotech superstar is in the spotlight as it nears a buy point amid continued stability and a growing dividend., Headline: Gilead Sciences Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.06% higher to $87.19 Wednesday, on what proved to be an all-around favorable trading session for the stock market,..., Headline: FDRR: Designed For Inflation And Still Unconvincing, source:SeekingAlpha, summary: Fidelity Dividend ETF for Rising Rates ETF invests in dividend stocks that should profit from rising rates. Here's a rundown on FDRR and whether it is right for you., Headline: Gilead Sciences (GILD) Gains But Lags Market: What You Should Know, source:Yahoo, summary: In the latest trading session, Gilead Sciences (GILD) closed at $87.19, marking a +0.06% move from the previous day., Headline: Moat Stocks Outperformed In Volatile 2022, source:SeekingAlpha, summary: U.S. equity markets ended 2022 on a down note in December as the typical year-end Santa Rally failed to materialize. Find out read more.",GILD
96,2023-01-12,"Headline: IBB: A History Of Outperformance During Recessions, source:SeekingAlpha, summary: iShares Biotechnology has outperformed the S&P 500 during all 3 recessions in the U.S. since inception in early 2001. See why I'm bullish about IBB ETF now., Headline: Meet Gilead’s COVID-19 Virus Variants Hunters, source:Yahoo, summary: NORTHAMPTON, MA / ACCESSWIRE / January 12, 2023 / Gilead Sciences Every time a serious new COVID-19 virus variant emerges, Gilead virologists Charlotte Hedskog and John Bilello, alongside their teams, mobilize as so-called ""variant hunters."" Their ..., Headline: Gilead Sciences Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slipped 1.69% to $85.72 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P...",GILD
97,2023-01-13,"Headline: 2023 Market Preview: Value Should Continue To Lead, source:SeekingAlpha, summary: The market's history after negative years is usually positive. What we expect to work in 2023: Industrials and consumer staples. Click for our market preview.",GILD
98,2023-01-15,"Headline: 25 Biggest California Companies and Stocks, source:Yahoo, summary: In this article, we will be taking a look at the 25 biggest California companies and stocks. To skip our detailed analysis, you can go directly to see the 5 Biggest California Companies and Stocks. California is not just the most populous state in the U.S. with over 39 million residents, but it is also […]",GILD
99,2023-01-16,"Headline: With 82% ownership of the shares, Gilead Sciences, Inc. (NASDAQ:GILD) is heavily dominated by institutional owners, source:Yahoo, summary: To get a sense of who is truly in control of Gilead Sciences, Inc. ( NASDAQ:GILD ), it is important to understand the...",GILD
100,2023-01-17,"Headline: Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed at $85.41 in the latest trading session, marking a -1% move from the prior day.",GILD
101,2023-01-18,"Headline: Covid Isn’t Going Away. New Drugs Are Coming., source:Yahoo, summary: Drug makers are preparing everything from a vaccine that comes as a pill to a better version of Paxlovid., Headline: 3 Stocks That Beat the S&P During the Great Recession, source:Yahoo, summary: Three stocks that outperformed the S&P 500 during the 2007-09 Great Recession were Gilead Sciences (NASDAQ: GILD), McDonald's (NYSE: MCD), and Walmart (NYSE: WMT).  Let's take a look at why these three stocks are recession resistant (including resistance to the effects of inflation), and why they make safe investments to hold in 2023.  Gilead Sciences is a top healthcare stock that is safer than most in a recession., Headline: 7 Cheap But Risky Biotech Stocks, source:MarketWatch, summary: Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%., Headline: Gilead plans 175,000-square-foot research center in Foster City, source:Yahoo, summary: The structure, on the south side of Gilead's campus, will house 300 to 350 people and could open in late 2026.",GILD
102,2023-01-19,"Headline: Decades-Long Effort to Enact Universal HIV Screening for Pregnant Women in Israel, source:Yahoo, summary: Dr. Hila Elinav burst into tears of joy when the Israeli Ministry of Health announced a sweeping new HIV screening policy for pregnant women in September., Headline: Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023, source:Yahoo, summary: FOSTER CITY, Calif., January 19, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2022 financial results and full year 2023 financial guidance will be released on Thursday, February 2 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s fourth quarter and full year 2022 financial results and provide a business update., Headline: ClearBridge Sustainability Leaders Strategy Q4 2022 Portfolio Manager Commentary, source:SeekingAlpha, summary: The ClearBridge Sustainability Leaders Strategy underperformed its Russell 3000 Index benchmark during the fourth quarter. Click here to read the full fund letter., Headline: Price Negotiations Are About to Reshape the Drug Industry, source:MarketWatch, summary: A new U.S. law could push big pharma companies toward more diverse drug pipelines and away from an era of high-priced and complex medicines.",GILD
103,2023-01-20,"Headline: The total return for Gilead Sciences (NASDAQ:GILD) investors has risen faster than earnings growth over the last three years, source:Yahoo, summary: By buying an index fund, investors can approximate the average market return. But if you buy good businesses at...",GILD
104,2023-01-21,"Headline: 3 Smart Stocks to Buy if a Recession Is on the Way, source:Yahoo, summary: Here's why they picked Gilead Sciences (NASDAQ: GILD), Johnson & Johnson (NYSE: JNJ), and Vertex Pharmaceuticals (NASDAQ: VRTX).  David Jagielski (Gilead Sciences): Investors can minimize their risk in the event of a recession by investing in businesses that provide essential products and services and that also pay a dividend to help offset declines in the event of dropping share prices.  Gilead Sciences meets both of those criteria, as its HIV treatments are vital to patients.",GILD
105,2023-01-22,"Headline: Gilead Sciences: Finally A Breakthrough, source:SeekingAlpha, summary: Gilead's solid earnings report is accompanied by many regulatory approvals for various products. See why there is ample room for GILD shares to rise further., Headline: Gilead Sciences: Potential To Continue Its Upward Trend, source:SeekingAlpha, summary: While Q3 results were not great, Gilead Sciences could beat expectations. See why the chances are high for GILD stock to continue its bullish upward trend., Headline: Gilead Looks Fully Valued For 2023, source:SeekingAlpha, summary: Gilead ended up delivering impressive returns for shareholders in 2022, although these gains only manifested fairly late in the year. Click here to find out why GILD stock is a Hold.",GILD
106,2023-01-23,"Headline: Gilead Added To Our 2023 Model Portfolio (Technical Analysis), source:SeekingAlpha, summary: Gilead is a low beta stock and portfolio managers have to be in these stocks during a bear market. Find out why I'm bullish on GILD stock., Headline: Healthcare Outlook 2023, source:SeekingAlpha, summary: Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. Read more here., Headline: Gilead (GILD) Gains 21% in a Year: Will the Trend Continue?, source:Yahoo, summary: Biotech giant Gilead (GILD) gains 21% in the past 12 months as its core HIV business maintains momentum despite volatility., Headline: GILD or GMAB: Which Is the Better Value Stock Right Now?, source:Yahoo, summary: GILD vs. GMAB: Which Stock Is the Better Value Option?, Headline: Gilead Sciences May Still Be Lowballing Q4 Guidance, source:SeekingAlpha, summary: Gilead Sciences is overdependent on their HIV franchise, but sales are still increasing. See why we are bullish on GILD stock at the current price.",GILD
107,2023-01-24,"Headline: Gilead Sciences: What To Do Ahead Of Q4 2022 Financial Report, source:SeekingAlpha, summary: As a leader in various therapeutic areas, Gilead Sciences' total revenue was $7,042 million in Q3 2022, up 12.5% QoQ. Read why I rate GILD stock a Sell., Headline: Gilead Sciences, Inc. (NASDAQ:GILD) Delivered A Weaker ROE Than Its Industry, source:Yahoo, summary: While some investors are already well versed in financial metrics (hat tip), this article is for those who would like..., Headline: Gilead (GILD) to Report Q4 Earnings: What's in the Cards?, source:Yahoo, summary: Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its fourth-quarter 2022 results., Headline: Gilead Sciences (GILD) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed the most recent trading day at $84.02, moving +0.95% from the previous trading session.",GILD
108,2023-01-26,"Headline: Companies Fight Back Against Premium Increases for Crucial Insurance, source:Yahoo, summary: Insurance rates are up for cars, homes and commercial property.  Insurers have raised premiums by 100% or more in recent years as demand for so-called directors and officers policies surged due to a wave of newly public companies and mounting lawsuits with large payouts.  Insurance that protects directors and officers when they are sued is essential for businesses., Headline: Gilead Sciences (GILD) Presents at the J.P. Morgan 41st Annual Healthcare Conference - Slideshow, source:SeekingAlpha, summary: The following slide deck was published by Gilead Sciences, Inc., Headline: Could Gilead Sciences Stock Help You Become a Millionaire?, source:Yahoo, summary: Consider investing in stocks that have both attractive growth opportunities and that pay an above-average dividend.  Before the end of last year, Gilead Sciences investors received some great news: The company's twice-yearly injectable treatment for HIV obtained approval from the Food and Drug Administration.  With the approval, Gilead has added a potential blockbuster to its portfolio as analysts project Sunlenca could hit a peak of $1.5 billion in annual revenue., Headline: Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy?, source:Yahoo, summary: Gilead (GILD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed the most recent trading day at $83.62, moving -0.54% from the previous trading session.",GILD
109,2023-01-27,"Headline: Tango Therapeutics: Upcoming Proof Of Concept Data Is A Major Catalyst, source:SeekingAlpha, summary: Tango Therapeutics' SPAC entry to the market and Gilead deal has put a large dollar figure besides its name. Click here for a major catalyst for TNGX stock., Headline: Gilead Sciences to Present at Upcoming Investor Conferences, source:Yahoo, summary: FOSTER CITY, Calif., January 27, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:",GILD
110,2023-01-30,"Headline: Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma, source:Yahoo, summary: SANTA MONICA, Calif. & REDWOOD CITY, Calif., January 30, 2023--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic collaboration to co-develop and co-commercialize Arcellx’s lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple myeloma is an incurable disease for most patients and the need remains for effective, sa, Headline: Why Gilead (GILD) is Poised to Beat Earnings Estimates Again, source:Yahoo, summary: Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.",GILD
111,2023-02-01,"Headline: Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer, source:Yahoo, summary: FOSTER CITY, Calif., February 01, 2023--Gilead awards $7.6 million in grants to 24 U.S.-based organizations through the newly created Toward Health Equity Oncology Grant(TM)., Headline: How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings, source:Yahoo, summary: Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates., Headline: Top 25 Smartest Companies To Buy According To Hedge Funds, source:Yahoo, summary: In this piece, we will take a look at the top 25 smartest companies to buy according to hedge funds. For more companies, head on over to Top 5 Smartest Companies To Buy According To Hedge Funds. Surviving in the modern day corporate world is not for the faint of heart. Business is a ruthless […], Headline: Drug/Biotech Stocks Q4 Earnings Due on Feb 2: GILD, MRK & Others, source:Yahoo, summary: Let's look at the four biotech/pharma companies slated to release quarterly results on Feb 2., Headline: Gilead Sciences Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.07% higher to $84.00 Wednesday, on what proved to be an all-around positive trading session for the stock market,...",GILD
112,2023-02-02,"Headline: Gilead Sciences: Toward Health Equity for Black People Impacted by TNBC, source:Yahoo, summary: NORTHAMPTON, MA / ACCESSWIRE / February 2, 2023 / Gilead Sciences Originally Published by Gilead Sciences Racism and the impact of social determinants of health drive disparities in outcomes for Black women impacted by triple-negative breast cancer ..., Headline: Gilead Sciences 4Q Profit Surges on Oncology, HIV Sales, source:MarketWatch, summary: By Denny Jacob Gilead Sciences Inc. posted a surge in profit in the latest quarter, as sales grew 2% based on higher sales in oncology and HIV coupled with..., Headline: Gilead Sciences Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 3.11% to $81.39 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500..., Headline: Stocks making the biggest moves after hours: Apple, Amazon, Ford and more, source:CNBC, summary: Several major U.S. companies reported disappointing results for their latest quarters, including a decline in sales for Apple. , Headline: Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results, source:Yahoo, summary: FOSTER CITY, Calif., February 02, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2022., Headline: Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend, source:Yahoo, summary: FOSTER CITY, Calif., February 02, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.7% in the company’s quarterly cash dividend, beginning in the first quarter of 2023. The increase will result in a quarterly dividend of $0.75 per share of common stock. The dividend is payable on March 30, 2023, to stockholders of record at the close of business on March 15, 2023. Future dividends will be subject to Board approval., Headline: Gilead Sciences, Inc. 2022 Q4 - Results - Earnings Call Presentation, source:SeekingAlpha, summary: The following slide deck was published by Gilead Sciences, Inc., Headline: Gilead Sciences, Inc. (GILD) Q4 2022 Earnings Call Transcript, source:SeekingAlpha, summary: Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Q4 2022 Earnings Conference Call February 2, 2023 4:30 PM ETCompany ParticipantsJacquie Ross - VP, IRDaniel O'Day - Chairman and CEOJohanna..., Headline: Gilead stock jumps 5% after Q4 beat, dividend increase, source:Yahoo, summary: Shares of Gilead Sciences Inc.  (GILD)  rose more than 5% in the extended session Thursday after the pharma company reported fourth-quarter earnings and sales above Wall Street expectations, saying higher sales elsewhere took the sting of falling revenue for its COVID-19 drug.  Gilead earned $1.6 billion, or $1.30 a share, compared with $376 million, or 30 cents a share, in the year-ago period in 2021., Headline: Gilead Sciences (GILD) Tops Q4 Earnings and Revenue Estimates, source:Yahoo, summary: Gilead (GILD) delivered earnings and revenue surprises of 11.33% and 12.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?, Headline: Gilead profit beats Street expectations on COVID and HIV sales, source:Reuters, summary: Gilead Sciences Inc on Thursday reported a higher-than-expected fourth-quarter profit driven by strong demand for its HIV and cancer drugs, while COVID-19 antiviral Veklury had sales that were double Wall Street estimates., Headline: Gilead Sciences (GILD) Q4 2022 Earnings Call Transcript, source:Yahoo, summary: Thank you for attending today's fourth quarter and full year 2022 Gilead Sciences earnings conference call.  Just after market closed today, we issued a press release with earnings results for the fourth quarter and full year 2022.  The speakers on today's call will be our chairman and chief executive officer, Daniel O'Day; our chief commercial officer, Johanna Mercier; our chief medical officer, Merdad Parsey; and our chief financial officer, Andrew Dickinson.",GILD
113,2023-02-03,"Headline: S&P 500 Futures Fall in Premarket Trading; Bill.com Holdings, Atlassian Lag, source:MarketWatch, summary: With U.S. stock markets set to open in two hours, (BYD) was up 5.8% in pre-market trading, and (FLR) was up 4.5%. (CLX), (GILD), and (BEP) were all posting..., Headline: Gilead (GILD) Reports Q4 Earnings: What Key Metrics Have to Say, source:Yahoo, summary: Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers., Headline: Is Gilead Sciences Stock a Screaming Buy After Its Strongest Results in 7 Years?, source:Yahoo, summary: Despite a slower start this year, Gilead appears to be in pretty good shape to resume its momentum.  CEO Dan O'Day stated in the press release announcing the numbers, ""2022 marked Gilead's strongest full-year growth in our base business since HCV sales peaked in 2015.""  Is Gilead Sciences stock a buy after its strongest results in seven years?, Headline: U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer, source:Yahoo, summary: FOSTER CITY, Calif., February 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) has approved Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in, Headline: U.S. FDA approves expanded use of Gilead's breast cancer drug , source:Reuters, summary: The U.S. Food and Drug Administration on Friday granted approval for expanded use of Gilead Sciences Inc's cancer drug, Trodelvy, the company said. (Reporting by Raghav Mahobe and Bhanvi Satija in Bengaluru; Editing by Shinjini Ganguli), Headline: UPDATE 3-Gilead's breast cancer drug gets U.S. FDA approval for third indication, source:Yahoo, summary: Gilead Sciences said on Friday the U.S. Food and Drug Administration had greenlighted the use of Trodelvy for a third indication, providing another treatment option for patients with the most common type of breast cancer.  The drug was approved for an advanced form of breast cancer with a subtype known as HR-positive/HER2-negative in patients, who had stopped responding to a hormone-based therapy and at least two earlier systemic therapies.  Gilead's Trodelvy will likely face competition from AstraZeneca-Daiichi Sankyo's Enhertu, which is approved to treat breast cancer patients with HER2-low type, a subset of HER2-negative breast cancer., Headline: Gilead's breast cancer drug secures U.S. FDA approval for expanded use, source:Reuters, summary: Gilead Sciences Inc said on Friday the U.S. Food and Drug Administration had greenlighted expanded use of Trodelvy to treat the most common type of breast cancer, marking the third approval for the drug., Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rose 3.82% to $84.50 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500..., Headline: 15 Best Dividend Leaders to Buy According to Hedge Funds, source:Yahoo, summary: In this article, we discuss 15 best dividend leaders to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Best Dividend Leaders to Buy According to Hedge Funds. First Trust Morningstar Dividend Leaders Index Fund (NYSE:FDL) is based on the 100 highest yielding stocks that have […], Headline: Dan O'Day delivers clear Gilead message: stability, sustainability, source:Yahoo, summary: Through acquisitions and organic research, the HIV and cancer drug developer is in a better position than it was three years ago, its chairman and CEO says., Headline: Gilead Sciences' Trovelvy Scores FDA Approval For Advanced/Metastatic Breast Cancer Setting, source:Yahoo, summary: The FDA has approved Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan-hziy) for adult patients with advanced or metastatic breast cancer. The approval covers unresectable locally advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. The approval is based on statistically significant and clinically meani, Headline: Gilead's breast cancer drug gets U.S. FDA approval for third indication, source:Reuters, summary: Gilead Sciences said on Friday the U.S. Food and Drug Administration had greenlighted the use of Trodelvy for a third indication, providing another treatment option for patients with the most common type of breast cancer., Headline: Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2022 Earnings Call Transcript, source:Yahoo, summary: Gilead Sciences, Inc. (NASDAQ:GILD) Q4 2022 Earnings Call Transcript February 2, 2023 Operator: Good afternoon. Thank you for attending today’s Fourth Quarter and Full Year 2022 Gilead Sciences Earnings Conference Call. My name is Henna, and I will be your moderator for today’s call. I would now like to pass the conference over to our […], Headline: Gilead Snags Another Cancer Win On The Heels Of Its Best Growth In 7 Years, source:Yahoo, summary: Gilead Sciences followed up a strong quarterly report with a third FDA approval for cancer drug Trodelvy, and GILD stock popped., Headline: Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology, source:Yahoo, summary: Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations., Headline: Gilead Sciences and 9 More Companies That Boosted Their Dividends This Week, source:MarketWatch, summary: Old Dominion Freight Line, which handles freight shipping logistics, said it will raise its quarterly dividend by 33% to 40 cents from 30 cents.",GILD
114,2023-02-04,"Headline: Dividend Champion, Contender, And Challenger Highlights: Week Of February 5, source:SeekingAlpha, summary: Dividend Champions list is monthly compilation of companies that consistently increased annual dividend payouts. Check out the full report of the week of February 5.",GILD
115,2023-02-06,"Headline: Is Gilead Sciences a Good Stock to Buy Now?, source:Yahoo, summary: Shares of Gilead Sciences (NASDAQ: GILD) marched higher on Thursday, Feb. 2 in response to a fourth-quarter earnings report that exceeded expectations.  A day later, the U.S. Food and Drug Administration (FDA) agreed to dramatically increase the addressable patient population for an important cancer drug called Trodelvy.  Gilead Sciences splashed out with a $21 billion acquisition of Immunomedics in 2020 for access to Trodelvy., Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rallied 2.20% to $86.36 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P..., Headline: Gilead's (GILD) Breast Cancer Drug Trodelvy Gets FDA Nod, source:Yahoo, summary: Gilead Sciences, Inc. (GILD) announces the FDA approval of their first-in-class, Trop-2 directed antibody-drug conjugate, Trodelvy, for the treatment of metastatic HR+/HER2- breast cancer in adult patients.",GILD
116,2023-02-07,"Headline: Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.75, source:Yahoo, summary: Gilead Sciences, Inc. ( NASDAQ:GILD ) will increase its dividend on the 30th of March to $0.75, which is 2.7% higher..., Headline: Gilead Sciences Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. sank 0.36% to $86.05 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",GILD
117,2023-02-08,"Headline: Why Gilead Sciences is a Top 25 Dividend Giant (GILD), source:ETF Channel, summary: No summary, Headline: Top 5 4th Quarter Trades of COZAD ASSET MANAGEMENT INC, source:GuruFocus, summary: No summary, Headline: Top 5 4th Quarter Trades of ICICI Prudential Asset Management Co Ltd, source:GuruFocus, summary: No summary, Headline: Oak Asset Management, LLC Buys 2, Sells 3 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: NeurAxis: Should You Buy This IPO?, source:TalkMarkets, summary: No summary, Headline: Gilead Sciences: 4 Questions With See Phan: Discovering New Therapies in Breast Cancer, source:Yahoo, summary: As a practicing physician and cancer researcher for more than 20 years, See Phan is all too familiar with the need for innovative new treatment options, especially for breast cancer., Headline: Goodman Financial CORP Buys 2, Sells 3 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: Gilead Sciences Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: No summary, Headline: Thoughts For Thursday: Risk-Off, Risk-On, source:TalkMarkets, summary: No summary",GILD
118,2023-02-09,"Headline: Moat Stocks Take Early Lead In 2023, source:Seeking Alpha, summary: No summary, Headline: Gilead`s Tecartus shows long-term overall survival in type of lymphoma, source:Seeking Alpha, summary: No summary, Headline: IN BRIEF: Gilead Sciences reports positive follow-up for Tecartus, source:Alliance News, summary: No summary, Headline: Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia, source:Yahoo, summary: SANTA MONICA, Calif., February 09, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus® (brexucabtagene autoleucel). Results from the analysis showed a median overall survival (OS) of 26 months and demonstrated that responses remained durable in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) with a consistent safety profile observed since the two-year analys, Headline: 2 Biotech Stocks That Could Make You Richer, source:Yahoo, summary: The biotech industry is a great place to look for such companies.  Let's look at two biotech stocks that could help make investors richer in the years ahead: Gilead Sciences (NASDAQ: GILD) and CRISPR Therapeutics (NASDAQ: CRSP).  Gilead Sciences is a biotech giant famous for its leadership in the market for HIV drugs., Headline: Biotech Stock Roundup: AMGN, GILD, BMY, REGN's Q4 Results, KPRX Up on Study Update, source:Yahoo, summary: Earnings results from Amgen (AMGN), Gilead (GILD) and others are the key highlights from the biotech sector during the past week., Headline: Kite's Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings, source:Yahoo, summary: Kite, a Gilead Sciences Inc (NASDAQ: GILD) company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel). The analysis showed a median overall survival (OS) of 26 months and demonstrated that responses remained durable in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), with a consistent safety profile observed since the two-year analysis. In the Phase 2 treated patient cohort (n=55, Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: No summary",GILD
119,2023-02-10,"Headline: Medicare mulls rebates in 2025 for drug prices rising faster than inflation, source:Seeking Alpha, summary: No summary, Headline: Gilead price target raised to $95 from $90 at Cowen, source:Thefly.com, summary: No summary, Headline: Gilead (GILD) Kite Reports Positive Data on CAR T-Cell Therapy, source:Yahoo, summary: Gilead (GILD) reports positive long-term results from the phase I/II study on Tecartus (brexucabtagene autoleucel) for acute lymphoblastic leukemia.",GILD
120,2023-02-11,"Headline: Galapagos: Crohn`s Disease Trial Failure, Still Maintaining A Buy Rating, source:Seeking Alpha, summary: No summary, Headline: Galapagos: Crohn's Disease Trial Failure, Still Maintaining A Buy Rating, source:SeekingAlpha, summary: On February 8th, 2023, Galapagos announced disappointing results of their phase 3 DIVERSITY Crohn's disease study; the company is no longer planning to file an MAA. Read more here., Headline: GLOBEFLEX CAPITAL L P Buys 4, Sells 1 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: Top 5 4th Quarter Trades of KLCM Advisors, Inc., source:GuruFocus, summary: No summary",GILD
121,2023-02-12,"Headline: COVID-19 emergency is ending; What it means for free vaccines and drugs, source:Seeking Alpha, summary: No summary, Headline: ARK Invest: The 7 Words That Explain Why Wall Street Can`t Stand Cathie Wood, source:InvestorPlace, summary: No summary, Headline: Guild Esports extends Fortnite contracts with two professional players, source:Alliance News, summary: No summary, Headline: Large Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers, source:TalkMarkets, summary: No summary, Headline: Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers, source:TalkMarkets, summary: No summary",GILD
122,2023-02-13,"Headline: Mizuho Securities Sticks to Its Buy Rating for Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Wainwright initiates Arcellx with a buy on CAR-T pipeline, partnership with Gilead`s Kite, source:Seeking Alpha, summary: No summary, Headline: Gilead Sciences Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.91% higher to $87.49 Monday, on what proved to be an all-around positive trading session for the stock market, with..., Headline: Gilead Sciences, Inc. (GILD) SVB Securities Global Biopharma Conference (Transcript), source:Seeking Alpha, summary: No summary",GILD
123,2023-02-14,"Headline: Gilead price target raised to $101 from $88 at Mizuho, source:Thefly.com, summary: No summary, Headline: Caxton Associates Buys 4, Sells 1 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: John Rogers Buys 3, Sells 2 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023, source:Yahoo, summary: FOSTER CITY, Calif., February 14, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new clinical and real-world data from the company’s HIV, COVID-19 and viral hepatitis research and development programs at the 30th Conference on Retroviruses and Opportunistic Infections (CROI) from February 19-22. Seventy abstracts, including late-breaking data, demonstrate Gilead’s continued expertise and leadership in virology with a commitment to advance the next wave of, Headline: Gilead Sciences Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 2.07% to $85.68 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500..., Headline: Top 5 4th Quarter Trades of Avalon Investment & Advisory, source:GuruFocus, summary: No summary",GILD
124,2023-02-15,"Headline: 4 Questions With Flavius Martin: Enhancing Innovation by Expanding Gilead`s Research Footprint, source:Accesswire, summary: No summary, Headline: Medicare mulls limiting per month costs for generic drugs at $2, source:Seeking Alpha, summary: No summary, Headline: 4 Questions With Flavius Martin: Enhancing Innovation by Expanding Gilead’s Research Footprint, source:Yahoo, summary: Innovation is at the core of Gilead's 35-year history of life-changing medicines. Through bold and transformative science, Gilead has developed therapies that have brought about a cure for hepatitis C, helped to transform the treatment and prevention of HIV and provided breakthrough therapies for people with cancer., Headline: Gilead Sciences Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slipped 0.74% to $85.05 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P..., Headline: Top 5 4th Quarter Trades of Nan Shan Life Insurance Co., Ltd., source:GuruFocus, summary: No summary",GILD
125,2023-02-16,"Headline: Elliott Wave Technical Analysis: Gilead Inc., source:TalkMarkets, summary: No summary, Headline: Gilead Sciences Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 1.95% to $83.39 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...",GILD
126,2023-02-17,"Headline: Top 5 4th Quarter Trades of HealthInvest Partners AB, source:GuruFocus, summary: No summary, Headline: VALUEWORKS LLC Buys 1, Sells 4 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: Gilead announces updated results from three cohorts of TROPHY-U-01 study, source:Thefly.com, summary: No summary, Headline: Gilead updates Phase 2 data for bladder cancer therapy Trodelvy, source:Seeking Alpha, summary: No summary, Headline: Kite CEO Christi Shaw leaving Gilead at end of March, source:Thefly.com, summary: No summary, Headline: AQR CAPITAL MANAGEMENT LLC Buys 3, Sells 2 in 4th Quarter, source:GuruFocus, summary: No summary, Headline: Trodelvy® Demonstrates Positive Efficacy Treating Both Platinum-Ineligible and Rapidly Progressing, Post-Platinum Metastatic Urothelial Cancer, source:Yahoo, summary: FOSTER CITY, Calif., February 17, 2023--Trodelvy Demonstrates Positive Efficacy in Metastatic Urothelial Cancer, Headline: Mobile Clinics Expand Access to Cancer Screenings in the U.S. South, source:Yahoo, summary: Sharneitha Bradford spends her days helping people access cancer diagnostic care, a role she embraces as a nurse navigator., Headline: Gilead Sciences Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. advanced 1.64% to $84.76 Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...",GILD
127,2023-02-20,"Headline: Billionaire Ken Griffin’s Top 10 High Dividend Stock Picks, source:Yahoo, summary: In this article, we discuss billionaire Ken Griffin’s top 10 high-dividend stock picks. You can skip our detailed analysis of Ken Griffin’s investment strategy, and go directly to read Billionaire Ken Griffin’s Top 5 High Dividend Stock Picks. Ken Griffin’s Citadel Investment Group is one of the 15 Biggest Hedge Funds in the World by […], Headline: 25 Most Profitable NASDAQ Stocks Today, source:Yahoo, summary: In this article, we will look at the 25 most profitable NASDAQ stocks today. If you want to explore similar stocks, you can also take a look at 10 Most Profitable NASDAQ Stocks Today. 2022 was one of the worst years for the NASDAQ, primarily because it is dominated by tech, and tech stocks crashed as […], Headline: Gilead (GILD) Reports Positive Data From Urothelial Cancer Study, source:Yahoo, summary: Gilead's (GILD) new and updated positive results from a phase II study show Trodelvy's rapid and durable responses for patients across a range of hard-to-treat types of mUC., Headline: Gilead says new data from four collaborative HIV studies reported at CROI, source:Thefly.com, summary: No summary, Headline: Gilead reports `positive data` from real-world studies of Veklury, source:Thefly.com, summary: No summary",GILD
128,2023-02-21,"Headline: Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.75, source:Yahoo, summary: Gilead Sciences, Inc. ( NASDAQ:GILD ) has announced that it will be increasing its dividend from last year's comparable..., Headline: Gilead Listed on the 2023 Bloomberg Gender-Equality Index, source:Yahoo, summary: Gilead's been listed on the 2023 Bloomberg Gender-Equality Index for our support of women's empowerment., Headline: Gilead Sciences Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slipped 0.14% to $84.64 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P..., Headline: Gilead Presents New Data From HIV Cure Research Program and Collaborations Exploring Novel Investigational Combinations and Strategies, source:Yahoo, summary: FOSTER CITY, Calif., February 21, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from four collaborative studies evaluating novel investigational combinations and strategies with the potential to target the HIV viral reservoir or enhance immune response to maintain virologic control in the absence of antiretroviral therapy (ART). These latest findings represent an ongoing multi-pronged approach in Gilead’s HIV cure research program. The data were presented at the Conference o, Headline: Veklury® (Remdesivir) Reduced Risk of Mortality in Hospitalized COVID-19 Patients Across all Variant Time Periods in a Real World Study of More than 500,000 Hospitalized Patients, source:Yahoo, summary: FOSTER CITY, Calif., February 21, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive data from three retrospective real-world studies which demonstrated that initiation of Veklury® (remdesivir) within the first two days of hospital admission can help reduce mortality and hospital readmission rates among all patients hospitalized with COVID-19, regardless of disease severity. A reduction in mortality was also observed in vulnerable populations, such as people living with cancer o, Headline: Gilead says its COVID-19 drug can help reduce deaths, shorten hospital stays, source:Yahoo, summary: MARKET PULSE Gilead Sciences Inc. (GILD) said Tuesday that its COVID-19 drug can help reduce deaths and readmission rates among patients hospitalized with COVID-19 and who received the drug, remdesivir, shortly after their hospital admission., Headline: S&P 500 Q4 2022 Earnings Review: Swing And A Miss, source:SeekingAlpha, summary: As we exit the peak period of earnings season, we review the S&P 500 2022 Q4 earnings season in more detail, providing both aggregate and company level insights., Headline: John Rogers` Firm Enters Carlyle Group Stake, Powers Up Generac Position, source:GuruFocus, summary: No summary",GILD
129,2023-02-22,"Headline: Mizuho Securities Sticks to Its Buy Rating for Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Gilead presents PoC data for investigational combination of lenacapavir, bNAbs, source:Thefly.com, summary: No summary, Headline: GSK`s long-acting HIV med Cabenuva equals Gilead`s daily Biktarvy, source:Seeking Alpha, summary: No summary, Headline: Gilead posts Phase 1 data to support twice yearly potential of HIV therapy, source:Seeking Alpha, summary: No summary, Headline: Kite Completes Acquisition of Tmunity, source:Yahoo, summary: SANTA MONICA, Calif., February 22, 2023--Kite, a Gilead Company (NASDAQ: GILD), today announced the completion of the previously announced transaction to acquire Tmunity Therapeutics (Tmunity), a clinical-stage, private biotech company focused on next-generation CAR T-therapies and technologies., Headline: GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill, source:Reuters, summary: British drugmaker GSK's HIV treatment division, ViiV Healthcare, published data on Wednesday showing its long-acting HIV injection is as effective as the market-leading daily pill made by Gilead Sciences Inc., Headline: IN BRIEF: Gilead hails results of study for Covid-19 drug Veklury, source:Alliance News, summary: No summary, Headline: Gilead Presents Positive Proof-of-Concept Data for Investigational Combination Regimen of Lenacapavir with Broadly Neutralizing Antibodies as a Potential Twice-Yearly Approach for the Treatment of HIV, source:Yahoo, summary: FOSTER CITY, Calif., February 22, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced data evaluating lenacapavir in combination with broadly neutralizing antibodies (bNAbs) teropavimab and zinlirvimab as a potential long-acting treatment regimen with twice-yearly dosing. Results from the Phase 1b clinical trial demonstrated the investigational combination was generally well tolerated with high efficacy in select virologically suppressed participants living with HIV. These data were prese, Headline: Gilead Sciences Touts Encouraging Data From Real World Studies Of Its Flagship COVID-19 Treatment, source:Yahoo, summary: Gilead Sciences Inc (NASDAQ: GILD) announced data from three retrospective real-world Veklury (remdesivir) studies for COVID-19 treatment. The studies demonstrated that initiating Veklury within the first two days of hospital admission can help reduce mortality and hospital readmission rates among all patients hospitalized with COVID-19, regardless of disease severity. A reduction in mortality was also observed in vulnerable populations. Related: WHO Recommends Gilead's COVID-19 Therapy For Seve, Headline: Gilead Sciences Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 1.35% to $83.50 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P..., Headline: Lightning Round: Stay long Berkshire Hathaway, source:CNBC, summary: Mad Money host Jim Cramer takes questions on specific stocks, including Berkshire Hathaway, VF Corp., Tesla, Teva Pharmaceuticals McKesson Corp., Equinix, Gilead Sciences and EQT Corp.",GILD
130,2023-02-23,"Headline: Gilead Sciences: Black HIV/AIDS Awareness Day, source:Yahoo, summary: NORTHAMPTON, MA / ACCESSWIRE / February 23, 2023 / Gilead Sciences: This Black HIV/AIDS Awareness Day, we recognize the major strides made to combat the disproportionate impact of HIV on Black communities - but there is more work to do. Learn ..., Headline: Gilead Sciences Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 1.15% to $82.54 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P..., Headline: Cambridge biotech Jounce to cut staff, merge with U.K. drug developer, source:Yahoo, summary: A Cambridge-based cancer company and longtime partner of pharma giant Gilead Sciences Inc. is merging with another firm, one day after announcing it would lay off most of its staff.",GILD
131,2023-02-24,"Headline: WHO panel is reviewing whether COVID vaccines need to be updated , source:DowJones, summary: Most of the week's COVID news is focused on vaccines, including the big slide in Moderna's revenue caused by falling demand., Headline: WHO panel is reviewing whether COVID vaccines need updating, as agency monitors 7 omicron subvariants, source:Yahoo, summary: Most of the week's COVID news is focused on vaccines, including the big slide in Moderna's revenue caused by falling demand., Headline: Gilead Sciences Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slipped 2.28% to $80.66 Friday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",GILD
132,2023-02-25,"Headline: Regeneron: Innovation And Disruption Done Right, source:SeekingAlpha, summary: Regeneron Pharmaceuticals' collaborative energy is strong and the medium-term looks good. Check out why we rate REGN stock a Hold for now., Headline: 3 Stocks to Buy Right Now That Are Cash Cows, source:Yahoo, summary: With this in mind, three Motley Fool contributors were asked to pick stocks to buy right now that are cash cows.  Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Vertex Pharmaceuticals (NASDAQ: VRTX).  Prosper Junior Bakiny (AbbVie): There are many ways in which a company can be deemed a ""cash cow.""",GILD
133,2023-02-26,"Headline: The one-year decline in earnings for Gilead Sciences NASDAQ:GILD) isn't encouraging, but shareholders are still up 38% over that period, source:Yahoo, summary: Passive investing in index funds can generate returns that roughly match the overall market. But if you pick the right..., Headline: Here's What David Siegel's Two Sigma Hedge Fund Loaded Up On to Close Out 2022, source:Fintel, summary: nan, Headline: 7 Cash-Rich Companies to Invest in During Economic Uncertainty, source:Yahoo, summary: While it’s generally good to be optimistic, in the market, it also pays to be realistic, thus incentivizing consideration for cash-rich stocks to buy. Here, we’re not necessarily talking about the most exciting ventures available. Rather, we’re targeting enterprises that have plenty of green-colored paper in the bank. This way, these cash-imbued entities can weather whatever storms might break out. At the same time, it doesn’t make too much sense to have plenty of cash if you’re also waist-deep",GILD
134,2023-02-27,"Headline: UK shareholder meetings calendar - next 7 days, source:Alliance News, summary: No summary, Headline: Gilead Sciences Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.29% higher to $80.89 Monday, on what proved to be an all-around favorable trading session for the stock market, with..., Headline: Top 10 Drug Companies in USA and Their China Reliance, source:Yahoo, summary: In this article, we will be taking a look at the top 10 drug companies in USA and their China reliance. To skip our detailed analysis of the pharmaceutical sector, you can go directly to see the Top 5 Drug Companies in USA and Their China Reliance. The US has long been reliant on China […], Headline: Moderna’s Covid Boom Is Ending. Why the Outlook Isn’t All Grim., source:MarketWatch, summary: Troubles that were put off during the biotech’s pandemic-era boom, notably various intellectual property wrinkles, are now coming home to roost.",GILD
135,2023-02-28,"Headline: Honoring the History and Impact of the Aids Memorial Quilt, source:Yahoo, summary: The San Francisco-based AIDS Memorial Quilt is the world's largest living memorial project., Headline: Gilead Sciences Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 0.45% to $80.53 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",GILD
136,2023-03-01,"Headline: Gilead: Good 3.7%+ Yield But More Growth Required, source:SeekingAlpha, summary: Gilead punches above its weight with its very attractive 3.7%+ dividend yield. Read to know if GILD stock can get back to its dividend growth rate., Headline: Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 1.17% to $79.59 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow...",GILD
137,2023-03-02,"Headline: Gilead Foundation Donating $1 Million for Relief Efforts in T��rkiye and Syria, source:Accesswire, summary: No summary, Headline: Interesting GILD Put And Call Options For April 14th, source:Stock Options Channel, summary: No summary, Headline: UK shareholder meetings calendar - next 7 days, source:Alliance News, summary: No summary, Headline: How Did Gilead Sciences, Inc.'s (NASDAQ:GILD) 22% ROE Fare Against The Industry?, source:Yahoo, summary: Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is..., Headline: Gilead Foundation Donating $1 Million for Relief Efforts in Türkiye and Syria, source:Yahoo, summary: As a way to support those impacted by Monday's devastating earthquake in Türkiye and Syria, the Gilead Foundation is donating $1 million for on-the-ground relief efforts., Headline: Gilead Sciences Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.04% higher to $79.62 Thursday, on what proved to be an all-around great trading session for the stock market, with...",GILD
138,2023-03-03,"Headline: Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Veru (VERU) and Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rose 1.82% to $81.07 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P..., Headline: Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed the most recent trading day at $81.07, moving +1.82% from the previous trading session.",GILD
139,2023-03-05,"Headline: What To Expect From Pfizer In The Post-COVID-19 Era, source:SeekingAlpha, summary: In Q4 2022, the company's revenue was $24.29 billion, up 1.9% from the last three months of 2021, despite a significant decrease in people's desire to vaccinate against COVID-19.",GILD
140,2023-03-06,"Headline: Analysts Offer Insights on Healthcare Companies: Addus Homecare (ADUS), Gilead Sciences (GILD) and Surgery Partners (SGRY), source:TipRanks, summary: No summary, Headline: What Contributed to Gilead Sciences (GILD)’s Outperformance in Q4?, source:Yahoo, summary: ClearBridge Investments, an investment management company, released its “ClearBridge Sustainability Leaders Strategy” fourth 2022 investor letter. A copy of the same can be downloaded here. The strategy underperformed its benchmark, the Russell 3000 Index, in the fourth quarter. In the quarter, the strategy gained in eight of the ten sectors it invested in on an absolute […], Headline: Healthcare Is Lagging But Biotech Offers Good Potential For Value And Trading, source:TalkMarkets, summary: No summary, Headline: Gilead Sciences Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.05% higher to $81.11 Monday, on what proved to be an all-around favorable trading session for the stock market, with...",GILD
141,2023-03-07,"Headline: Biden to announce plan to keep Medicare solvent beyond 2050, source:Seeking Alpha, summary: No summary, Headline: Blue Star Capital swings to loss after fair valuation movements, costs, source:Alliance News, summary: No summary, Headline: My Dividend Stock Portfolio: New February Record - 99 Holdings With 32 Buys And 4 Sales, source:SeekingAlpha, summary: Inflation and (expected) actions by the Federal Reserve continue to dominate market movements. Click here to read more about the dividend stocks., Headline: Gilead Sciences, Inc. (GILD) Presents at Cowen 43rd Annual Healthcare Conference (Transcript), source:SeekingAlpha, summary: Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Cowen 43rd Annual Healthcare Conference March 7, 2023 11:10 AM ETCompany ParticipantsAndy Dickinson - Chief Financial OfficerConference Call..., Headline: 2 Healthcare Stocks That Could Help Set You Up for Life, source:Yahoo, summary: Let's look at two stocks that can help you grow your wealth for decades: Gilead Sciences (NASDAQ: GILD) and Medtronic (NYSE: MDT).  Gilead Sciences is a major biotech company whose primary therapeutic area of focus is HIV.  The company has become a leader in this field thanks to products such as Biktarvy and Descovy, which are among the most-prescribed medicines in the HIV and HIV pre-exposure prophylaxis (PrEP) markets, respectively., Headline: Gilead Sciences Inc. stock falls Tuesday, still outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slipped 1.02% to $80.28 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P..., Headline: U.S. Wide-Moat Stocks On Sale - The March 2023 Heat Map, source:SeekingAlpha, summary: We are only interested in those targets that are attractively valued in historical comparison. Click here for our 3-step process that focuses on wide-moat stocks.",GILD
142,2023-03-08,"Headline: Is Gilead Sciences, Inc. (NASDAQ:GILD) Trading At A 50% Discount?, source:Yahoo, summary: Key Insights The projected fair value for Gilead Sciences is US$159 based on 2 Stage Free Cash Flow to Equity Gilead..., Headline: Gilead Sciences: Global Community Accountability Groups Pave Way Forward for Inclusive Clinical Trials, source:Yahoo, summary: Gilead Sciences (left to right) Bridget Ndagaano Jjuuko, Executive Director, ACTS 101 Uganda and Yvette Raphael, Executive Director, Advocacy for the Prevention of HIV/AIDS in South Africa., Headline: Gilead Sciences Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 0.10% to $80.20 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...",GILD
143,2023-03-09,"Headline: Gilead Sciences: Underlying Growth Obscured By Veklury Swings, source:SeekingAlpha, summary: Gilead Sciences, Inc. got very lucky with its Veklury anti-viral, as it proved very valuable in combatting Covid-19. Click here for more on GILD stock prospects., Headline: 37 Upcoming Dividend Increases, Including 2 Dividend Kings, source:SeekingAlpha, summary: All these stocks have at least 5 fiscal years of dividend growth history and come from the U.S. Dividend Champions List. Click here to see our exclusive list., Headline: Gilead Sciences Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 1.56% to $78.95 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500..., Headline: Gilead Sciences (GILD) Stock Moves -1.55%: What You Should Know, source:Yahoo, summary: In the latest trading session, Gilead Sciences (GILD) closed at $78.96, marking a -1.55% move from the previous day.",GILD
144,2023-03-10,"Headline: Assuming No-Growth, Gilead Is The Safest Choice Among The Large Biotechs, source:SeekingAlpha, summary: Gilead has a strong credit profile and a low cost of equity. Find out why for an investor seeking relative safety, GILD stock is worth a look., Headline: Ex-Dividend Reminder: Gilead Sciences, Atrion and CONMED, source:Dividend Channel, summary: No summary, Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.70% higher to $79.50 Friday, on what proved to be an all-around grim trading session for the stock market, with the...",GILD
145,2023-03-11,"Headline: Dividend Champion, Contender, And Challenger Highlights: Week Of March 12, source:SeekingAlpha, summary: A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.",GILD
146,2023-03-12,"Headline: Gilead Sciences, Inc. (NASDAQ:GILD) is a favorite amongst institutional investors who own 84%, source:Yahoo, summary: Key Insights Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to..., Headline: Arcellx initiated with a Buy at Stifel, source:Thefly.com, summary: No summary",GILD
147,2023-03-13,"Headline: Gilead Sciences Inc. stock underperforms Monday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.01% higher to $79.51 Monday, on what proved to be an all-around grim trading session for the stock market, with the...",GILD
148,2023-03-14,"Headline: Gilead Sciences Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rallied 1.28% to $79.77 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P...",GILD
149,2023-03-15,"Headline: AbbVie, Gilead, Seagen among firms fined for raising prices faster than inflation, source:Seeking Alpha, summary: No summary, Headline: Stacey Bledsoe`s Resolve To Make Clinical Trials Available to Everyone, source:Accesswire, summary: No summary, Headline: The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector, source:InvestorPlace, summary: No summary, Headline: Stacey Bledsoe's Resolve To Make Clinical Trials Available to Everyone, source:Yahoo, summary: NORTHAMPTON, MA / ACCESSWIRE / March 15, 2023 / Gilead Sciences Stacey Bledsoe's life took a personal and professional turn in 2015, when her father was diagnosed with lung cancer. A nurse by training, Stacey asked his oncologist whether she could ..., Headline: Gilead Sciences, Inc. (GILD) Presents at Barclays 2023 Global Healthcare Conference (Transcript), source:SeekingAlpha, summary: Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Barclays 2023 Global Healthcare Conference March 15, 2023 10:00 AM ETCompany ParticipantsMerdad Parsey - Chief Medical OfficerConference Call..., Headline: First Drugs Facing Medicare Price Penalty Are Named, source:Yahoo, summary: U.S. health officials listed 27 medications whose prices rose faster than inflation, triggering rebates under a new federal law., Headline: Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 0.15% to $79.65 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500..., Headline: Medicare identifies drug makers that will owe penalties for raising prices on 27 drugs faster than rate of inflation, source:Yahoo, summary: The Biden administration is making good on promises to help lower drug costs, though the impact is largely for Medicare patients.",GILD
150,2023-03-16,"Headline: PBE: Healthcare Dashboard For March, source:SeekingAlpha, summary: Healthcare equipment is the less attractive subsector regarding both valuation and quality. Click here to find out why PBE is a Hold., Headline: JPMorgan biotech/pharma analysts to hold KOL analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Gilead Sciences (NASDAQ:GILD) Seems To Use Debt Quite Sensibly, source:Yahoo, summary: Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously..., Headline: Here’s Why Gilead Sciences (GILD) Outperformed in Q4, source:Yahoo, summary: Ariel Investments, an investment management company, released its “Ariel Global Strategy” fourth-quarter investor letter. A copy of the same can be downloaded here. In the fourth quarter, the Ariel Global Composite delivered a 10.72% gross of fees compared to a +9.76% return for the primary MSCI ACWI Index and a +14.21% gain for the MSCI ACWI […], Headline: IN BRIEF: Guild Esports enters AI-driven technology partnership, source:Alliance News, summary: No summary, Headline: Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain?, source:Yahoo, summary: Gilead (GILD) gains 34% in the past 12 months as its HIV business and rapidly growing oncology business maintain momentum despite volatility., Headline: Gilead Sciences Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.25% higher to $79.85 Thursday, on what proved to be an all-around great trading session for the stock market, with..., Headline: Gilead Sciences (GILD) Gains But Lags Market: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed at $79.85 in the latest trading session, marking a +0.25% move from the prior day.",GILD
151,2023-03-17,"Headline: Gilead Sciences Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 3.18% to $77.31 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",GILD
152,2023-03-19,"Headline: Nurix: Promising Early Data From This Protein Degrader Company, source:Seeking Alpha, summary: No summary",GILD
153,2023-03-20,"Headline: Gilead exercises option to exclusively license NX-0479 from Nurix Therapeutics, source:Thefly.com, summary: No summary, Headline: Gilead exercises option to license Nurix`s NX-0479, source:Thefly.com, summary: No summary, Headline: Nurix`s stock rallies on Gilead`s option, source:MarketWatch, summary: No summary, Headline: First Republic Bank's stock plummets and Peloton's stock falls while New York Community Bank shares soar, and other stocks on the move, source:MarketWatch, summary: NYCB stock benefits from news it is snapping up some assets of failed Signature Bank., Headline: Gilead licenses protein degrader from Nurix Therapeutics, source:Seeking Alpha, summary: No summary, Headline: First Republic Bank`s stock plummets and Peloton`s stock falls while New York Community Bank shares soar, and other stocks on the move, source:MarketWatch, summary: No summary, Headline: Gilead Exercises Option to License Nurix’s IRAK4 Targeted Protein Degrader Development Candidate, NX-0479, source:Yahoo, summary: FOSTER CITY, Calif. & SAN FRANCISCO, March 20, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation therapies, today announced that Gilead has exercised its option to exclusively license Nurix’s investigational targeted protein degrader molecule NX‑0479. This bivalent degrader, designated GS-6791, is the first development candidate resulting from the previously announced Nurix-Gil, Headline: Oppenheimer reiterates Outperform on Nurix Therapeutics following Gilead news, source:Thefly.com, summary: No summary, Headline: Nurix’s stock rallies on Gilead’s option, source:Yahoo, summary: MARKET PULSE Shares of Nurix Therapeutics Inc. (NRIX) gained about 6% in premarket trading on Monday after Gilead Sciences Inc. (GILD) said it exercised the option to exclusively license Nurix’s targeted protein degrader molecule, which is being considered as a tool to treat inflammatory conditions like rheumatoid arthritis., Headline: Gilead Exercises First License Option Under Agreement With Nurix Therapeutics, source:Yahoo, summary: Gilead Sciences Inc (NASDAQ: GILD) has exercised its option to license Nurix Therapeutics Inc's (NASDAQ: NRIX) investigational targeted protein degrader molecule NX-0479 exclusively. This bivalent degrader, GS-6791, is the first development candidate from the previously announced Nurix-Gilead collaboration. GS-6791 is a potent, selective, oral IRAK4 degrader with potential applications in rheumatoid arthritis (RA) and other inflammatory diseases. Under the terms of the Collaboration, Nurix will, Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rallied 2.78% to $79.46 Monday, on what proved to be an all-around favorable trading session for the stock market, with the...",GILD
154,2023-03-21,"Headline: Kite announces primary OS analysis results of Phase 3 ZUMA-7 study, source:Thefly.com, summary: No summary, Headline: Gilead`s Kite unit touts survival benefit of Yescarta in large B-cell lymphoma, source:Seeking Alpha, summary: No summary, Headline: Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma, source:Yahoo, summary: SANTA MONICA, Calif., March 21, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta in OS versus historical treatment, which was the standard of care (SOC) in a curative setting for nearly 30 years, for initial treatment of adult patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-li, Headline: Nurix's (NRIX) Stock Up Due to License Option Exercise by Gilead, source:Yahoo, summary: Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX 0479., Headline: Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. dropped 0.40% to $79.14 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: Gilead's Flagship CAR T-cell Therapy Shows Improved Overall Survival In Pretreated Lymphoma Patients, source:Yahoo, summary: Kite, a Gilead Science Inc (NASDAQ: GILD) company, announced the primary overall survival (OS) analysis results of the Phase 3 ZUMA-7 study. The results showed a statistically significant improvement for Yescarta in OS versus historical treatment, which was the standard of care (SOC) in a curative setting for nearly 30 years, for initial treatment of adult patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) within 12 months of completion of first-line therapy. Historical SOC is a, Headline: Oppenheimer emerging biotech analyst to hold analyst/industry conference call, source:Thefly.com, summary: No summary",GILD
155,2023-03-22,"Headline: Vectoring In On Vir Biotechnology, source:SeekingAlpha, summary: Vir Biotechnology is a San Francisco-based commercial-stage immunological concern focused on the development of treatments for infectious diseases. Read more about VIR here., Headline: Groups Around the World Work to Eliminate Hepatitis C by Meeting People Where They Are, source:Yahoo, summary: NORTHAMPTON, MA / ACCESSWIRE / March 22, 2023 / Gilead Sciences Every Friday for more than two years, a community church in North Wales, U.K., would transform into a one-stop shop of social services for people experiencing homelessness. Everything ..., Headline: Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities, source:Yahoo, summary: FOSTER CITY, Calif., March 22, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $3 million in grant funding to eight organizations to provide services to communities disproportionately impacted by HIV in rural areas in the United States. My Brother’s Keeper, based in Ridgeland, Mississippi, will provide technical assistance and capacity building to the organizations funded through this initiative. These grants are part of Gilead’s ongoing Zeroing In™ program, Headline: Gilead Sciences Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 1.68% to $77.81 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500..., Headline: Gilead (GILD) Announces OS Data on Yescarta From ZUMA-7 Study, source:Yahoo, summary: Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical standard of care in curative setting., Headline: Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed at $77.81 in the latest trading session, marking a -1.68% move from the prior day., Headline: Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Akero Therapeutics (AKRO), source:TipRanks, summary: No summary",GILD
156,2023-03-23,"Headline: Gilead, Pionyr Immunotherapeutics change 2020 exclusive option agreements, source:Thefly.com, summary: No summary, Headline: Gilead waives rights to acquire immune-oncology biotech Pionyr, source:Seeking Alpha, summary: No summary, Headline: Pionyr Immunotherapeutics and Gilead Change Exclusive Option Agreement, source:Business Wire, summary: No summary, Headline: Gilead Sciences Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rose 1.22% to $78.76 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P..., Headline: Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval, source:Yahoo, summary: Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.",GILD
157,2023-03-24,"Headline: Final Trades: Bunge, Hershey, Gilead & more, source:CNBC, summary: The ""Halftime Report"" traders give their top picks to watch for the second half., Headline: Gilead Sciences Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rose 1.57% to $80.00 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",GILD
158,2023-03-25,"Headline: MCN: Strong Performance, But Premium Persists, source:Seeking Alpha, summary: No summary, Headline: The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket, source:InvestorPlace, summary: No summary, Headline: Dividend Champion, Contender, And Challenger Highlights: Week Of March 26, source:SeekingAlpha, summary: A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the companies with upcoming ex-dividend dates.",GILD
159,2023-03-26,"Headline: NuCana Craters after EU Patent Problems, source:TipRanks, summary: No summary",GILD
160,2023-03-27,"Headline: Model N stock rises as Morgan Stanley starts coverage with overweight rating, source:Seeking Alpha, summary: No summary, Headline: NuCana falls 36% after setback for patent dispute in EU for Gilead`s antiviral, source:Seeking Alpha, summary: No summary, Headline: Oppenheimer emerging biotech analyst to hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Gilead Sciences Could Retreat Further From Here, source:Yahoo, summary: Biopharmaceutical company Gilead Sciences  makes and distributes many drugs but today I am more interested in the position of the charts and indicators.  Bottom-line strategy: GILD is a volatile stock that can move up or down quickly depending on the results of any given drug or treatment., Headline: Gilead Sciences Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slumped 0.53% to $79.58 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",GILD
161,2023-03-28,"Headline: Gilead Sciences Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. advanced 1.75% to $80.97 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P..., Headline: Gilead Sciences (GILD) Gains As Market Dips: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed at $80.99 in the latest trading session, marking a +1.77% move from the prior day.",GILD
162,2023-03-29,"Headline: Investors more bullish on Gilead Sciences (NASDAQ:GILD) this week as stock climbs 4.1%, despite earnings trending downwards over past year, source:Yahoo, summary: The simplest way to invest in stocks is to buy exchange traded funds. But if you pick the right individual stocks, you..., Headline: Gilead Sciences Announces $3 Million in Grant Funding to Eight Organizations Addressing HIV Disparities in Rural U.S. Communities, source:Yahoo, summary: Gilead Sciences, Inc. (Nasdaq:GILD) today announced it is providing a total of $3 million in grant funding to eight organizations to provide services to communities disproportionately impacted by HIV in rural areas in the United States. My Brother's Keeper, based in Ridgeland, Mississippi, will provide technical assistance and capacity building to the organizations funded through this initiative., Headline: Gilead Sciences Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.40% higher to $81.29 Wednesday, on what proved to be an all-around positive trading session for the stock market,..., Headline: Is It Time to Buy These Ultra-Cheap Dividend Stocks?, source:Yahoo, summary: High-quality dividend stocks can be a great way to tilt the odds in your favor as an investor.  The core reason is that top-shelf dividend stocks generally have a long-standing shareholder base due to the reliability of their payouts.",GILD
163,2023-03-30,"Headline: Arcellx price target raised to $39 from $35 at SVB Securities, source:Thefly.com, summary: No summary, Headline: Gilead Sciences: Don`t Be Scared Post Run-Up, source:Seeking Alpha, summary: No summary, Headline: Texas judge blocks Obamacare for HIV drugs, cancer screenings, source:Seeking Alpha, summary: No summary, Headline: Gilead Sciences: Don't Be Scared Post Run-Up, source:SeekingAlpha, summary: There's no denying that Gilead has made poor acquisition choices. However, the cost is gone and the GILD cash flow should come. Click for more on GILD stock., Headline: Texas judge blocks Obamacare for free HIV drugs, cancer screenings, source:Seeking Alpha, summary: No summary, Headline: Gilead Sciences Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.20% higher to $81.45 Thursday, on what proved to be an all-around favorable trading session for the stock market,...",GILD
164,2023-03-31,"Headline: My Top 10 High Dividend Yield Stocks To Invest In April 2023, source:SeekingAlpha, summary: In todayâs article, I will present you with my top 10 high Dividend Yield stocks to invest in for April 2023. Read more here., Headline: Gilead Sciences Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rallied 1.87% to $82.97 Friday, on what proved to be an all-around favorable trading session for the stock market, with the...",GILD
165,2023-04-02,"Headline: Is Gilead Sciences, Inc.'s (NASDAQ:GILD) 22% ROE Strong Compared To Its Industry?, source:Yahoo, summary: One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...",GILD
166,2023-04-03,"Headline: CMS shortens list of drugs subject to new Medicare rebates in 2025, source:Seeking Alpha, summary: No summary, Headline: Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags, source:TalkMarkets, summary: No summary, Headline: Gilead Sciences Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.33% higher to $83.24 Monday, on what proved to be an all-around great trading session for the stock market, with the..., Headline: Gilead Sciences (GILD) Gains But Lags Market: What You Should Know, source:Yahoo, summary: In the latest trading session, Gilead Sciences (GILD) closed at $83.24, marking a +0.33% move from the previous day.",GILD
167,2023-04-04,"Headline: Gilead Sciences Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 1.35% to $82.12 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500..., Headline: Gilead details promising early COVID antiviral data, setting up larger studies, source:Yahoo, summary: Gilead Sciences Inc on Tuesday unveiled data from the first human study of its experimental oral COVID-19 antiviral, saying the results in healthy volunteers cleared the way for two large Phase III trials of the drug that have begun enrolling patients.  The drug, obeldesivir and previously known as GS-5245, is designed to keep the coronavirus that causes COVID from replicating in the body and overwhelming a patient's immune system.  Once metabolized, it works in the same way as Gilead's older intravenous COVID treatment Veklury (remdesivir), which targets virus replication through inhibition of the viral RNA polymerase., Headline: U.S. Wide-Moat Stocks On Sale - The April 2023 Heat Map, source:SeekingAlpha, summary: We believe that the most widely used valuation multiples are terribly flawed. Click here for a complete analysis.",GILD
168,2023-04-05,"Headline: GILD - Chart Of The Week, source:TalkMarkets, summary: No summary, Headline: Gilead Sciences: Overcoming COVID-19 in Early 2020: Keith`s Story, source:Accesswire, summary: No summary, Headline: Gilead said to be in late-stage trials for oral COVID therapy, source:Seeking Alpha, summary: No summary, Headline: InflaRx upgraded to Buy at Guggenheim after Gohibic gets COVID EUA, source:Thefly.com, summary: No summary, Headline: Gilead Sciences: Overcoming COVID-19 in Early 2020: Keith’s Story, source:Yahoo, summary: Early in 2020, Keith Prowell was making the most of his retirement in New York and staying active with swimming and tai chi., Headline: Gilead Sciences Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. advanced 1.86% to $83.65 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the..., Headline: WHO chief expects COVID emergency to end this year, source:Seeking Alpha, summary: No summary",GILD
169,2023-04-06,"Headline: FDA forces pre-term birth drug off the market after 12 years, source:Seeking Alpha, summary: No summary, Headline: 6 Reasons to Buy Gilead Sciences Stock, source:Yahoo, summary: Gilead Sciences (NASDAQ: GILD) is a top healthcare company with a market capitalization north of $100 billion.  Whether you're a dividend investor or interested in growth, this is the type of investment that has something for everyone, and that can be a good fit for any portfolio.  What I like a lot about Gilead is that the company has a strong, sound HIV business at its core., Headline: Gilead Sciences Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slumped 0.33% to $83.37 Thursday, on what proved to be an all-around positive trading session for the stock market, with the...",GILD
170,2023-04-07,"Headline: RBC Capital Sticks to Its Hold Rating for Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Magic Formula Dividend Portfolio For April, source:SeekingAlpha, summary: The following is a dividend portfolio strategy for large caps that score the highest amongst Joel Greenblatt's Magic Formula screener. Read more about the list here.",GILD
171,2023-04-09,"Headline: 3 Dividend Stocks Billionaires Seem to Love, source:Yahoo, summary: There is no shortage of corporations that pay dividends, but they aren't all created equal.  Let's look at three dividend stocks that got the investing attention of some billionaires: Gilead Sciences (NASDAQ: GILD), Microsoft (NASDAQ: MSFT), and Apple (NASDAQ: AAPL).  Gilead Sciences is a leading biotech company with a particular focus on the HIV drug market., Headline: Is Gilead Sciences, Inc. (NASDAQ:GILD) Trading At A 49% Discount?, source:Yahoo, summary: Key Insights Gilead Sciences' estimated fair value is US$163 based on 2 Stage Free Cash Flow to Equity Gilead Sciences...",GILD
172,2023-04-10,"Headline: GSK Vs. Bristol-Myers Squibb: Who`s More Underrated By Mr. Market, source:Seeking Alpha, summary: No summary, Headline: GSK Vs. Bristol-Myers Squibb: Who's More Underrated By Mr. Market, source:SeekingAlpha, summary: GSK's dividend yield is 3.58%, slightly higher than Bristol-Myers Squibb's 3.22%. BMY's EBITDA margin was 43.7% for 2022, 11.4% more than GSK. Read more here., Headline: If You Invested $10,000 in Gilead Sciences in 2013, This Is How Much You Would Have Today, source:Yahoo, summary: Gilead Sciences (NASDAQ: GILD) is a top HIV treatment company that has a bright future ahead.  In 2022, Gilead's top line was flat as a drop in COVID-related sales offset gains the company achieved in other areas of its business.  In 2017, for instance, Gilead's revenue declined by 14% to $26.1 billion as the company saw double-digit declines in revenue for multiple products., Headline: Gilead Sciences Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slipped 0.92% to $82.60 Monday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: Gilead Sciences: Patience, source:SeekingAlpha, summary: Gilead Sciences ended 2022 on a solid note. The 2023 guidance (ex-Covid-19 contribution), though, feels a touch light. Click here for my take on GILD stock., Headline: Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: No summary",GILD
173,2023-04-11,"Headline: 12 Best Covid Treatment Stocks to Buy Today, source:Yahoo, summary: In this piece, we will take a look at the 12 best covid treatment stocks to buy today. For more stocks, head on over to 5 Best Covid Treatment Stocks to Buy Today. If there’s one thing that can be said for sure, it’s that the coronavirus pandemic has changed the world. The deadly disease, […], Headline: DivHut Portfolio Update: March 2023, source:SeekingAlpha, summary: The system is clearly broken, and has been for a while; however, I could find comfort in one thing, my dividends. Four figures in a month is a win in my book., Headline: Why Healthcare Stocks Are A Prescription For Investors In Q2 2023, source:SeekingAlpha, summary: The recent drop in biopharma stocks presents a buying opportunity for investors. Find out why XLV seems like the best fit.",GILD
174,2023-04-12,"Headline: Dividend Income Update March 2023, source:TalkMarkets, summary: No summary, Headline: Gilead price target raised to $85 from $81 at Morgan Stanley, source:Thefly.com, summary: No summary, Headline: Gilead Sciences Now Barely A Hold, Market Looks Uninspired (Rating Downgrade), source:SeekingAlpha, summary: Gilead Sciences has lagged the broad market since previous coverage. Guidance is lackluster. Despite that GILD is a hold now, explore more here., Headline: Could Gilead Sciences Stock Help You Become a Millionaire?, source:Yahoo, summary: Gilead Sciences (NASDAQ: GILD) stock has been a standout among biotech companies over the past year, with its shares up more than 36%.  Fourth-quarter sales rose 2% year over year to $7.4 billion, led by increased sales of oncology, HIV, and hepatitis C virus therapies.  This year, Gilead expects revenue to slide to between $26 billion and $26.5 billion, with Veklury sales hard to gauge., Headline: My Dividend Stock Portfolio: New All-Time Dividend Record - 99 Holdings With 25 Buys, source:SeekingAlpha, summary: My dividend income in March amounted to a record $950. This represents growth of 61% Y/Y and 40% sequentially. Click here for a detailed analysis., Headline: Gilead Sciences: 4 Questions: Global Experts Convene To Identify Key Measures to Long-Term Success in HIV, source:Yahoo, summary: NORTHAMPTON, MA / ACCESSWIRE / April 12, 2023 / Gilead Sciences: Originally published by Gilead Sciences Dr. Jeffrey Lazarus was studying at New York University in the late 1980s when he saw first-hand the devastation of the HIV epidemic. ..., Headline: Gilead Sciences Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 0.46% to $82.16 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500..., Headline: Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed at $82.16 in the latest trading session, marking a -0.46% move from the prior day., Headline: Morgan Stanley Maintains Gilead Sciences (GILD) Equal-Weight Recommendation, source:Fintel, summary: nan",GILD
175,2023-04-13,"Headline: Gilead Sciences, Inc. (NASDAQ:GILD) is a favorite amongst institutional investors who own 84%, source:Yahoo, summary: Key Insights Institutions' substantial holdings in Gilead Sciences implies that they have significant influence over..., Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rallied 1.35% to $83.27 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023, source:Yahoo, summary: FOSTER CITY, Calif., April 13, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its first quarter 2023 financial results will be released on Thursday, April 27, 2023 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s first quarter 2023 financial results and provide a business update., Headline: Gilead Sciences Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: No summary",GILD
176,2023-04-14,"Headline: Nurix Therapeutics Shares Rise 21% on 1Q Performance, source:MarketWatch, summary: By Denny Jacob Nurix Therapeutics Inc. shares rose 21% to $12.21 after narrowing its loss and posting higher revenue in the latest quarter. The clinical...",GILD
177,2023-04-15,"Headline: 3 Dividend Stocks to Buy and Hold for the Next Decade, source:Yahoo, summary: The best ones even pay you to hold them for years via generous dividends.  Three Motley Fool contributors identified their picks for dividend stocks to buy and hold for the next decade.  Here's why they chose AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ).",GILD
178,2023-04-16,"Headline: Gilead announces results from several COVID-19 clinical, real-world studies, source:Thefly.com, summary: No summary, Headline: Veklury® (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations, source:Yahoo, summary: FOSTER CITY, Calif., April 16, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive results from several COVID-19 clinical and real-world evidence studies being presented at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). A Phase 3 clinical study demonstrated that Veklury® (remdesivir) was generally well tolerated in people with moderate to severe renal impairment. Additional data includes a retrospective real-world study which demonstrated that",GILD
179,2023-04-17,"Headline: Johnson & Johnson: 4 Key Areas Of Focus Ahead Of Q1 Earnings, source:SeekingAlpha, summary: nan, Headline: Gilead Sciences Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: No summary",GILD
180,2023-04-18,"Headline: COWZ ETF: A Cash Cow for Your Portfolio, source:TipRanks, summary: No summary, Headline: Gilead Sciences (NASDAQ:GILD) Has A Pretty Healthy Balance Sheet, source:Yahoo, summary: Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously..., Headline: Jounce Acquisition: Exploring Whether It Is Worth It To Pay Up For CVR Value, source:SeekingAlpha, summary: nan, Headline: Hookipa Pharma: A Speculative Biotech Worthy Of A Spot On My Watch List, source:SeekingAlpha, summary: nan, Headline: Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: In the latest trading session, Gilead Sciences (GILD) closed at $83.78, marking a +0.18% move from the previous day.",GILD
181,2023-04-19,"Headline: Gilead Sciences: Breaking Down Barriers To Access in HIV and Beyond: A Perspective, source:Yahoo, summary: NORTHAMPTON, MA / ACCESSWIRE / April 19, 2023 / Gilead Sciences When I came to Gilead in 2019, I did so in part because of the revolutionary way this company thinks about bringing therapies to those who could benefit. Health equity and access ..., Headline: Will Gilead (GILD) Beat Estimates Again in Its Next Earnings Report?, source:Yahoo, summary: Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report., Headline: Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.39% higher to $84.11 Wednesday, on what proved to be an all-around dismal trading session for the stock market, with..., Headline: Strong Quant Screens Say These 7 Growth Stocks Are a Buy, source:Yahoo, summary: Strong quantitative screens will show investors a variety of growth stocks to buy. For example, StockRover is a screening service that scores stocks on three key metrics. One, growth scores are based on five year historical growth, compared to forward EBITDA estimates. Two, quality scores depend on profitability and a healthy balance sheet. Three, value scores are based on the usual price-to-earnings multiple and earnings per share predictability. Quant scores offer investors a numerical charact",GILD
182,2023-04-20,"Headline: Final Trades: Gilead, Vertex, Wynn & more, source:CNBC, summary: The ""Halftime Report"" traders give their top picks to watch for the second half., Headline: Get Income On Gilead Stock, Or Buy It At A Discount With This Option Trade, source:Yahoo, summary: Gilead Sciences is showing high volatility due to the upcoming earnings announcement next Thursday.  The goal is to either have the put expire worthless and keep the premium, or to be assigned and acquire the stock below the current price.  It's important that anyone selling puts understands that they may be assigned 100 shares at the strike price, if the stock is below the strike price at expiration., Headline: Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release, source:Yahoo, summary: Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.69% higher to $84.69 Thursday, on what proved to be an all-around dismal trading session for the stock market, with..., Headline: Notable Friday Option Activity: GILD, SAVA, SONO, source:Stock Options Channel, summary: No summary, Headline: Gilead Sciences Now #76 Largest Company, Surpassing Elevance Health, source:The Online Investor, summary: No summary",GILD
183,2023-04-21,"Headline: OmniAb a new buy at Benchmark on technology to develop monoclonal antibodies, source:Seeking Alpha, summary: No summary, Headline: Earnings Week Ahead: Amazon, Meta Platforms, Alphabet, Coca-Cola, Boeing, and more, source:Seeking Alpha, summary: No summary, Headline: 12 Best Pharma Dividend Stocks To Buy in 2023, source:Yahoo, summary: In this article, we discuss 12 best pharma dividend stocks to buy in 2023. You can skip our detailed analysis of the pharmaceutical sector and its outlook this year, and go directly to read 5 Best Pharma Dividend Stocks To Buy in 2023. The pharmaceutical industry in the US is one of the largest in […], Headline: Will HIV and Oncology Propel Gilead's (GILD) Q1 Earnings?, source:Yahoo, summary: Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its first-quarter 2023 results., Headline: Gilead Sciences Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rallied 2.22% to $86.57 Friday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: Unusual Call Option Trade in Gilead Sciences (GILD)  Worth $140.52K, source:Fintel, summary: nan",GILD
184,2023-04-24,"Headline: Second Quarter Outlook For Biotech Stocks, source:SeekingAlpha, summary: nan, Headline: SDOG: ETF With A Simple And Sensible Strategy, But Average Result, source:SeekingAlpha, summary: nan, Headline: Gilead Sciences Inc. stock underperforms Monday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.15% higher to $86.70 Monday, on what proved to be an all-around great trading session for the stock market, with the..., Headline: Gilead Sciences Releases Inaugural ESG Impact Report, source:Yahoo, summary: Gilead Sciences recently released its inaugural Environmental, Social and Governance (ESG) Impact Report., Headline: COWG ETF: Investing in Stocks with High Free Cash Flow Margins, source:TipRanks, summary: No summary",GILD
185,2023-04-25,"Headline: Gilead Sciences Q1 2023 Earnings Preview - Keeping The Faith, source:SeekingAlpha, summary: Gilead's Q1 2023 earnings will be announced on Thursday, April 27th. Check out my long-term and post earnings price targets for GILD stock., Headline: Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Legend Biotech (LEGN) and GE Healthcare Technologies Inc (GEHC), source:TipRanks, summary: No summary, Headline: 2 Excellent Dividend Stocks to Buy for Less Than $100, source:Yahoo, summary: With that in mind, let's look at two dividend-paying companies whose shares are trading for less than $100 right now: Gilead Sciences (NASDAQ: GILD) and Pfizer (NYSE: PFE).  The past three years have been an up-and-down battle for Gilead Sciences.  Filgotinib was supposed to be Gilead Sciences' next blockbuster, so this was a blow for the company., Headline: Robert W. Baird Reaffirms Their Hold Rating on Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: 3 Cash-Rich Biotech Stocks to Bet on for the Long Haul, source:Yahoo, summary: The Federal Reserve’s recent interest rate hikes mean banks charge much higher interest rates for loans. The interest on loans can be considered the price of borrowing more money. And since acquiring cash now costs more money, it’s becoming much more complicated for companies to invest. For biotech stocks, the pain is clearly borne by investors, who choose to dive into these capital-intensive businesses. For a cash-strapped company, the rising cost of money can be a death sentence. But cash-rich, Headline: Incyte (INCY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release, source:Yahoo, summary: Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations., Headline: Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 1.28% to $85.59 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500..., Headline: 3 Biotech Stocks To Watch Today, source:StockMarket, summary: Biotech stocks for your late-April 2023 watchlist., Headline: RBC Capital Reiterates Gilead Sciences (GILD) Sector Perform Recommendation, source:Fintel, summary: nan",GILD
186,2023-04-26,"Headline: EU publishes proposed reforms for pharma industry, source:Seeking Alpha, summary: No summary, Headline: Gilead set to continue revenue beat streak with Q1 results, source:Seeking Alpha, summary: No summary, Headline: Drug/Biotech Stocks' Q1 Earnings Due Apr 27: LLY, ABBV & More, source:Yahoo, summary: Let's look at the five biotech/pharma companies slated to release quarterly results on Apr 27., Headline: Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slipped 2.16% to $83.74 Wednesday, on what proved to be an all-around rough trading session for the stock market, with the S&P..., Headline: GLOBAL BRIEFING: Samsung posts weakest profit in 14 years in Q1, source:Alliance News, summary: No summary, Headline: Notable companies reporting after market close, source:Thefly.com, summary: No summary, Headline: Gilead options imply 3.8% move in share price post-earnings, source:Thefly.com, summary: No summary, Headline: Gilead Sciences reports Q1 adjusted EPS $1.37, consensus $1.54, source:Thefly.com, summary: No summary, Headline: Gilead reports Q1 Biktarvy sales up 24% y/y, source:Thefly.com, summary: No summary, Headline: Gilead backs FY23 adjusted EPS view $6.60-$7.00, consensus $6.84, source:Thefly.com, summary: No summary, Headline: Gilead Sciences beats revenue estimates but misses profit consensus, source:Seeking Alpha, summary: No summary, Headline: Gilead slips after cutting 2023 earnings guidance, source:Seeking Alpha, summary: No summary, Headline: Gilead Sciences (GILD) Gets a Buy from Mizuho Securities, source:TipRanks, summary: No summary",GILD
187,2023-04-27,"Headline: Better Buy: Pfizer vs. Gilead, source:Yahoo, summary: Two great examples are Pfizer (NYSE: PFE) and Gilead Sciences (NASDAQ: GILD).  Pfizer is facing two challenges right now.  First, demand for its coronavirus vaccine and treatment is falling as we move toward a post-pandemic situation., Headline: Merck Q1 Earnings: Delivering Strong Results, source:SeekingAlpha, summary: Merck reported Q1 results and beat estimates on both lines. Read why I believe that MRK is a good long-term holding, but not a great buy any longer., Headline: Gilead Earnings Fall Short, Stock Tumbles, source:MarketWatch, summary: Aales of its cancer and HIV drugs rose, while sales of its Covid-19 antiviral fell., Headline: Gilead Sciences 1Q Adjusted Earnings Decline on Lower Revenue, Higher Expenses, source:MarketWatch, summary: By Bob Henderson Gilead Sciences Inc. on Thursday reported a first-quarter adjusted earnings decline of 65% that it attributed to lower revenue and higher..., Headline: Gilead shares fall after mixed results, as weaker COVID-19 drug remand weighs, source:MarketWatch, summary: Gilead Sciences Inc. on Thursday cut one of its profit forecasts and reported first-quarter profit that missed expectations., Headline: Gilead: Q1 Earnings Snapshot, source:Associated Press, The, summary: No summary, Headline: Gilead Sciences, Inc. 2023 Q1 - Results - Earnings Call Presentation, source:SeekingAlpha, summary: The following slide deck was published by Gilead Sciences, Inc., Headline: Gilead reduces earnings guidance as first quarter sales fall 2%, source:Alliance News, summary: No summary, Headline: Stocks making the biggest moves after hours: Amazon, Intel, Snap, Pinterest and more, source:CNBC, summary: These are the stocks posting the largest moves in extended trading., Headline: Gilead Sciences Announces First Quarter 2023 Financial Results, source:Yahoo, summary: FOSTER CITY, Calif., April 27, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first quarter of 2023., Headline: UPDATE 1-Gilead profit misses Wall Street expectations as COVID drug sales decline, source:Reuters, summary: Gilead Sciences Inc on Thursday reported a lower-than-expected first-quarter profit as sales from COVID-19 antiviral Veklury declined more than anticipated, and its shares fell more than 2%., Headline: Gilead profit misses Wall Street expectations as COVID drug sales decline, source:Reuters, summary: Gilead Sciences Inc on Thursday reported a lower-than-expected first-quarter profit as sales from COVID-19 antiviral Veklury declined more than anticipated, and its shares fell more than 2%., Headline: Gilead Stock Dives As Light Profit Hamstrings Strong Cancer Drug Sales, source:Yahoo, summary: Biotech giants Gilead Sciences and Amgen posted mixed quarters on Thursday — leading GILD stock and Amgen stock to topple., Headline: Gilead Sciences, Inc. (GILD) Q1 2023 Earnings Call Transcript, source:SeekingAlpha, summary: Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Q1 2023 Earnings Conference Call April 27, 2023 4:30 AM ETCompany ParticipantsJacquie Ross - VP, IRDaniel O'Day - Chairman and CEOJohanna Mercier..., Headline: Gilead Sciences (GILD) Q1 Earnings and Revenues Lag Estimates, source:Yahoo, summary: Gilead (GILD) delivered earnings and revenue surprises of -15.95% and 0.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?, Headline: Analysts Conflicted on These Healthcare Names: Edwards Lifesciences (EW), Gilead Sciences (GILD) and Revance Therapeutics (RVNC), source:TipRanks, summary: No summary",GILD
188,2023-04-28,"Headline: Analysts` Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD), Encompass Health (EHC) and PROCEPT BioRobotics (PRCT), source:TipRanks, summary: No summary, Headline: Gilead assumed with an Overweight at Piper Sandler, source:Thefly.com, summary: No summary, Headline: Jefferies Sticks to Their Buy Rating for Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: No summary, Headline: Video: Nasdaq 100 Movers: GILD, INTC, source:Market News Video, summary: No summary, Headline: Gilead`s hepatitis B therapy Vemlidy gets EMA nod for use in kids above 6, source:Seeking Alpha, summary: No summary, Headline: Why Gilead Sciences Stock Is Falling Today, source:Yahoo, summary: Gilead Sciences Inc (NASDAQ: GILD) reported Q1 FY23 sales decreased 4% Y/Y to $6.35 billion, slightly above the consensus of $6.33 billion, due to lower Veklury (remdesivir) sales, partially offset by increased sales in HIV and Oncology. ""Biktarvy outperformed once again, and Oncology revenue increased 59% year-over-year, driven by Trodelvy and Cell Therapy,"" said Daniel O'Day, Gilead's Chairman & CEO. Product sales decreased by 3% to $6.3 billion; excluding Veklury, product sales increased 15%, Headline: Gilead Sciences Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slipped 1.60% to $82.21 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P..., Headline: Gilead's (GILD) Q1 Earnings Miss, Veklury Sales Plunge, source:Yahoo, summary: Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales., Headline: Gilead Sciences (GILD) Q1 2023 Earnings Call Transcript, source:Yahoo, summary: Jacquie, please go ahead.  The speakers on today's call will be our chairman and chief executive officer, Daniel O'Day; our chief commercial officer, Johanna Mercier; our chief medical officer, Merdad Parsey; and our chief financial officer, Andrew Dickinson., Headline: RBC Capital Maintains Gilead Sciences (GILD) Sector Perform Recommendation, source:Fintel, summary: nan",GILD
189,2023-04-29,"Headline: Gilead Sciences (NASDAQ:GILD) sheds 5.0% this week, as yearly returns fall more in line with earnings growth, source:Yahoo, summary: If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly..., Headline: 27 Largest Biotech Companies in the US, source:Yahoo, summary: In this article, we take a look at 27 largest biotech companies in the US. You can skip our detailed analysis of the biotech industry and go directly to the 5 Largest Biotech Companies in the US. The largest biotech companies in the US have a total market cap of $88 trillion. Latest Developments in […]",GILD
190,2023-04-30,"Headline: Gilead Sciences (GILD) Declares $0.75 Dividend, source:Fintel, summary: nan",GILD
191,2023-05-01,"Headline: Gilead Sciences: A Mixed First Quarter, source:SeekingAlpha, summary: Gilead Sciences saw strong sales growth in the first quarter. Click here to find out why GILD stock is a Buy., Headline: SVB Securities Remains a Hold on Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Gilead Sciences Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 0.96% to $81.42 Monday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500..., Headline: Morgan Stanley Maintains Gilead Sciences (GILD) Equal-Weight Recommendation, source:Fintel, summary: nan, Headline: Gilead Sciences to Present at Upcoming Investor Conferences, source:Yahoo, summary: FOSTER CITY, Calif., May 01, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:",GILD
192,2023-05-02,"Headline: Analysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX) and Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Gilead, US square off in billion-dollar HIV drug patent trial, source:Reuters, summary: Gilead Sciences Inc is headed to trial in Delaware federal court this week to fight claims that it owes the U.S. government a share of multibillion-dollar profits from its HIV-prevention drug regimen., Headline: Gilead Sciences' (NASDAQ:GILD) Shareholders Will Receive A Bigger Dividend Than Last Year, source:Yahoo, summary: Gilead Sciences, Inc. ( NASDAQ:GILD ) will increase its dividend from last year's comparable payment on the 29th of..., Headline: Gilead Sciences battles U.S. government in court over HIV prevention patent, source:CNBC, summary: The U.S. claims Gilead's drugs Truvada and Descovy infringe on CDC patents. , Headline: Gilead Sciences Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 1.20% to $80.44 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500..., Headline: Gilead vs. CDC: The $1B Showdown Over HIV Drug Profits, source:Yahoo, summary: Gilead Sciences Inc (NASDAQ: GILD) is reportedly looking to fight claims that it owes the U.S. government a share of over $1 billion in profits from its HIV-treatment drug Truvada that could help prevent the disease. It generated sales of $147 million in 2022 compared to $371 million a year ago. The FDA approved Gilead's Truvada for HIV prevention in 2012 and its related drug Descovy for the same purpose in 2019. Descovy sales came in at 1.87 billion versus $1.7 billion in 2021. The government i, Headline: GLOBAL BRIEFING: European stocks called up ahead of Fed rate decision, source:Alliance News, summary: No summary, Headline: Gilead call volume above normal and directionally bullish, source:Thefly.com, summary: No summary, Headline: You Can Have Dividends and Growth. Here’s How. , source:MarketWatch, summary: Gilead Sciences and Merck offer attractive dividends and the potential for growth in a sluggish economy.",GILD
193,2023-05-03,"Headline: Big Pharma Stocks Offer Income and Growth Potential. The Case for Gilead Sciences and Merck., source:Yahoo, summary: Gilead Sciences and Merck offer attractive dividends and the potential for growth in a sluggish economy., Headline: Gilead Versus AbbVie: The Better Bet After Q1, 2023 Earnings, source:SeekingAlpha, summary: nan, Headline: Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts, source:Yahoo, summary: The recent national conversation on hepatitis C (HCV) is an encouraging step towards viral hepatitis elimination in the U.S. With its long history of leadership in viral hepatitis, Gilead continues to support efforts that focus on HCV elimination. Gilead is proud that its medicines have treated over four million individuals living with HCV globally., Headline: Gilead Sciences Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 1.23% to $79.45 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500..., Headline: GILD June 23rd Options Begin Trading, source:Stock Options Channel, summary: No summary, Headline: WHO meeting is set to decide whether to end COVID emergency, source:Seeking Alpha, summary: No summary",GILD
194,2023-05-04,"Headline: Gilead wins EU nod for full approval of hepatitis delta virus therapy, source:Seeking Alpha, summary: No summary, Headline: CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV), source:Yahoo, summary: FOSTER CITY, Calif., May 04, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Hepcludex® (bulevirtide) for the treatment of adults with chronic HDV and compensated liver disease, and recommended granting full Marketing Authorisation (MA) that is no longer subject to specific obligations. Bulevirtide was initially granted conditional marketing authoris, Headline: Gilead Sciences Stock Has Only Done This in 1 of the Past 7 Years, source:Yahoo, summary: Gilead Sciences (NASDAQ: GILD) has a bright future ahead with HIV treatment Sunlenca obtaining approval from the Food and Drug Administration last year and cancer drug Trodelvy continuing to show strong growth.  Why has Gilead Sciences stock struggled?  The simple reason for Gilead's woes is that the business has had trouble generating growth., Headline: Gilead Sciences Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 1.17% to $78.52 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",GILD
195,2023-05-05,"Headline: 10 Best Stocks To Buy For A Stock Market Game, source:Yahoo, summary: In this article, we will be taking a look at the 10 best stocks to buy for a stock market game. To see more of these stocks, you can go directly to see the 5 Best Stocks To Buy For A Stock Market Game. Investing in Penny Stocks In a time when the markets are […], Headline: 2 Magnificent Dividend Stocks to Buy Before the Next Recession, source:Yahoo, summary: Let's look at two great dividend stocks to consider buying before the economy worsens: Gilead Sciences (NASDAQ: GILD) and Amgen (NASDAQ: AMGN).  Gilead Sciences is a biotech company with a particular focus on developing HIV medicines.  It has helped Gilead Sciences' revenue stay afloat as the company failed to earn approval for important candidates., Headline: Final Trades: Chevron, American Express & Gilead, source:CNBC, summary: The ""Halftime Report"" traders give their top picks to watch for the second half., Headline: Gilead Sciences Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rose 1.57% to $79.75 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",GILD
196,2023-05-07,"Headline: InvestingPro exclusive: 5 biotech beasts to get your hands on, source:Yahoo, summary: Here is your VIP list of Pro Picks for the week, offered exclusively to InvestingPro subscribers: a hand-picked selection of S&P 500 stocks that InvestingPro awarded a high financial health score of at least 2.75 out of 5.00., Headline: Gilead Sciences, Inc. (NASDAQ:GILD) Delivered A Better ROE Than Its Industry, source:Yahoo, summary: While some investors are already well versed in financial metrics (hat tip), this article is for those who would like..., Headline: Gilead management to meet virtually with Oppenheimer, source:Thefly.com, summary: No summary",GILD
197,2023-05-08,"Headline: Rates Have Risen. Here Are 5 Stocks With Little Debt, source:GuruFocus, summary: No summary, Headline: You Can Have Dividends and Growth. Here’s How., source:Yahoo, summary: Gilead Sciences and Merck offer attractive dividends and the potential for growth in a sluggish economy., Headline: Gilead Sciences Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 1.45% to $78.59 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...",GILD
198,2023-05-09,"Headline: Hookipa Pharma announces first patient dosed in Phase 1a/b trial of HB-400, source:Thefly.com, summary: No summary, Headline: Gilead acquires XinThera, terms undisclosed, source:Thefly.com, summary: No summary, Headline: Gilead Sciences to Buy Private Biotech XinThera >GILD, source:MarketWatch, summary: By Colin Kellaher Gilead Sciences on Tuesday said it is bolstering its early pipeline in oncology and inflammation through the acquisition of privately held..., Headline: Gilead adds to oncology, inflammation portfolio with XinThera acquisition, source:Seeking Alpha, summary: No summary, Headline: Gilead wins jury verdict in patent battle with U.S. govt. over HIV therapy, source:Seeking Alpha, summary: No summary, Headline: Gilead Strengthens Early Pipeline in Oncology and Inflammation Through the Acquisition of XinThera, source:Yahoo, summary: FOSTER CITY, Calif., May 09, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the acquisition of all outstanding shares of XinThera, a privately held biotech company in San Diego. The acquisition complements Gilead’s existing clinical development priorities by adding additional pipeline assets for well-validated targets in oncology and inflammation., Headline: Gilead Sciences defeats U.S. government lawsuit alleging HIV drug patent violations, source:CNBC, summary: The U.S. government had accused Gilead Science of violating patents for drugs used in the HIV prevention regimen PrEP., Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.27% higher to $78.80 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with..., Headline: UPDATE 1-Gilead Sciences prevails in US government lawsuit over HIV drug patents, source:Yahoo, summary: A federal jury on Tuesday found that Gilead Sciences Inc did not infringe U.S. patents with its HIV-prevention regimens using the drugs Truvada and Descovy, handing the government a defeat in its billion-dollar lawsuit.  The Delaware jury found the government's patents were invalid and not infringed following a five-day trial and a morning of deliberations.  The federal government had argued that Gilead failed to compensate the U.S. Centers for Disease Control and Prevention (CDC) for discovering that its drug Truvada, which was first approved to treat HIV, could also help prevent infection by the virus., Headline: Gilead Sciences prevails in US government lawsuit over HIV drug patents, source:Reuters, summary: A federal jury on Tuesday found that Gilead Sciences Inc did not infringe U.S. patents with its HIV-prevention regimens using the drugs Truvada and Descovy, handing the government a defeat in its billion-dollar lawsuit., Headline: 15 Biggest Immunotherapy Companies in the World, source:Yahoo, summary: In this article, we will take a look at the 15 biggest immunotherapy companies in the world. If you want to see more companies in this selection, go to the 5 Biggest Immunotherapy Companies in the World. The immunotherapy industry is a rapidly growing field that is focused on developing treatments that harness the power […]",GILD
199,2023-05-10,"Headline: G1 Therapeutics trilaciclib cuts adverse events linked to Trodelvy in breast cancer patients, source:Seeking Alpha, summary: No summary, Headline: Guild Esports expects revenue growth on strong first half trading, source:Alliance News, summary: No summary, Headline: First Week of July 21st Options Trading For Gilead Sciences (GILD), source:Stock Options Channel, summary: No summary, Headline: Gilead Emphasizes Unique Ways To Hire Top Talent, source:Yahoo, summary: When Jamari Brooks was looking for a new job last fall, he knew he wanted his future employer to have a few key qualities., Headline: Gilead Sciences Inc. stock falls Wednesday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 0.88% to $78.11 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P..., Headline: Gilead management to meet virtually with Oppenheimer, source:Thefly.com, summary: No summary",GILD
200,2023-05-11,"Headline: Here's Why We Think Gilead Sciences (NASDAQ:GILD) Might Deserve Your Attention Today, source:Yahoo, summary: Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks..., Headline: Gilead Sciences Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.76% higher to $78.70 Thursday, on what proved to be an all-around dismal trading session for the stock market, with...",GILD
201,2023-05-12,"Headline: Gilead Sciences Stock: Bear vs. Bull, source:Yahoo, summary: You may know of Gilead Sciences (NASDAQ: GILD) because of its blockbuster coronavirus treatment Veklury.  In fact, the S&P 500 has outperformed Gilead over the past five years.  Gilead has struggled to consistently deliver annual revenue growth ever since its hepatitis C portfolio's revenue reached a peak back in 2015., Headline: Gilead Sciences Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 0.67% to $78.17 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500...",GILD
202,2023-05-13,"Headline: Gilead Sciences, Inc. (GILD) Presents at BofA Securities 2023 Health Care Conference (Transcript), source:SeekingAlpha, summary: Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) BofA Securities 2023 Health Care Conference May 9, 2023 2:20 PM ETCompany ParticipantsAndy Dickinson - CFOConference Call ParticipantsGeoff...",GILD
203,2023-05-14,"Headline: Gilead Sciences Strikes New Deal with Arcus Biosciences, source:TipRanks, summary: No summary",GILD
204,2023-05-15,"Headline: Arcus to receive upfront payment of $35M from Gilead in expanded research pact, source:Thefly.com, summary: No summary, Headline: Expanded Gilead- Arcus pact may result in up to $1B in payments to Arcus, source:Thefly.com, summary: No summary, Headline: Gilead: Arcus deal may reduce Gilead`s FY23 GAAP and non-GAAP EPS by 2c, source:Thefly.com, summary: No summary, Headline: Arcus Biosciences jumps 2% amid expanded inflammation pact with Gilead, source:Thefly.com, summary: No summary, Headline: Gilead projects earnings impact after expanding research deal with Arcus, source:Seeking Alpha, summary: No summary, Headline: Gilead expands research with Arcus to include inflammatory disease, source:Alliance News, summary: No summary, Headline: Gilead Sciences and Arcus Biosciences Expand Partnership to Include Research Programs in Inflammation, source:Yahoo, summary: FOSTER CITY, Calif., & HAYWARD, Calif., May 15, 2023--Gilead Sciences, Inc. (Nasdaq:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced that the companies have expanded the previously announced research collaboration focused on oncology to include therapies for the treatment of inflammatory diseases. The expanded collaboration builds upon Gilead’s growing presence in inflammatory disease and serves as a step towards broadening Arcus’ capabilities and portfolio beyond oncology and into, Headline: Gilead Sciences Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.27% higher to $78.38 Monday, on what proved to be an all-around favorable trading session for the stock market, with..., Headline: Positive Report for Gilead Sciences (GILD) from BMO Capital, source:TipRanks, summary: No summary, Headline: Gilead upgraded to Outperform from Market Perform at BMO Capital, source:Thefly.com, summary: No summary",GILD
205,2023-05-16,"Headline: What You Missed On Wall Street On Tuesday, source:Thefly.com, summary: No summary, Headline: Ensoma Closes Series B Extension, Bringing Total Round to $135 Million, source:Business Wire, summary: No summary, Headline: Street Wrap: Today`s Top 15 Upgrades, Downgrades, Initiations, source:Thefly.com, summary: No summary, Headline: GILD Stock Price Predictions: Is Gilead Sciences Really Worth $100?, source:InvestorPlace, summary: No summary, Headline: Why Is Guardforce AI (GFAI) Stock Up Today?, source:InvestorPlace, summary: No summary, Headline: Gilead Sciences (NASDAQ:GILD) Is Paying Out A Larger Dividend Than Last Year, source:Yahoo, summary: The board of Gilead Sciences, Inc. ( NASDAQ:GILD ) has announced that it will be paying its dividend of $0.75 on the..., Headline: GDC Stock Alert: Why Is GD Culture Group Up 106% Today?, source:InvestorPlace, summary: No summary, Headline: Abortion pill case heads back to federal appeals court: What`s at stake, source:MarketWatch, summary: No summary, Headline: What You Missed On Wall Street This Morning, source:Thefly.com, summary: No summary, Headline: What To Expect From GSK In 2023, source:Seeking Alpha, summary: No summary, Headline: Gilead Sciences, Inc. (GILD) Presents at RBC Capital Markets Global Healthcare Conference (Transcript), source:SeekingAlpha, summary: Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) RBC Capital Markets Global Healthcare Conference May 16, 2023 11:00 AM ETCompany ParticipantsMerdad Parsey - Chief Medical OfficerConference Call..., Headline: Arcus (RCUS) & Gilead Re-Collaborate for Inflammatory Diseases, source:Yahoo, summary: Arcus (RCUS) surges as it expands its previous research collaboration with partner Gilead, to focus on developing therapies for inflammatory diseases., Headline: BMO Capital Upgrades Gilead Sciences (GILD), source:Fintel, summary: nan, Headline: Gilead Sciences Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. dropped 0.08% to $78.32 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P..., Headline: Gilead Appoints Cindy Perettie Executive Vice President of Kite, source:Yahoo, summary: FOSTER CITY, Calif., May 16, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Cindy Perettie will join the company as Executive Vice President of Kite, a Gilead Company, overseeing the cell therapy business, and will become a member of Gilead’s senior leadership team, effective May 30.",GILD
206,2023-05-17,"Headline: Gilead to present advances across its oncology pipeline at ASCO Annual Meeting, source:Thefly.com, summary: No summary, Headline: GILD Makes Notable Cross Below Critical Moving Average, source:Dividend Channel, summary: No summary, Headline: Gilead taps former Roche exec to lead Kite unit, source:Seeking Alpha, summary: No summary, Headline: Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023, source:Yahoo, summary: FOSTER CITY, Calif. & SANTA MONICA, Calif., May 17, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 30 abstracts during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. These data reinforce the strength of Gilead and Kite Oncology’s transformative science in hard-to-treat cancers., Headline: 3 Analyst Upgrades That Smart Investors Won`t Ignore, source:InvestorPlace, summary: No summary, Headline: Gilead Sciences Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.63% higher to $78.81 Wednesday, on what proved to be an all-around great trading session for the stock market, with..., Headline: 3 Analyst Upgrades That Smart Investors Won’t Ignore, source:Yahoo, summary: Even the most experienced investors have only so many hours in the day to perform their due diligence. That’s where analyst ratings can be helpful. Analyst upgrades and downgrades frequently move stocks. Analysts spend a great deal of time covering a particular stock or an entire sector. This gives them access to information and company insiders that retail investors don’t have. One of an analyst’s key responsibilities is to issue a rating and/or price target for the stocks that they cover. Many, Headline: Former Immunomedics CFO pleads guilty to insider trading, source:Reuters, summary: The former chief financial officer of a New Jersey biotechnology company pleaded guilty on Wednesday to insider trading, after prosecutors said he had given nonpublic information about a new breast cancer drug to his girlfriend at the time.",GILD
207,2023-05-18,"Headline: Arcellx a buy at Truist on unique cancer cell therapies, source:Seeking Alpha, summary: No summary, Headline: Gilead Sciences Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slipped 0.76% to $78.21 Thursday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: 5 High Yield Stocks With Steady Dividend Growth And An Attractive Valuation, source:SeekingAlpha, summary: I consider companies that combine a relatively high Dividend Yield and Dividend Growth Rate to be particularly attractive for dividend income investors. Read more here., Headline: Catalyst watch: Eyes on Ford event, Virgin Galactic launch, Nvidia earnings and Microsoft conference, source:Seeking Alpha, summary: No summary",GILD
208,2023-05-19,"Headline: Gilead Sciences Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.81% higher to $78.85 Friday, on what proved to be an all-around dismal trading session for the stock market, with the...",GILD
209,2023-05-20,"Headline: 3 Relatively Safe Stocks to Buy if a Recession Is on the Way, source:Yahoo, summary: Here's why three Motley Fool contributors think that AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Johnson & Johnson (NYSE: JNJ) are relatively safe stocks to buy if a recession is declared this year.  Prosper Junior Bakiny (AbbVie): It may be hard to believe that AbbVie is a safe stock right now.",GILD
210,2023-05-21,"Headline: Billions of dollars at stake as FDA shortcut allows half-proven drugs - report, source:Seeking Alpha, summary: No summary, Headline: Gilead Sciences, Inc. (NASDAQ:GILD) is favoured by institutional owners who hold 85% of the company, source:Yahoo, summary: Key Insights Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to...",GILD
211,2023-05-22,"Headline: Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years, source:Benzinga, summary: No summary, Headline: Gilead Sciences Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. sank 0.29% to $78.62 Monday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500...",GILD
212,2023-05-23,"Headline: My Dividend Stock Portfolio: New April Dividend Record - 99 Holdings With 21 Buys, source:SeekingAlpha, summary: Markets are racing higher as earnings season turned out much better than expected. Click here to read more., Headline: Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 0.05% to $78.58 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500..., Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: No summary",GILD
213,2023-05-24,"Headline: 14 Best Healthcare Dividend Stocks to Buy, source:Yahoo, summary: In this article, we will take a look at 14 best healthcare dividend stocks to buy. You can skip our detailed analysis of the healthcare sector and dividend stocks, and go directly to read 5 Best Healthcare Dividend Stocks to Buy. The healthcare sector in the US encompasses a wide range of providers, facilities, and […], Headline: Cramer's Lightning Round: Stay away from Gilead Sciences, source:CNBC, summary: ""Mad Money"" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed., Headline: Lightning Round: Cloudflare has had a couple bad quarters but should be able to 'get it together', source:CNBC, summary: Mad Money' host Jim Cramer weighs in on stocks including: RB Global, Cloudflare, Bank of Hawaii, Mosaic Co., Gilead Sciences, and Lendingtree., Headline: Gilead Sciences Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: No summary",GILD
214,2023-05-25,"Headline: 14 Best Biotech Stocks To Buy According To Hedge Funds, source:Yahoo, summary: In this piece, we will take a look at 14 best biotechnology stocks to buy according to hedge funds. For more stocks, head on over to 5 Best Biotech Stocks To Buy According To Hedge Funds. Biotechnology is one of the hottest sectors these days. A handful of industries, such as space exploration, artificial intelligence, […], Headline: Gilead call volume above normal and directionally bullish, source:Thefly.com, summary: No summary, Headline: Here's Why Gilead Sciences (NASDAQ:GILD) Can Manage Its Debt Responsibly, source:Yahoo, summary: The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says..., Headline: How Gilead’s Supportive Culture Helps Working Parents: LJ’s Story, source:Yahoo, summary: NORTHAMPTON, MA / ACCESSWIRE / May 25, 2023 / Gilead Sciences When LJ Mizzi joined Gilead in 2013, she already had a personal connection to the company. ""A Gilead medicine saved the life of a loved one, so I was excited to begin a career here ..., Headline: Gilead Sciences Stock Reaches 80-Plus Relative Strength Rating Benchmark, source:Yahoo, summary: Gilead Sciences shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81., Headline: Gilead Sciences to Present at Upcoming Investor Conference, source:Yahoo, summary: FOSTER CITY, Calif., May 25, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:",GILD
215,2023-05-26,"Headline: Gilead announces CHMP reccomendation for the use of Veklury, source:Thefly.com, summary: No summary, Headline: CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis, source:Yahoo, summary: FOSTER CITY, Calif., May 26, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) granted a positive opinion for the use of Veklury® (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. The European Commission (EC) will review the CHMP recommendation and, if adopted, Veklury will become the first and only authorized antiviral COVID-19 treatment that, Headline: Gilead's COVID drug Veklury gets EMA greenlight for expanded use, source:Seeking Alpha, summary: No summary, Headline: TD Cowen pharma/biotech analysts hold an analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Drugmakers Released a Ton of New Cancer Treatment Data. The Biggest Developments., source:MarketWatch, summary: Ahead of the American Society of Clinical Oncology meeting, Pfizer, Merck, and other companies released scientific abstracts of papers that they'll present..., Headline: 10 Health Care Stocks Whale Activity In Today's Session, source:Benzinga, summary: No summary, Headline: Gilead's (GILD) Veklury Gets Positive CHMP View for Extended Use, source:Yahoo, summary: Gilead (GILD) obtains positive opinion for the use of Veklury in COVID-19 patients with severe renal impairment, including those on dialysis, from the European Medicines Agency's CHMP., Headline: Gilead's Veklury gets positive opinion from EU's CHMP for Covid, source:Alliance News, summary: No summary, Headline: Gilead Sciences Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 0.72% to $77.09 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",GILD
216,2023-05-27,"Headline: Stocks Going Ex-Dividend In June 2023, source:TalkMarkets, summary: No summary",GILD
217,2023-05-28,"Headline: Drug pricing watchdog raises alarm over upcoming liver disease meds, source:Seeking Alpha, summary: No summary",GILD
218,2023-05-29,"Headline: Oppenheimer biotech analyst to hold a reception, source:Thefly.com, summary: No summary",GILD
219,2023-05-30,"Headline: Gilead Sciences (NASDAQ:GILD) Is Paying Out A Larger Dividend Than Last Year, source:Yahoo, summary: Gilead Sciences, Inc.'s ( NASDAQ:GILD ) dividend will be increasing from last year's payment of the same period to..., Headline: Gilead Sciences Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. dropped 0.99% to $76.33 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P...",GILD
220,2023-05-31,"Headline: Gain Therapeutics: Undervalued Based On Drug Development Platform And Lead Parkinson's Asset, source:SeekingAlpha, summary: Gain Therapeutics is furthering drug development in unique way and SEE-Tx platform may be useful for a larger pharma company. See why I rate GANX a strong buy., Headline: Bilal Piperdi on How Gilead Is Striving To Create New Possibilities for People With Lung Cancer, source:Yahoo, summary: After finishing medical school in the late 1990s, Bilal Piperdi wanted to follow his mentor into the field of thoracic oncology, the specialized area that focuses on lung cancer., Headline: Gilead: Pharma Play Worth Watching On Multitude Of ASCO Data Readouts, source:SeekingAlpha, summary: Gilead Sciences, Inc. is expected to offer 30 Abstract Presentations at the ASCO 2023 meeting to be held between June 2 - 6 of 2023. Click here for more on GILD stock., Headline: 2 Large Cap Biotech Stocks To Watch Right Now, source:StockMarket, summary: Large-cap biotech stocks to check out in the stock market today.",GILD
221,2023-06-01,"Headline: July 14th Options Now Available For Gilead Sciences, source:Stock Options Channel, summary: No summary, Headline: Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA, source:Yahoo, summary: FOSTER CITY, Calif. & SANTA MONICA, Calif., June 01, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the upcoming 2023 European Hematology Association (EHA) Annual Congress being held in Frankfurt, Germany, June 8-11, and virtually June 14-15., Headline: 15 Best Healthcare Stocks To Buy Now, source:Yahoo, summary: In this article, we will take a look at the 15 best healthcare stocks to buy now. For more stocks, head on over to 5 Best Healthcare Stocks To Buy Now. In the midst of uncertain economic conditions globally, the healthcare sector has displayed a notable degree of resilience. Historically, the demand for healthcare products […], Headline: Gilead Sciences Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slumped 0.95% to $76.21 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: Catalyst Watch: Apple's WWDC event, OPEC fallout and REITs on display, source:Seeking Alpha, summary: No summary, Headline: Cantor Fitzgerald biotech analyst to hold analyst/industry conference call, source:Thefly.com, summary: No summary",GILD
222,2023-06-02,"Headline: Oppenheimer biotech analyst to hold a reception, source:Thefly.com, summary: No summary, Headline: Gilead continues to make regulatory progress, says Argus, source:Thefly.com, summary: No summary, Headline: 3 Undervalued Biotech Stocks to Buy Before They Blast Off, source:Yahoo, summary: When investors hear the words “undervalued biotech stocks to buy,” they frequently think of companies in the clinical trial stage. That’s understandable. If you can buy a company’s stock before it releases a game-changing drug or therapeutic into the market, you can make a fortune. That line of thinking was displayed in 2020 when many biotech companies raced to produce a Covid-19 vaccine. But every investor also knows that many of those moonshots never pan out. That’s not the kind of uncertainty, Headline: Gilead Sciences Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rose 2.20% to $77.89 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P..., Headline: Gilead, Arcus announce updated results from interim analysis of ARC-7 study, source:Thefly.com, summary: No summary",GILD
223,2023-06-03,"Headline: 3 Dividend Stocks You Can Buy Without Any Hesitation, source:Yahoo, summary: Three Motley Fool contributors identified dividend stocks that should be easy buy decisions for investors.  Here's why they think Bristol Myers Squibb (NYSE: BMY), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE) are investments you can make in June without any hesitation.  David Jagielski (Bristol Myers Squibb):  Bristol Myers Squibb has been paying dividends for more than 90 consecutive years., Headline: Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study, source:Yahoo, summary: FOSTER CITY, Calif., & HAYWARD, Calif., June 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced updated results from an interim analysis of the ARC-7 study in patients with first-line, metastatic non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutations. ARC-7 is the first Phase 2, randomized, open-label study evaluating the comb",GILD
224,2023-06-04,"Headline: Wall Street Breakfast: The Week Ahead, source:SeekingAlpha, summary: Investors head into next week with the debt ceiling crisis resolved for the near term., Headline: Mizuho Securities Keeps Their Buy Rating on Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Those who invested in Gilead Sciences (NASDAQ:GILD) a year ago are up 28%, source:Yahoo, summary: Passive investing in index funds can generate returns that roughly match the overall market. But investors can boost..., Headline: Biotech stocks could soon get a M&A boost. Here are 3 likely takeover plays., source:MarketWatch, summary: No summary, Headline: Gilead says new lung cancer antibody still improving survival rates, source:Alliance News, summary: No summary",GILD
225,2023-06-05,"Headline: Gilead Sciences (GILD) Receives a Buy from BMO Capital, source:TipRanks, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), IGM Biosciences (IGMS) and GT Biopharma (GTBP), source:TipRanks, summary: No summary, Headline: Kite's Yescarta CAR T-cell therapy shows longer OS vs. SOC in study, source:Thefly.com, summary: No summary, Headline: Gilead: Trodelvy delivered meaningful improvement in median OS in study, source:Thefly.com, summary: No summary, Headline: IN BRIEF: Gilead says Trodelvy shows survival advantage in study, source:Alliance News, summary: No summary, Headline: Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma, source:Yahoo, summary: SANTA MONICA, Calif., June 05, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announces detailed results from the overall survival (OS) analysis of the landmark Phase 3 ZUMA-7 study of Yescarta® (axicabtagene ciloleucel [axi-cel]) CAR T-cell therapy compared with historical standard of care (SOC) as initial treatment in the curative setting for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL). Yescarta is the first treatment in nearly 30 years to demonstrate a significan, Headline: Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer, source:Yahoo, summary: FOSTER CITY, Calif., June 05, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced longer-term overall survival (OS) results from the Phase 3 TROPiCS-02 study evaluating Trodelvy® (sacituzumab govitecan-hziy) versus comparator chemotherapy (physicians’ choice of chemotherapy, TPC) in patients with HR+/HER2- (IHC0, IHC1+, IHC2+/ISH-) metastatic breast cancer who received endocrine-based therapies and at least two chemotherapies. In this exploratory analysis, Trodelvy demonstrated a clinical, Headline: Gilead Sciences Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. dropped 0.22% to $77.72 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P..., Headline: Gilead (GILD), Arcus Announce Results From Mid-Stage NSCLC Study, source:Yahoo, summary: Gilead (GILD) and Arcus announce data from the interim analysis of the mid-stage ARC-7 study on domvanalimab in the NSCLC study., Headline: Barclays Reaffirms Their Hold Rating on Gilead Sciences (GILD), source:TipRanks, summary: No summary",GILD
226,2023-06-06,"Headline: Why Gilead Sciences is a Top Socially Responsible Dividend Stock (GILD), source:ETF Channel, summary: No summary, Headline: Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today, source:Benzinga, summary: No summary, Headline: Gilead says Tecartus demonstrates 78% CR rate in real-world evidence analysis, source:Thefly.com, summary: No summary, Headline: U.S. Wide-Moat Stocks On Sale - The June 2023 Heat Map, source:SeekingAlpha, summary: Our 3-step process focuses on wide-moat stocks (as per Morningstarâs rating). Click here to see the heat map of the most investable candidates for June 2023., Headline: Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma, source:Yahoo, summary: SANTA MONICA, Calif., June 06, 2023--Kite, a Gilead Company (Nasdaq: GILD), today announces findings from the largest real-world analysis to date of Tecartus® (brexucabtagene autoleucel) in patients with relapsed or refractory mantle cell lymphoma (R/R MCL), which show that outcomes of Tecartus therapy had consistent high complete response (CR) and overall response rates (ORR), regardless of type of prior treatment, including: Bruton's tyrosine kinase inhibitor (BTKi), bendamustine or autologous, Headline: Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 1.96% to $76.20 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P..., Headline: IN BRIEF: Gilead reports Tecartus study shows good response rates, source:Alliance News, summary: No summary",GILD
227,2023-06-07,"Headline: AbTherx Announces License Agreement with Gilead, source:Yahoo, summary: AbTherx, Inc., a privately held biotech company focused on accelerating the discovery and development of antibody therapeutics, today announced a license agreement with Gilead Sciences, Inc. (NASDAQ:GILD). The license agreement will provide AbTherx rights to Gilead's recently acquired novel transgenic mouse technologies, which were developed by three of the AbTherx founders., Headline: Gilead Sciences Enters Oversold Territory, source:Dividend Channel, summary: No summary, Headline: 3 Biotech Stocks That Could Skyrocket in the Next 12 Months, source:Yahoo, summary: Navigating the turbulent waters in the biotech space is no mean feat. With the sector’s inherent volatility due to testing clinical trials and regulatory hurdles, the road toward market approval can be incredibly challenging. However, for the savvy investor, promising biotech stocks to buy can translate into significant returns. According to Grand View Research, the global biotech market reached an impressive $1.37 trillion valuation last year. Additionally, analysts anticipate a compound annual, Headline: Gilead Sciences: Living with a Rare Blood Cancer: Marion’s Story, source:Yahoo, summary: Marion grew up very healthy, never even getting colds or the flu - but that changed as she got older., Headline: Gilead Sciences, Inc. (GILD) Jefferies Global Healthcare Conference Transcript, source:SeekingAlpha, summary: Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Jefferies Global Healthcare Conference June 7, 2023 11:00 AM ETCompany ParticipantsJohanna Mercier - Chief Commercial OfficerConference Call..., Headline: Gilead Sciences Inc. stock falls Wednesday, still outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. sank 0.16% to $76.08 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the Dow..., Headline: Gilead Sciences (GILD) Stock Moves -0.16%: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed the most recent trading day at $76.08, moving -0.16% from the previous trading session., Headline: Gilead Sciences (GILD) Shares Cross Above 200 DMA, source:Dividend Channel, summary: No summary",GILD
228,2023-06-08,"Headline: Bank of America Securities Sticks to Their Hold Rating for Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Interesting GILD Put And Call Options For July 28th, source:Stock Options Channel, summary: No summary, Headline: Gilead Sciences Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rose 3.05% to $78.40 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P..., Headline: Pfizer Or Gilead Sciences? Let's Ask Peter Lynch, source:SeekingAlpha, summary: This article employs Lynch's approach to evaluate Pfizer and Gilead Sciences. Read on to see which of the two is a better dividend stock according to Peter Lynch.",GILD
229,2023-06-09,"Headline: Cantor Fitzgerald biotech analyst to hold analyst/industry conference call, source:Thefly.com, summary: No summary, Headline: Gilead Sciences, Inc. (NASDAQ:GILD) Will Pay A US$0.75 Dividend In Four Days, source:Yahoo, summary: It looks like Gilead Sciences, Inc. ( NASDAQ:GILD ) is about to go ex-dividend in the next 4 days. The ex-dividend date..., Headline: 10 Health Care Stocks With Whale Alerts In Today's Session, source:Benzinga, summary: No summary, Headline: 2 Top Biotech Stocks to Buy in June, source:Yahoo, summary: Biotech stocks have taken investors on an unpredictable ride so far in 2023.  Two of the better biotech stocks I see this month are Gilead Sciences (NASDAQ: GILD) and Vertex Pharmaceuticals (NASDAQ: VRTX).  While Gilead's shares are down more than 11% so far this year, Vertex's shares are up more than 14%., Headline: Gilead Sciences Inc. stock underperforms Friday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 0.36% to $78.12 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",GILD
230,2023-06-11,"Headline: Dividend Champion, Contender, And Challenger Highlights: Week Of June 11, source:SeekingAlpha, summary: A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the full weekly update.",GILD
231,2023-06-12,"Headline: IN BRIEF: Guild Esports signs deal to build 'sim racing' facility, source:Alliance News, summary: No summary, Headline: 5 Stocks to Buy With Explosive 500% Potential, source:InvestorPlace, summary: No summary, Headline: Gilead Sciences, Inc. (GILD) Goldman Sachs 44th Annual Global Healthcare Conference (Transcript), source:SeekingAlpha, summary: Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Goldman Sachs 44th Annual Global Healthcare Conference June 12, 2023 1:40 PM ETCompany ParticipantsDaniel OâDay - Chairman & CEOMerdad Parsey..., Headline: Gilead Sciences Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slumped 0.33% to $77.86 Monday, on what proved to be an all-around favorable trading session for the stock market, with the...",GILD
232,2023-06-13,"Headline: Gilead Sciences (NASDAQ:GILD) Is Increasing Its Dividend To $0.75, source:Yahoo, summary: Gilead Sciences, Inc. ( NASDAQ:GILD ) has announced that it will be increasing its dividend from last year's comparable..., Headline: Top 20 Most Profitable Pharmaceutical Companies In The World, source:Yahoo, summary: In this article, we will be covering the top 20 most profitable pharmaceutical companies in the world. If you wish to see the top ones, head straight to the Top 5 Most Profitable Pharmaceutical Companies In The World. Undoubtedly, the pharmaceutical industry stands as one of the most financially rewarding and essential sectors worldwide, leading […], Headline: Gilead Sciences goes ex dividend tomorrow, source:Seeking Alpha, summary: No summary, Headline: Gilead Sciences Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.76% higher to $78.45 Tuesday, on what proved to be an all-around positive trading session for the stock market, with..., Headline: Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed the most recent trading day at $78.45, moving +0.76% from the previous trading session.",GILD
233,2023-06-14,"Headline: Gilead to Present Latest Liver Disease Research at the European Association for the Study of the Liver (EASL) Congress 2023, source:Yahoo, summary: FOSTER CITY, Calif., June 14, 2023--Gilead Sciences, Inc. (Nasdaq:GILD) today announced new data to be presented at the European Association for the Study of the Liver (EASL) Congress 2023, June 21-24, 2023. Key findings from more than 70 presentations will include Week 96 data from the pivotal Phase 3 study of Hepcludex® (bulevirtide) evaluating the efficacy and safety for the treatment of hepatitis delta virus (HDV) and late-breaking data on the impact of continued treatment with bulevirtide., Headline: My Dividend Stock Portfolio: New All-Time Dividend Record - 99 Holdings With 25 Buys, source:SeekingAlpha, summary: US stocks ended May with solid gains and extended their strong performance into June, boosted by positive labor market data and the debt ceiling bill's progress., Headline: Asian American Women Engineers Find Community and Purpose at Gilead, source:Yahoo, summary: NORTHAMPTON, MA / ACCESSWIRE / June 14, 2023 / Gilead Sciences When Vicky Choi began her career as an engineer, she noticed that women and Asian people overall were well represented in the field - but that Asian women weren't reflected in upper ..., Headline: Gilead Sciences Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.32% higher to $77.95 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with..., Headline: Galapagos appoints Thad Huston as CFO and COO as of July 1, source:Thefly.com, summary: No summary",GILD
234,2023-06-15,"Headline: Arcus Biosciences: Gilead Partnered TIGIT Pioneer Excites But Frustrates, source:Seeking Alpha, summary: No summary, Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rose 1.35% to $79.00 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&P...",GILD
235,2023-06-16,"Headline: Gilead Sciences Inc. stock falls Friday, still outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slumped 0.18% to $78.86 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P...",GILD
236,2023-06-18,"Headline: How to Retire Rich: Biotech Stocks Edition, source:Yahoo, summary: Among the most difficult endeavors when it comes to deciphering the best retirement planning stocks is to identify companies that will remain relevant for years, if not decades to come. While no guarantees exist for anything, those who focus on investing in biotech own a clear advantage. Almost surely, the underlying sector – which falls under the broad healthcare industry – is permanently relevant. Further, I submitted a query on ChatGPT to extract key reasons why biotech stocks for retirement",GILD
237,2023-06-19,"Headline: PBE: Healthcare Dashboard For June, source:SeekingAlpha, summary: Pharma/biotechnology and healthcare providers are slightly undervalued relative to 11-year averages. Click here for the June edition of the Healthcare Dashboard.",GILD
238,2023-06-20,"Headline: IN BRIEF: Guild Esports completes fundraise for working capital, source:Alliance News, summary: No summary, Headline: Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death, source:Yahoo, summary: The FDA placed a study of Arcellx's multiple myeloma drug on hold after a patient died, leading ACLX stock to crumble Tuesday., Headline: Gilead Sciences Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 1.46% to $77.71 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500..., Headline: Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed the most recent trading day at $77.71, moving -1.46% from the previous trading session.",GILD
239,2023-06-21,"Headline: Arcellx's CAR-T Hold: Turmoil, Triumphs, And Trading Tips, source:SeekingAlpha, summary: Arcellx's CART-ddBCMA program faces a clinical hold due to a patient's death. Find out why I advise investors to hold ACLX stock., Headline: Gilead Sciences Supports the LGBTQ+ Community in Oakland: Love Is the Answer, source:Yahoo, summary: NORTHAMPTON, MA / ACCESSWIRE / June 21, 2023 / Gilead Sciences: As a young gay man growing up in Detroit, Joe Hawkins witnessed the stigma and discrimination against the LGBTQ+ community. And when he entered the military in the 1980s, during the ..., Headline: 2 Biotech Stocks You Can Buy and Hold for the Next Decade, source:Yahoo, summary: Biotech companies use living organisms to develop their therapies, and much like some living things, biotech stocks can be notoriously volatile.  Part of that is due to the complexities of making biotech therapies.  The success rate for biotech start-ups is low, but Gilead Sciences (NASDAQ: GILD), founded 36 years ago and Regeneron Pharmaceuticals (NASDAQ: REGN), founded 35 years ago, have already stood the test of time., Headline: Gilead Sciences Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. sank 0.13% to $77.61 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",GILD
240,2023-06-22,"Headline: Gilead announces completion of marketing authorization in Japan for Yescarta, source:Thefly.com, summary: No summary, Headline: Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan, source:Yahoo, summary: SANTA MONICA, Calif., June 22, 2023--Kite Pharma, Inc., a Gilead Company (Nasdaq: GILD), today announced that the Marketing Authorization in Japan for Yescarta® (axicabtagene ciloleucel), a chimeric antigen receptor (CAR) T-cell therapy, has been transferred from Daiichi Sankyo Co., Ltd. to Gilead Sciences K.K., the Japan subsidiary of Gilead Sciences, Inc., Headline: Gilead notes transfer of Yescarta marketing authorisation from Daiichi, source:Alliance News, summary: No summary, Headline: Gilead Sciences Inc. stock rises Thursday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.64% higher to $78.11 Thursday, on what proved to be an all-around mixed trading session for the stock market, with...",GILD
241,2023-06-23,"Headline: Gilead announces Week 96 results from MYR301 clinical trial, source:Thefly.com, summary: No summary, Headline: IN BRIEF: Guild Esports inks one-year deal with Secretlab for chairs, source:Alliance News, summary: No summary, Headline: Hepcludex® (Bulevirtide) Demonstrates Sustained Efficacy and Safety Profile in People With Chronic Hepatitis Delta Virus at 96 Weeks, source:Yahoo, summary: FOSTER CITY, Calif., June 23, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced Week 96 results from the pivotal MYR301 Phase 3 clinical trial evaluating the first-in-class entry inhibitor Hepcludex® (bulevirtide) for the treatment of adults with chronic hepatitis delta (HDV) infection. These new data presented at the European Association for the Study of the Liver (EASL) Congress 2023 reinforce the role of bulevirtide as an efficacious and well-tolerated treatment for the management of, Headline: Gilead announces CHMP recommendation for the use of Trodelvy, source:Thefly.com, summary: No summary, Headline: Gilead's Trodelvy for breast cancer endorsed by EMA panel, source:Seeking Alpha, summary: No summary, Headline: Gilead Gets Positive European Opinion for Additional Indication for Trodelvy, source:MarketWatch, summary: By Robb M. Stewart Gilead Sciences has received a positive response from the European Medicines Agency's Committee for Medicinal Products for Human Use on an..., Headline: Analysts Conflicted on These Healthcare Names: Gilead Sciences (GILD), Sarepta Therapeutics (SRPT) and Intra-Cellular Therapies (ITCI), source:TipRanks, summary: No summary, Headline: Gilead Receives CHMP Positive Opinion for Trodelvy® in Pre-Treated HR+/HER2- Metastatic Breast Cancer, source:Yahoo, summary: FOSTER CITY, Calif., June 23, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for Trodelvy® (sacituzumab govitecan) as monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the adva, Headline: IN BRIEF: Gilead Sciences says test results show Hepcludex effective, source:Alliance News, summary: No summary, Headline: Gilead's Chronic Hepatitis Delta Infection Treatment Shows Sustained Efficacy, Safety Profile At Two Years, source:Yahoo, summary: Gilead Sciences Inc (NASDAQ: GILD) announced Week 96 results from the MYR301 Phase 3 clinical trial evaluating bulevirtide for chronic hepatitis delta (HDV) infection. Bulevirtide is the only approved treatment for HDV in Europe and is not approved in the U.S. The Week 96 findings demonstrated improved combined response compared to Week 48, with no signs of treatment resistance and sustained virologic response with continued bulevirtide monotherapy. Prolonged bulevirtide treatment showed clinica, Headline: Gilead Sciences Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slipped 0.82% to $77.47 Friday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500..., Headline: Gilead Sciences (GILD) Announces Positive HDV Treatment Data, source:Yahoo, summary: Gilead Sciences, Inc. (GILD) announces data on Hepcludex that reinforces the potential of bulevirtide as an effective and well-tolerated treatment for chronic HDV after 96 weeks.",GILD
242,2023-06-25,"Headline: Dividend Champion, Contender, And Challenger Highlights: Week Of June 25, source:SeekingAlpha, summary: A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read more to see the June 25th weekly update., Headline: GILD Crosses Above 4% Yield Territory, source:Dividend Channel, summary: No summary",GILD
243,2023-06-26,"Headline: Gilead Sciences Inc. stock underperforms Monday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slipped 1.17% to $76.56 Monday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500..., Headline: Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion, source:Yahoo, summary: Gilead's breast cancer drug Trodelvy gets positive CHMP opinion for a second indication in Europe., Headline: Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed the most recent trading day at $76.56, moving -1.17% from the previous trading session.",GILD
244,2023-06-27,"Headline: Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slipped 0.72% to $76.01 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with the..., Headline: 10 Martin Shkreli Stock Picks and Their Performance, source:Yahoo, summary: In this article, we will take a look at the 10 Martin Shkreli stock picks and their performance. To see more such companies, go directly to 5 Martin Shkreli Stock Picks and Their Performance. Martin Shkreli a.k.a. “Pharma Bro” is known for a variety of reasons, many of which are tinged with notoriety. He cofounded […]",GILD
245,2023-06-28,"Headline: Gilead Sciences adds $10.99M to AlloVir stake, source:Thefly.com, summary: No summary, Headline: Gilead Sciences Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.22% higher to $76.18 Wednesday, on what proved to be an all-around grim trading session for the stock market, with..., Headline: Gilead Sciences' Debt Overview, source:Benzinga, summary: No summary, Headline: Looking Into Gilead Sciences's Recent Short Interest, source:Benzinga, summary: No summary",GILD
246,2023-06-29,"Headline: A Drug for Itchy Dogs Costs $1,200. Why Is the Human Equivalent $43,000?, source:Yahoo, summary: If your eczema is making you itchy, your doctor might prescribe Dupixent, a Sanofi monoclonal antibody therapy with a U.S. list price of around $43,000 a year.  On a biological level, there’s little difference between them: Dupixent targets proteins in the human immune system called interleukin-4 and interleukin- 13, while Cytopoint targets a protein in the dog immune system called interleukin-31.  While Cytopoint was licensed by the U.S. Department of Agriculture, Zoetis’ (ticker: ZTS) other two monoclonal antibodies were approved by the Food and Drug Administration., Headline: GILD August 11th Options Begin Trading, source:Stock Options Channel, summary: No summary, Headline: With 85% ownership, Gilead Sciences, Inc. (NASDAQ:GILD) boasts of strong institutional backing, source:Yahoo, summary: Key Insights Institutions' substantial holdings in Gilead Sciences implies that they have significant influence over..., Headline: Hepatitis C cure is not reaching overwhelming majority of patients due to financial barriers, source:CNBC, summary: Hepatitis C is often referred to as the silent killer because the initial infection has few to no symptoms. , Headline: Gilead Sciences Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slumped 0.22% to $76.01 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P...",GILD
247,2023-06-30,"Headline: Amgen Inc. Dividend Stock Analysis, source:TalkMarkets, summary: No summary, Headline: This Is What Whales Are Betting On Gilead Sciences, source:Benzinga, summary: No summary, Headline: Medicare revises guidance on drug price negotiations amid lawsuits, source:Seeking Alpha, summary: No summary, Headline: 10 Health Care Stocks With Whale Alerts In Today's Session, source:Benzinga, summary: No summary, Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. advanced 1.39% to $77.07 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P..., Headline: Gilead Sciences : Prevails in HIV Antitrust Trial, source:Finnhub, summary: Foster City, Calif., June 30, 2023 - Gilead Sciences, Inc.  announced today that a jury in the U.S. District Court for the Northern District of California returned a verdict in favor..., Headline: AlloVir: Several Late-Stage Programs Make This Worth A Look, source:SeekingAlpha, summary: A good thing about AlloVir is that it is already having its drug posoleucel being explored in several phase 3 studies. Read more about ALVR here.",GILD
248,2023-07-01,"Headline: Gilead, Teva acquitted in pay for delay generic HIV drugs case, source:Seeking Alpha, summary: No summary",GILD
249,2023-07-03,"Headline: Gilead receives positive verdict from US court in HIV antitrust trial, source:Alliance News, summary: No summary, Headline: HQH: Deep Discount Presents An Opportunity, source:SeekingAlpha, summary: Tekla Healthcare Investors focuses on biotech subsector of healthcare, leading to potential volatility and potential for high returns. Read my analysis of HQH., Headline: Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed at $76.72 in the latest trading session, marking a -0.46% move from the prior day.",GILD
250,2023-07-04,"Headline: Guild Esports sees shares rise on first British F4 Esports entry, source:Alliance News, summary: No summary, Headline: Gilead Sciences: An Evolving Biopharma Navigating Through Challenges And Opportunities, source:SeekingAlpha, summary: Gilead's Q1 2023 revenues fell to $6.4bn, offset by positive developments in their promising oncology drug, Trodelvy. See why GILD stock is a Hold.",GILD
251,2023-07-05,"Headline: Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amneal Pharmaceuticals (AMRX), Replimune Group (REPL) and Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Why the 5 Highest-Yielding Nasdaq Stocks Could Rip Higher With the Red-Hot Summer Rally, source:247WallSt, summary: No summary, Headline: NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment, source:Benzinga, summary: No summary, Headline: Gilead Sciences (GILD) Gets a Buy from Jefferies, source:TipRanks, summary: No summary, Headline: Those who invested in Gilead Sciences (NASDAQ:GILD) a year ago are up 27%, source:Yahoo, summary: The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by..., Headline: Gilead Sciences Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.68% higher to $77.24 Wednesday, on what proved to be an all-around poor trading session for the stock market, with..., Headline: The 3 Best Biotech Stocks to Buy In July, source:Yahoo, summary: Although it’s been a difficult year for biotechnology stocks, there are still plenty of reasons for investors to be bullish on the sector. Many of the biggest innovations in medicine are occurring at small and midsized biotech companies in the U.S. These are the incubators for medical advancements and where important scientific breakthroughs are happening. New products and treatments are boosting sales and earnings at biotech companies, making them great long-term investments. Although the S&P B",GILD
252,2023-07-06,"Headline: DBS Keeps Their Buy Rating on Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Gilead raises stake in Arcus Biosciences to 35%, source:Thefly.com, summary: No summary, Headline: U.S. Wide-Moat Stocks On Sale - The July 2023 Heat Map, source:SeekingAlpha, summary: Our 3-step process focuses on wide-moat stocks. We're only interested in targets attractively valued in historical comparison. Read what investors need to know., Headline: 4 Big Pharma Stocks On Sale Right Now , source:MarketWatch, summary: The key is to buy a basket of the cheap ones, so that gains in a few of them can offset disappointing performance in others., Headline: Gilead Sciences Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 1.29% to $76.24 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",GILD
253,2023-07-07,"Headline: Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Biogen (BIIB) and Crinetics Pharmaceuticals (CRNX), source:TipRanks, summary: No summary, Headline: 14 Best NASDAQ Dividend Stocks To Buy, source:Yahoo, summary: In this article, we discuss 14 best NASDAQ dividend stocks to buy. You can skip our detailed analysis of dividend stocks and their returns over the years, and go directly to read 5 Best NASDAQ Dividend Stocks To Buy. NASDAQ is commonly associated with technology and growth-oriented companies that usually don’t pay dividends but there […], Headline: Gilead Sciences Inc. stock falls Friday, underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. shed 2.39% to $74.42 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500...",GILD
254,2023-07-09,"Headline: Acumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023, source:Seeking Alpha, summary: No summary, Headline: Fly Intel: Top five weekend stock stories, source:Thefly.com, summary: No summary, Headline: Pfizer among big pharma stocks on sale right now, Barron's says, source:Thefly.com, summary: No summary, Headline: Goldman Sachs sees rays of hope in underperforming health sector, source:Seeking Alpha, summary: No summary, Headline: Gilead call volume above normal and directionally bullish, source:Thefly.com, summary: No summary",GILD
255,2023-07-10,"Headline: Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?, source:Benzinga, summary: No summary, Headline: RBC Capital Keeps Their Hold Rating on Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt, source:Yahoo, summary: David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the..., Headline: Gilead Sciences Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. advanced 1.71% to $75.69 Monday, on what proved to be an all-around positive trading session for the stock market, with the..., Headline: AlloVir: 'Takes One To Know One', source:SeekingAlpha, summary: Allovir's lead product, posoleucel, is in Phase III clinical trials and targets six viral pathogens in immunocompromised individuals. Find out why ALVR stock is a Strong Buy.",GILD
256,2023-07-11,"Headline: Gilead price target lowered to $81 from $84 at Barclays, source:Thefly.com, summary: No summary, Headline: Barclays Sticks to Their Hold Rating for Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Wells Fargo highlights Nasdaq 100 rebalance trade opportunities, source:Seeking Alpha, summary: No summary, Headline: Starbucks and 6 More Stocks That Could Get a Boost From the Nasdaq 100 Rebalance, source:MarketWatch, summary: Starbucks, Mondelez, and Booking are among the possible outperformers from the index’s weighting changes, according to Wells Fargo., Headline: Barclays Maintains Gilead Sciences (GILD) Equal-Weight Recommendation, source:Fintel, summary: nan, Headline: Morgan Stanley Reiterates Gilead Sciences (GILD) Equal-Weight Recommendation, source:Fintel, summary: nan, Headline: Gilead Sciences Inc. stock rises Tuesday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.57% higher to $76.12 Tuesday, on what proved to be an all-around great trading session for the stock market, with the..., Headline: 7 Tech Stocks to Watch on July 14, source:InvestorPlace, summary: No summary, Headline: Gilead Just Bought $30 Million More of 2 Biotech Stocks, source:MarketWatch, summary: Gilead recently increased stakes in AlloVir, a developer of drugs to treat or prevent viral diseases, and Arcus Biosciences, a biopharmaceutical firm...",GILD
257,2023-07-12,"Headline: ClearBridge All Cap Value Strategy Q2 2023 Portfolio Manager Commentary, source:SeekingAlpha, summary: The ClearBridge All Cap Value Strategy outperformed its Russell 3000 Value Index during the second quarter of 2023. Click here to read the full fund letter., Headline: 10 Health Care Stocks With Whale Alerts In Today's Session, source:Benzinga, summary: No summary, Headline: Gilead Sciences Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.34% higher to $76.38 Wednesday, on what proved to be an all-around positive trading session for the stock market,..., Headline: Half-Time Heroes: Moat Stocks Lead As Second Half Kicks Off, source:SeekingAlpha, summary: Morningstarâs strategy of focusing on quality companies at attractive prices has powered its Moat Index to its strongest first-half performance since 2007, putting it ahead of the S&P 500.",GILD
258,2023-07-13,"Headline: Gilead announces two public-private partnerships, source:Thefly.com, summary: No summary, Headline: Gilead inks deals to improve HIV treatment uptake in children, source:Seeking Alpha, summary: No summary, Headline: With The Massive NASDAQ Rebalance Coming Soon 7 ‘Strong Buy’ Stocks Could Explode Higher, source:247WallSt, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and Regeneron (REGN), source:TipRanks, summary: No summary, Headline: Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries, source:Yahoo, summary: FOSTER CITY, Calif., July 13, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) is pleased to announce two public-private partnerships. The first will accelerate the development of an investigational dispersible pediatric formulation containing emtricitabine and tenofovir alafenamide (F/TAF). The second aims to develop investigational pediatric formulations of TAF and sofosbuvir (SOF) designed to eliminate bitterness., Headline: Interesting GILD Put And Call Options For September 1st, source:Stock Options Channel, summary: No summary, Headline: Gilead: Assessing How Shares Will Trade Over Upcoming Months (Technical Analysis), source:SeekingAlpha, summary: Gilead Sciences' 12-month dividend growth rate of 2.8% is behind the inflation rate, suggesting a negative real return over the next year. Click here to read more., Headline: Gilead Sciences Inc. stock rises Thursday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.43% higher to $76.71 Thursday, on what proved to be an all-around great trading session for the stock market, with..., Headline: Gilead Sciences (GILD) Gains But Lags Market: What You Should Know, source:Yahoo, summary: In the latest trading session, Gilead Sciences (GILD) closed at $76.71, marking a +0.43% move from the previous day.",GILD
259,2023-07-14,"Headline: Gilead announces FDA approval of Veklury sNDA, source:Thefly.com, summary: No summary, Headline: Gilead Sciences says FDA has approved Veklury in COVID patients with severe kidney disease, source:MarketWatch, summary: No summary, Headline: Gilead Covid-19 Drug Remdesivir Cleared by FDA to Treat Renal Disease, source:Finnhub, summary: By Dean Seal 


  Gilead Sciences said regulators have approved its antiviral remdesivir, sold under the name brand Veklury, for Covid-19 patients with severe renal impairment, including those on..., Headline: IN BRIEF: Gilead gets FDA approval for Veklury to treat renal disease, source:Alliance News, summary: No summary, Headline: Gilead COVID therapy Veklury approved for those with renal impairment, source:Seeking Alpha, summary: No summary, Headline: FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis, source:Yahoo, summary: FOSTER CITY, Calif., July 14, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury® (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. With this approval, Veklury is now the first and only approved antiviral COVID-19 treatment that can be used across all stages of renal disease. More than 1 in 7 (37 million) people in the U.S., Headline: Gilead Sciences Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.63% higher to $77.19 Friday, on what proved to be an all-around mixed trading session for the stock market, with the..., Headline: More Challenges Await AbbVie Following A Disappointing Quarter, source:SeekingAlpha, summary: AbbVie Inc., one of the leaders in the global immunology market, will release its financial report for the second quarter of 2023. Click here to read more., Headline: FDA Approves Gilead's Remdesivir For COVID-19 Treatment Patients With Severe Renal Impairment, source:Yahoo, summary: The FDA approved Gilead Sciences Inc's (NASDAQ: GILD) supplemental new drug application for using Veklury (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. With this approval, Veklury is now the first and only approved antiviral COVID-19 treatment that can be used across all stages of renal disease. More than 1 in 7 (37 million) people in the U.S. are estimated to have chronic kidney disease (CKD) and are at increased risk of COVID-19-related morbidity, Headline: Dividend Income Update June 2023, source:SeekingAlpha, summary: The beginning of every month is exciting for all dividend income investors as we look back at the previous month and see how much passive dividend income our portfolios generated. ",GILD
260,2023-07-16,"Headline: Eli Lilly, Merck among top pharma picks in Barclays Q2 preview, source:Seeking Alpha, summary: No summary, Headline: Price Over Earnings Overview: Gilead Sciences, source:Benzinga, summary: No summary",GILD
261,2023-07-17,"Headline: IN BRIEF: Guild Esports signs digital advertising deal with Pixels AI, source:Alliance News, summary: No summary, Headline: Gilead Sciences to Release Second Quarter 2023 Financial Results on Thursday, August 3, 2023, source:Finnhub, summary: FOSTER CITY - Gilead Sciences, Inc.  announced today that its second quarter 2023 financial results and guidance will be released on Thursday, August 3, 2023 after the market closes.
At 5:00 p.m...., Headline: Buying These 2 Stocks Is a Good Way to Hedge Against a Market Crash, source:Yahoo, summary: If you're worried about the stock market crashing, then now is a good time to review your portfolio allocation.  Gilead (NASDAQ: GILD) is a biotechnology company with a broad portfolio of drugs focused on the treatment of HIV, viral hepatitis, and several cancers.  Gilead's pipeline also has dozens of candidates at various stages of development and clinical trials., Headline: Gilead's (GILD) Veklury Gets FDA Nod for Label Expansion, source:Yahoo, summary: Gilead's (GILD) antiviral treatment Veklury (remdesivir) has now been approved for the treatment of COVID-19 patients with severe renal impairment, including those on dialysis., Headline: Gilead Sciences Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.38% higher to $77.48 Monday, on what proved to be an all-around great trading session for the stock market, with the...",GILD
262,2023-07-18,"Headline: Gilead price target lowered to $95 from $100 at BMO Capital, source:Thefly.com, summary: No summary, Headline: SARS-CoV-2 Is Not Done Yet — Could This New Drug In Clinical Trials Be The Safest Option For Treating COVID-19?, source:Benzinga, summary: No summary, Headline: My Dividend Stock Portfolio: New June Dividend Record - 99 Holdings With 28 Buys, source:SeekingAlpha, summary: The broad S&P500 edged up 1.2% in June, while the Dow Jones rose slightly by 0.8% during the month. Click here to see my complete dividend stock portfolio list., Headline: Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today, source:Benzinga, summary: No summary, Headline: Gilead Sciences Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.96% higher to $78.22 Tuesday, on what proved to be an all-around favorable trading session for the stock market, with...",GILD
263,2023-07-19,"Headline: Gilead price target lowered to $80 from $85 at Cantor Fitzgerald, source:Thefly.com, summary: No summary, Headline: Peering Into Gilead Sciences's Recent Short Interest, source:Benzinga, summary: No summary, Headline: 3 Healthcare Stocks to Buy and Hold for the Next 10 Years, source:Yahoo, summary: The healthcare sector is unlikely to become obsolete anytime soon, but individual companies can very much get left behind if they fail to keep up with the changing dynamics of the industry.  Let's look at three healthcare stocks that are leaders or innovators in their respective niches and could provide excellent returns in the next 10 years: Vertex Pharmaceuticals (NASDAQ: VRTX), Moderna (NASDAQ: MRNA), and Gilead Sciences (NASDAQ: GILD).  Vertex Pharmaceuticals has soundly beaten the market in the past 10 years, and the company is in an excellent position to do so in the next decade., Headline: Gilead Showcases Latest HIV Pipeline Progress and the Impact of Global Collaboration on Health Equity Efforts at IAS 2023, source:Yahoo, summary: FOSTER CITY, Calif., July 19, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming contributions to the 12th International AIDS Society Conference on HIV Science (IAS 2023), taking place in Brisbane, Australia, and virtually, from July 23-26, 2023. As the leader in HIV innovation, Gilead will provide updates on its signature initiatives and key collaborations while sharing new scientific data from its research and development programs. The breadth of data presented at the meet, Headline: Gilead Sciences: Putting a Spotlight on the Mental Health Needs of LGBTQ+ Youth, source:Yahoo, summary: Across the country, LGBTQ+ youth face challenges that are negatively affecting their mental health. Some find themselves not feeling accepted by their family or friends, or being verbally harassed at school., Headline: The 7 Most Undervalued Nasdaq Stocks to Buy Now: July 2023, source:Yahoo, summary: The Nasdaq is known for its high-flying growth stocks, and with good reason. But there’s more to the index than just those aggressive names. In fact, there are even many Nasdaq stocks suitable for people following value investing strategies. The Nasdaq isn’t just a technology index either. There are Nasdaq stocks to buy in industries as diverse as telecom, banks, and financial service companies. The Nasdaq 100 Index has been off to a roaring start in the first half of this year. But fear not; th, Headline: Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: Gilead Sciences (GILD) closed the most recent trading day at $78.96, moving +0.95% from the previous trading session.",GILD
264,2023-07-20,"Headline: Bullish Two Hundred Day Moving Average Cross - GILD, source:Dividend Channel, summary: No summary, Headline: Gilead announces $8M in funding through Gilead Relink program, source:Thefly.com, summary: No summary, Headline: A Note On Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE and Debt To Equity, source:Yahoo, summary: Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is..., Headline: Center for Disease Analysis Foundation Announces Receipt of an $8 Million Grant From Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States, source:Finnhub, summary: The Center for Disease Analysis Foundation  announced today that it received an $8 million grant from Gilead Sciences  as part of Gilead’s Relink grant program. CDA Foundation will disperse the..., Headline: Cantor Fitzgerald Maintains Gilead Sciences (GILD) Neutral Recommendation, source:Fintel, summary: nan, Headline: Center for Disease Analysis Foundation  Announces Receipt of an $8 Million Grant from Gilead Sciences  to Relink Hepatitis B and C Patients to Care in the United States, source:Yahoo, summary: LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care. Despite the availability of existing tr, Headline: Gilead Announces $8 Million in Grant Funding for Viral Hepatitis Relink Program in the U.S., source:Yahoo, summary: FOSTER CITY, Calif., July 20, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it is providing a total of $8 million in funding through a new grant program in the United States called Gilead Relink, which is focused on bringing diagnosed but untreated people living with hepatitis C virus (HCV) or hepatitis B virus (HBV) back into care. The CDA Foundation (CDAF), based in Lafayette, Colorado, will act as the lead organization for the program and be responsible for implementing and overs, Headline: Gilead Sciences Inc. stock underperforms Thursday when compared to competitors despite daily gains, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rose 1.24% to $79.94 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the Dow..., Headline: Gilead Sciences Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: No summary",GILD
265,2023-07-21,"Headline: Gilead to discontinue Phase 3 ENHANCE study of magrolimab plus azacitidine, source:Thefly.com, summary: No summary, Headline: Gilead abandons phase 3 study of magrolimab for myelodysplastic syndromes, source:Seeking Alpha, summary: No summary, Headline: Gilead ends late-stage trial of blood cancer treatment, source:MarketWatch, summary: Shares of Gilead Sciences Inc. dropped nearly 2% in the extended session Friday after the pharma company said it has ended a late-stage trial of a treatment..., Headline: Gilead Discontinues Study of Immunotherapy to Treat Blood Cancers, source:MarketWatch, summary: By Denny Jacob Gilead Sciences has discontinued its Phase 3 study of magrolimab in higher-risk myelodysplastic syndromes. The biopharmaceutical company said..., Headline: Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS, source:Yahoo, summary: FOSTER CITY, Calif., July 21, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes (MDS) has been discontinued due to futility based on a planned analysis. The safety data seen in this study is consistent with the known magrolimab profile and adverse events that are typical in this patient population. Gilead recommends discontinuing treatment with magrolimab in patients with MDS. Magrolimab is a potential first-in-clas, Headline: Pfizer, Gilead, GSK set to dominate infectious diseases market, source:Seeking Alpha, summary: No summary",GILD
266,2023-07-22,"Headline: Gilead Sciences : Statement on New York Times' Story on TDF and TAF Development for HIV, source:Finnhub, summary: Foster City, Calif., July 22, 2023 -Gilead Sciences provided the following statement pre-publication to the reporters for the New York Times in response to their questions before their...",GILD
267,2023-07-23,"Headline: Governor DeSantis Says He Would Sue the Drug Company Gilead for Trying to Save Lives, source:TalkMarkets, summary: No summary, Headline: Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities, source:Yahoo, summary: FOSTER CITY, Calif., July 23, 2023--Gilead Sciences Inc. (Nasdaq: GILD) today announced its largest commitment to health equity for Australian and Canadian Indigenous communities. The initiative will support programs addressing societal barriers to care that persistently contribute to the transmission of HIV and viral hepatitis within Indigenous communities., Headline: New Biktarvy® Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic, source:Yahoo, summary: FOSTER CITY, Calif., July 24, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from multiple studies reinforcing Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) as a treatment option for a broad range of people with HIV. The latest findings include key insights into the treatment of virologically suppressed pregnant women and children two years of age or older (weighing at least 14 kg to less than 25 kg) and positive Week 96 data, Headline: Eaton Vance Worldwide Health Sciences Fund Buys Vertex Pharmaceuticals, Exits Dechra Pharmaceuticals, source:GuruFocus, summary: No summary, Headline: Gilead Sciences Inc. stock falls Monday, underperforms market, source:MarketWatch, summary: No summary",GILD
268,2023-07-24,"Headline: Gilead lambasts patent lawsuit coverage in mixed week for drug trials, source:Alliance News, summary: No summary, Headline: Gilead announces results from multiple Biktarvy studies, source:Thefly.com, summary: No summary, Headline: AMC shares surge after judge rejects APE conversion plan, Tesla stock slips on downgrade and other stocks on the move, source:MarketWatch, summary: Here are some of the biggest movers of the day: AMC Entertainment, Tesla and Gilead Sciences., Headline: Gilead profited by delaying new version of a drug, NY Times reports, source:Thefly.com, summary: No summary, Headline: Bank of America Securities Reaffirms Their Hold Rating on Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Gilead price target lowered to $80 from $81 at Barclays, source:Thefly.com, summary: No summary, Headline: Gilead presents new data on lenacapavir, source:Thefly.com, summary: No summary, Headline: Cognizant expands relatonship with Gilead, source:Thefly.com, summary: No summary, Headline: Expert Ratings for Gilead Sciences, source:Benzinga, summary: No summary, Headline: Bank of America, Bank of New York Mellon And 2 Other Stocks Insiders Are Selling, source:Benzinga, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Exelixis (EXEL) and Becton Dickinson (BDX), source:TipRanks, summary: No summary, Headline: Gilead price target lowered to $100 from $105 at Piper Sandler, source:Thefly.com, summary: No summary, Headline: Analysts Are Bullish on Top Healthcare Stocks: Gilead Sciences (GILD), Becton Dickinson (BDX), source:TipRanks, summary: No summary, Headline: Cognizant, Gilead Extend Service Agreement Worth $800M, source:MarketWatch, summary: By Ben Glickman Cognizant Technology Solutions said Monday it would continue to manage Gilead Sciences' global information technology infrastructure for five..., Headline: Cognizant, Gilead Extend Service Agreement Worth $800 Million, source:Finnhub, summary: By Ben Glickman 


   Cognizant Technology Solutions said Monday it would continue to manage Gilead Sciences' global information technology infrastructure for five years in a deal worth up to $800..., Headline: Cognizant and Gilead sign a $800M agreement, expands partnership, source:Seeking Alpha, summary: No summary, Headline: Gilead Sciences, Inc. - New Biktarvy Data Presented at IAS 2023 Further Demonstrate Safety and Efficacy Profile in a Broad Range of People and Communities Affected by the Global HIV Epidemic, source:Finnhub, summary: FOSTER CITY - Gilead Sciences, Inc.  today announced results from multiple studies reinforcing Biktarvy  as a treatment option for a broad range of people with HIV.
The latest findings include key..., Headline: Gilead to Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS, source:Finnhub, summary: FOSTER CITY - Gilead Sciences, Inc.  today announced that the Phase 3 ENHANCE study in higher-risk myelodysplastic syndromes  has been discontinued due to futility based on a planned analysis.
The..., Headline: Cognizant agrees USD800 million IT infrastructure deal with Gilead, source:Alliance News, summary: No summary, Headline: Cognizant and Gilead Extend Partnership with Five-Year Service Agreement Estimated at $800 Million, source:Yahoo, summary: Cognizant (NASDAQ: CTSH) today announced an expansion of its relationship with Gilead Sciences (NASDAQ: GILD). Gilead is a leading biopharmaceutical company advancing innovative medicines to prevent and treat life-threatening diseases. Under the agreement, Cognizant will manage Gilead's global IT infrastructure, platforms, applications and advanced analytics, and lead initiatives designed to accelerate its digital transformation. The agreement includes renewal and expansion of Cognizant services, Headline: Stocks making the biggest moves midday: AMC Entertainment, Mattel, Chevron, Spotify and more, source:CNBC, summary: These are the stocks posting the largest moves in midday trading. , Headline: Gilead (GILD) Ends Myelodysplastic Syndromes Study on Magrolimab, source:Yahoo, summary: Gilead Sciences, Inc. (GILD) discontinues phase III ENHANCE study, evaluating the potential of magrolimab as a treatment for higher-risk myelodysplastic syndromes, due to futility based on a planned analysis., Headline: Gilead Sciences, Inc. Presents New Data Reinforcing the Efficacy, Safety, and Tolerability Profile of Lenacapavir from the Phase 2/3 Capella Trial, source:Finnhub, summary: Gilead Sciences, Inc. presented new data reinforcing the efficacy, safety, and tolerability profile of lenacapavir, including patient-reported outcomes  from the Phase 2/3 CAPELLA trial. These latest..., Headline: Barclays Maintains Gilead Sciences (GILD) Equal-Weight Recommendation, source:Fintel, summary: nan, Headline: Cantor Fitzgerald Reiterates Gilead Sciences (GILD) Neutral Recommendation, source:Fintel, summary: nan, Headline: Piper Sandler Maintains Gilead Sciences (GILD) Overweight Recommendation, source:Fintel, summary: nan, Headline: S&P 500 Gains and Losses Today: Oil Industry Stocks Surge as Oil Prices Rise, source:Yahoo, summary: U.S. equities gained after better-than-expected second quarter earnings reports, with the S&P 500 rising 0.4% on Monday, July 24, 2023., Headline: Gilead stops trial of cancer drug that was central to $4.9 billion deal, source:Yahoo, summary: A Gilead Sciences Inc. drug targeting a protein — usurped by cancers to send a ""don't eat me signal"" to the immune system — failed a late-stage clinical trial three years after the company made it the center of a $4.9 billion acquisition.  Foster City-based Gilead (NASDAQ: GILD) said it recommended stopping the late-stage study of the drug magrolimab, which headlined the company's April 2020 acquisition of Forty Seven Inc., in higher-risk myelodysplastic syndromes.  Studies of the drug are continuing in two ongoing trials in solid tumors and two pivotal studies in acute myeloid leukemia., Headline: Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV, source:Yahoo, summary: FOSTER CITY, Calif., July 24, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today presented new data reinforcing the efficacy, safety, and tolerability profile of lenacapavir, including patient-reported outcomes (PRO) from the Phase 2/3 CAPELLA trial. These latest findings underscore the role of lenacapavir, the first long-acting injectable HIV treatment medication administered twice-yearly, as a person-centric therapy option and its transformative potential impact on the future of coordinated HIV, Headline: GLOBAL BRIEFING: Beijing pledges support for faltering economy, source:Alliance News, summary: No summary, Headline: Gilead says twice-yearly lenacapavir has ""sustained impact"" on HIV, source:Alliance News, summary: No summary, Headline: Gilead Sciences Inc. stock falls Tuesday, underperforms market, source:MarketWatch, summary: No summary",GILD
269,2023-07-25,"Headline: Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ), Tonix Pharma (TNXP) and Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Gilead Sciences, Inc. - Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People with HIV, source:Finnhub, summary: FOSTER CITY - Gilead Sciences, Inc.  today presented new data reinforcing the efficacy, safety, and tolerability profile of lenacapavir, including patient-reported outcomes  from the Phase 2/3..., Headline: GSK, J&J tout Cabenuva preference over Gilead's Biktarvy, source:Seeking Alpha, summary: No summary, Headline: Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know, source:Yahoo, summary: In the latest trading session, Gilead Sciences (GILD) closed at $77.23, marking a -0.55% move from the previous day., Headline: Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: No summary",GILD
270,2023-07-26,"Headline: Truist Financial Reaffirms Their Buy Rating on Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know, source:Yahoo, summary: In the latest trading session, Gilead Sciences (GILD) closed at $77.19, marking a -0.05% move from the previous day., Headline: Gilead Sciences Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: No summary",GILD
271,2023-07-27,"Headline: 20 Countries With Highest Rates Of AIDS, source:Yahoo, summary: In this article, we will be taking a look at the 20 countries with the highest rate of AIDS. If you are not interested in reading the details, head straight to the 5 Countries With Highest Rates of AIDS. AIDS, or Acquired Immunodeficiency Syndrome, remains a pressing global health concern, and its impact varies significantly […], Headline: EC approves Gilead's Trodelvy for pre-treated HR+/HER2- metastatic breast cancer, source:Thefly.com, summary: No summary, Headline: European Commission Approves Gilead's Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer, source:Finnhub, summary: -- Approval Based on Clinically Meaningful Overall Survival Benefit Demonstrated in the TROPiCS-02 Study in Pre-Treated HR+/HER2-  Metastatic Breast Cancer vs. Physician’s Choice of Chemotherapy..., Headline: European Commission Approves Gilead’s Trodelvy® For Pre-Treated HR+/HER2- Metastatic Breast Cancer, source:Yahoo, summary: FOSTER CITY, Calif., July 27, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) approved Trodelvy® (sacituzumab govitecan) as a monotherapy for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting., Headline: Earnings week ahead: Amazon, Apple, Pfizer, Starbucks, Uber and more, source:Seeking Alpha, summary: No summary, Headline: Gilead Sciences Inc. stock rises Friday, still underperforms market, source:MarketWatch, summary: No summary",GILD
272,2023-07-28,"Headline: GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION'S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030, source:Yahoo, summary: Gilead Sciences, Inc. (Nasdaq: GILD) today announced the launch of the 2023 Gilead ALL4LIVER Grant, a grant program with the theme of 'Test. Link. Prioritize', designed to support innovative projects that drive testing, improve linkage to care and/or elevate viral hepatitis on the public health agenda. The ALL4LIVER Grant will support initiatives around the world (excluding the United States) across hepatitis C, hepatitis B or hepatitis D. Eligible organizations can submit funding applications o, Headline: Here's Why We Think Gilead Sciences (NASDAQ:GILD) Might Deserve Your Attention Today, source:Yahoo, summary: It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story..., Headline: Unveiling AbbVie's Hidden Risks: Cautionary Notes For Investors, source:SeekingAlpha, summary: AbbVie's Q2 2023 financial results exceeded expectations, driven by strong sales of innovative drugs Skyrizi and Rinvoq. Click here to read more., Headline: Gilead (GILD) Gears Up to Report Q2 Earnings: What's in Store?, source:Yahoo, summary: Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports its second-quarter 2023 results.",GILD
273,2023-07-29,"Headline: 3 Stocks Retirees Should Absolutely Love, source:Yahoo, summary: Dividend stocks can practically be a retiree's best friend.  Three Motley Fool contributors were asked to identify healthcare dividend stocks they think retirees should absolutely love now.  Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE).",GILD
274,2023-07-30,"Headline: Gilead Sciences Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: No summary",GILD
275,2023-07-31,"Headline: Robert W. Baird Remains a Hold on Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: See Which Of The Latest 13F Filers Holds Gilead Sciences, source:Preferred Stock Channel, summary: No summary, Headline: Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: No summary",GILD
276,2023-08-01,"Headline: With 85% ownership, Gilead Sciences, Inc. (NASDAQ:GILD) boasts of strong institutional backing, source:Yahoo, summary: Key Insights Given the large stake in the stock by institutions, Gilead Sciences' stock price might be vulnerable to..., Headline: Buy Alert: 3 Biotech Stocks Nearing Super Attractive Entry Points, source:Yahoo, summary: The biotechnology sector is huge and growing. Grand View Research forecasts that the industry will reach $3.88 trillion by 2030, growing at a compound annual growth rate of 14%. Despite the massive amount of revenue being generated, most biotech companies remain small and medium-sized enterprises. Many of the companies operating in the space are start-ups. Yet they are performing cutting-edge research and developing life-saving innovations that are in high demand. This presents an opportunity fo, Headline: Gilead Sciences Inc. stock remains steady Wednesday, still outperforms market, source:MarketWatch, summary: No summary",GILD
277,2023-08-02,"Headline: Mizuho Securities Sticks to Their Buy Rating for Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Gilead seen reporting higher Q2 earnings, despite drop in COVID-19 drug sales, source:Seeking Alpha, summary: No summary, Headline: Unusually active option classes on open August 2nd, source:Thefly.com, summary: No summary, Headline: Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities, source:Yahoo, summary: Gilead Sciences Inc. (Nasdaq:GILD) announced its largest commitment to health equity for Australian and Canadian Indigenous communities., Headline: GLOBAL BRIEFING: China's services see strong growth in July, source:Alliance News, summary: No summary, Headline: Stocks Mitigate Losses Ahead Of Apple, Amazon Earnings; Treasury Yields Rocket On Debt Frenzy: Thursday's Market Drivers, source:Benzinga, summary: No summary, Headline: Notable companies reporting after market close, source:Thefly.com, summary: No summary, Headline: Gilead reports Q2 adjusted EPS $1.34, consensus $1.64, source:Thefly.com, summary: No summary, Headline: Gilead cuts FY23 EPS view to $6.45-$6.80 from $6.60-$7.00, consensus $6.73, source:Thefly.com, summary: No summary, Headline: Gilead Sciences Non-GAAP EPS of $1.34 misses by $0.30, revenue of $6.59B beats by $140M, source:Seeking Alpha, summary: No summary, Headline: Gilead Sciences declares $0.75 dividend, source:Seeking Alpha, summary: No summary, Headline: Gilead’s stock slides 2% after Q2 profit lags consensus and as company lowers guidance, source:MarketWatch, summary: No summary, Headline: Gilead Sciences Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: No summary",GILD
278,2023-08-03,"Headline: Apple among BofA picks for options opportunity on earnings surprise, source:Seeking Alpha, summary: No summary, Headline: Gilead’s profit lags consensus but sales beat, sending stock up after hours, source:MarketWatch, summary: No summary, Headline: Gilead Sciences Announces Its Largest Commitment to Health Equity for Australian and Canadian Indigenous Communities, source:Finnhub, summary: - $6 Million USD in Funding Will Help Address Health Disparities Among Indigenous Communities with a Focus on HIV and Viral Hepatitis - Type of Content Press Release Layout Standard Format..., Headline: Gilead boosts 2023 sales projection but cuts EPS outlook, source:Seeking Alpha, summary: No summary, Headline: Analysts Are Neutral on Top Healthcare Stocks: Definitive Healthcare Corp (DH), DENTSPLY SIRONA (XRAY), source:TipRanks, summary: No summary, Headline: US Stock Futures Dip As Apple, Amazon Earnings Loom: Analyst Warns Of 'Perfectly Normal' 5% Pullback This Month, source:Benzinga, summary: No summary, Headline: Gilead Ups Product Sales Outlook, Cuts EPS View, source:MarketWatch, summary: By Paul Ziobro Gilead Sciences raised the midpoint of its full-year guidance for product sales while reducing the range for its earnings outlook after..., Headline: Gilead's profit lags consensus but sales beat, sending stock up after hours, source:MarketWatch, summary: Gilead's quarterly revenue topped estimates and it tweaked guidance., Headline: Gilead Sciences 2Q Profit Down On HIV Litigation, Higher Costs, source:Finnhub, summary: Gilead Sciences 2Q Profit Down On HIV Litigation, Higher Costs 

  By Paul Ziobro 

  Gilead Sciences posted a drop in second-quarter profit, which was hit by a settlement in HIV antitrust..., Headline: Gilead Upgrades Product Sales Outlook, Cuts EPS View, source:Finnhub, summary: By Paul Ziobro 

  Gilead Sciences raised the midpoint of its full-year guidance for product sales while reducing the range for its earnings outlook after posting mixed second-quarter results. 

 ..., Headline: Gilead Sciences Announces Second Quarter 2023 Financial Results, source:Yahoo, summary: FOSTER CITY, Calif., August 03, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter of 2023., Headline: Gilead quarterly profit falls on COVID sales drop, legal settlement charge, source:Yahoo, summary: (Reuters) -Gilead Sciences on Thursday reported lower second-quarter profit as costs from a legal settlement and sharply lower sales of its COVID-19 treatment offset another strong performance by HIV drugs.  The drugmaker raised its full-year revenue forecast, even as it trimmed its estimate for COVID antiviral Veklury due to lower pandemic-related hospitalizations.  Gilead reported second-quarter earnings of $1.34 per share excluding items, on total revenue of $6.6 billion, down from $1.58 a share and revenue of $6.26 billion in the year-ago quarter., Headline: Gilead Sciences Cuts Profit Forecast on Legal Settlement, source:Yahoo, summary: CEO Daniel O'Day said the biopharma company is ""overperforming significantly, excluding one-time items."", Headline: UPDATE 1-Gilead quarterly profit falls on COVID sales drop, legal settlement charge, source:Yahoo, summary: Gilead Sciences on Thursday reported lower second-quarter profit as costs from a legal settlement and sharply lower sales of its COVID-19 treatment offset another strong performance by HIV drugs.  The drugmaker raised its full-year revenue forecast, even as it trimmed its estimate for COVID antiviral Veklury due to lower pandemic-related hospitalizations.  Gilead reported second-quarter earnings of $1.34 per share excluding items, on total revenue of $6.6 billion, down from $1.58 a share and revenue of $6.26 billion in the year-ago quarter., Headline: Gilead Sciences, Inc. (GILD) Q2 2023 Earnings Call Transcript, source:SeekingAlpha, summary: Gilead Sciences, Inc. (NASDAQ:NASDAQ:GILD) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ETCompany ParticipantsJacquie Ross - Vice President, Investor RelationsDaniel O'Day -..., Headline: Will An Earnings Miss Cloud Gilead's Massive Cancer Treatment Growth?, source:Yahoo, summary: Two of Gilead's cancer drugs topped second-quarter sales expectations Thursday. GILD stock rose slightly in late action., Headline: Gilead Sciences (GILD) Q2 Earnings Lag Estimates, source:Yahoo, summary: Gilead (GILD) delivered earnings and revenue surprises of -16.25% and 2.98%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?, Headline: Gilead (GILD) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates, source:Yahoo, summary: The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals., Headline: Amazon shares rally 10%, but Apple’s dip, and other stocks on the move, source:MarketWatch, summary: No summary, Headline: Barclays Remains a Hold on Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Gilead Sciences Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: No summary",GILD
279,2023-08-04,"Headline: Gilead Sciences (GILD) Q2 2023 Earnings Call Transcript, source:Yahoo, summary: Thank you for attending Gilead Sciences second quarter 2023 earnings conference call.  The press release, slides and supplementary data are available on the Investors section of our website at gilead.com.  The speakers on today's call will be our chairman and chief executive officer, Daniel O'Day, our chief commercial officer, Johanna Mercier; our chief medical officer, Merdad Parsey, and our chief financial officer, Andrew Dickinson., Headline: Gilead files automatic mixed securities shelf, source:Thefly.com, summary: No summary, Headline: Gilead files for mixed shelf offering, source:Seeking Alpha, summary: No summary, Headline: BMO Capital Releases a Buy Rating on Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Gilead Sciences second quarter net profit falls; lowers profit outlook, source:Alliance News, summary: No summary, Headline: Piper Sandler Sticks to Their Buy Rating for Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Gilead Sciences Q2 Earnings: 'Transitional' Quarter Delivers Mixed Results, source:SeekingAlpha, summary: Gilead's HIV division contributed $4.6 billion and its oncology division generated $728 million in revenues. Read how one-off costs hit profitability in Gilead's latest earnings., Headline: Amgen Inc: A Strong Contender in the Drug Manufacturers Industry with a GF Score of 85, source:GuruFocus, summary: No summary, Headline: Gilead's Plots A Massive Move Into Oncology: A Third Of Sales By 2030, source:Yahoo, summary: Gilead expects a third of sales to come from its cancer treatments by 2030, and GILD stock jumped Friday despite a mixed earnings report., Headline: Is Gilead Sciences (GILD) Fairly Valued? An In-Depth Analysis, source:Yahoo, summary: With a daily gain of 4.63% and an Earnings Per Share (EPS) of 4.43, Gilead Sciences Inc (NASDAQ:GILD) has been attracting attention in the investment community.  This article aims to answer the pressing question: is Gilead Sciences (NASDAQ:GILD) fairly valued?  Gilead Sciences, a company with a rich portfolio of therapies for life-threatening infectious diseases, has a history of acquisitions that have expanded its focus to pulmonary and cardiovascular diseases and cancer., Headline: Gilead's (GILD) Q2 Earnings Miss, Revenues Beat on Oncology, source:Yahoo, summary: Gilead's (GILD) Q2 earnings miss on litigation charges while revenues beat on strong oncology and HIV franchise., Headline: Gilead Plots A Massive Move Into Oncology: A Third Of Sales By 2030, source:Yahoo, summary: Gilead expects a third of sales to come from its cancer treatments by 2030, and GILD stock jumped Friday despite a mixed earnings report.",GILD
280,2023-08-05,"Headline: Is Gilead Sciences (GILD) Stock Fairly Valued? A Comprehensive Analysis, source:GuruFocus, summary: No summary, Headline: RBC Capital Maintains Gilead Sciences (GILD) Sector Perform Recommendation, source:Fintel, summary: nan, Headline: Morgan Stanley Maintains Gilead Sciences (GILD) Equal-Weight Recommendation, source:Fintel, summary: nan",GILD
281,2023-08-06,"Headline: Is Gilead Sciences (GILD) Stock Worth Your Investment? A Comprehensive Valuation Analysis, source:GuruFocus, summary: No summary, Headline: Gilead Sciences, Inc.'s (NASDAQ:GILD) Intrinsic Value Is Potentially 68% Above Its Share Price, source:Yahoo, summary: Key Insights Gilead Sciences' estimated fair value is US$132 based on 2 Stage Free Cash Flow to Equity Gilead Sciences..., Headline: Ikena falls on acquisition of Pionyr in all-stock deal, source:Seeking Alpha, summary: No summary, Headline: Analysts Offer Insights on Healthcare Companies: CVS Health (CVS) and Gilead Sciences (GILD), source:TipRanks, summary: No summary",GILD
282,2023-08-07,"Headline: Gilead Sciences: Mixed Signals, Again, source:SeekingAlpha, summary: Gilead Sciences seeks future growth through diversification and pipeline conversion. Click here to see why GILD stock is a Buy., Headline: Monday’s Top Wall Street Analyst Upgrades and Downgrades: Amazon, Apple, Block, Coinbase, Datadog, Fortinet, Gilead Sciences, Moderna, Nvidia, PayPal, Petrobras and More, source:247WallSt, summary: No summary, Headline: Amgen Inc: A Strong Contender in the Drug Manufacturers Industry with a High GF Score, source:GuruFocus, summary: No summary, Headline: Gilead Sciences Inc. stock rises Monday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rose 2.53% to $80.67 Monday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",GILD
283,2023-08-08,"Headline: Robert W. Baird Keeps Their Hold Rating on Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: GLOBAL BROKER RATINGS: Deutsche Bank cuts WPP; UBS ups Smith & Nephew, source:Alliance News, summary: No summary, Headline: My Dividend Stock Portfolio: New July Dividend Record - 99 Holdings With 26 Buys, source:SeekingAlpha, summary: Investment activity remained robust, and dividend income hit a record high. Additionally, passive income equivalent to almost 5 weeks of work was earned in 2023., Headline: Gilead Sciences (GILD) Receives a Buy from Truist Financial, source:TipRanks, summary: No summary, Headline: 2 High-Yield Dividend Stocks to Buy on the Dip, source:Yahoo, summary: Income-seeking investors tend to be drawn to high dividend yields.  A high yield from the dividend of a great company is highly sought after.  There are plenty of stocks with competitive dividend yields worth serious consideration for investors., Headline: Wall Street Analysts Are Bullish on Top Healthcare Picks, source:TipRanks, summary: No summary, Headline: Amgen Inc: A Strong Contender in the Drug Manufacturers Industry with a GF Score of 85, source:GuruFocus, summary: No summary, Headline: Ligand Reports Second Quarter 2023 Financial Results, source:Business Wire, summary: No summary, Headline: Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 0.73% to $80.08 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...",GILD
284,2023-08-09,"Headline: Gilead Sciences a Top 25 Dividend Giant With 3.75% Yield (GILD), source:ETF Channel, summary: No summary, Headline: Gilead Sciences: A Cut Above the Rest: Innovative Barbershop Program Educates Indigenous Men About HIV, source:Yahoo, summary: NORTHAMPTON, MA / ACCESSWIRE / August 9, 2023 / Gilead Sciences: How do you educate people about difficult-to-talk-about, yet incredibly important, health topics? And which settings are ideal for such conversations? Those were the questions plaguing ..., Headline: Gilead Sciences Inc. stock rises Wednesday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.11% higher to $80.17 Wednesday, on what proved to be an all-around poor trading session for the stock market, with..., Headline: U.S. Wide-Moat Stocks On Sale - The August 2023 Heat Map, source:SeekingAlpha, summary: Discover our 3-step process for identifying undervalued wide-moat stocks, including a heat map of top investable candidates. Click here to read our picks., Headline: The 3 Best Biotech Stocks to Buy in August, source:Yahoo, summary: Many healthcare stocks suffer from COVID fatigue as profits fall amid a global decline in the virus’ spread. But medical innovations and technological breakthroughs are rapidly transforming the healthcare landscape, and biotech stocks are garnering unprecedented attention in the investment community. These companies, operating at the intersection of biology and technology, promise groundbreaking treatments, therapies and solutions to some of the world’s most persistent medical challenges. As the",GILD
285,2023-08-10,"Headline: How Is The Market Feeling About Gilead Sciences?, source:Benzinga, summary: No summary, Headline: Gilead Sciences Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 0.21% to $80.00 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the S&P...",GILD
286,2023-08-11,"Headline: Gilead call volume above normal and directionally bullish, source:Thefly.com, summary: No summary, Headline: Gilead Sciences (NASDAQ:GILD) stock performs better than its underlying earnings growth over last year, source:Yahoo, summary: These days it's easy to simply buy an index fund, and your returns should (roughly) match the market. But investors can..., Headline: $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today, source:Benzinga, summary: No summary, Headline: Gilead Sciences Inc. stock remains steady Friday, still outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. were unchanged Friday, on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones...",GILD
287,2023-08-13,"Headline: 13 Best Wide Moat Stocks To Buy According To Hedge Funds, source:Yahoo, summary: In this piece, we will take a look at the 13 best wide moat stocks to buy according to hedge funds. If you want to skip our primer on wide moat investing, then head on over to 5 Best Wide Moat Stocks To Buy According To Hedge Funds. Among the countless ways in which companies […], Headline: Gilead Sciences Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: No summary",GILD
288,2023-08-14,"Headline: Arcellx up 10% as FDA lifts clinical hold, source:Seeking Alpha, summary: No summary, Headline: Piper Sandler Remains a Buy on Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Gilead Sciences Inc. stock falls Tuesday, still outperforms market, source:MarketWatch, summary: No summary",GILD
289,2023-08-15,"Headline: Gilead and Tentarix in pact to find therapies for cancer, inflamation, source:Thefly.com, summary: No summary, Headline: Gilead has option to acquire up to three Tentarix subs for $80M per subsidiary, source:Thefly.com, summary: No summary, Headline: Gilead sees transaction with Tentarix to reduce EPS by 3c-4c, source:Thefly.com, summary: No summary, Headline: Gilead and Tentarix partner to develop protein therapeutics, source:Seeking Alpha, summary: No summary, Headline: We Think Gilead Sciences (NASDAQ:GILD) Can Stay On Top Of Its Debt, source:Yahoo, summary: The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says..., Headline: Gilead and Tentarix to Discover and Develop Novel Therapies to Address Unmet Medical Needs Across Cancer and Inflammation, source:Yahoo, summary: FOSTER CITY, Calif. & SAN DIEGO, August 15, 2023--Gilead Sciences, Inc. (Nasdaq:GILD) and Tentarix Biotherapeutics today announced that the companies established three multi-year collaborations leveraging Tentarix’s proprietary Tentacles™ platform to discover and develop multi-functional, conditional protein therapeutics for oncology and inflammatory diseases. Designed to enhance both therapeutic benefit and safety, these molecules have the potential to conditionally target immune cells related, Headline: UPDATE 1-Gilead ties up with Tentarix for cancer, inflammatory disease therapies, source:Yahoo, summary: Gilead Sciences said on Tuesday it had entered into an agreement with privately held Tentarix Biotherapeutics to develop therapies for cancer and inflammatory diseases.  Tentarix will receive upfront payments and an equity investment totaling $66 million from Gilead, which has the option to buy up to three of the drug developer's units for $80 million each, the companies said.  The deal gives Gilead access to Tentarix's proprietary drug development platform for antibody-based therapies that specifically target immune cells related to the disease without activating other immune cells that may lead to adverse events., Headline: Mizuho Securities Remains a Buy on Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: No summary",GILD
290,2023-08-16,"Headline: Gilead’s Focus on Ending the HIV Epidemic for Children Everywhere, source:Yahoo, summary: NORTHAMPTON, MA / ACCESSWIRE / August 16, 2023 / Gilead Sciences ""I am tired, so tired. When will this end?"" That's the refrain that Dr. Eva Natukunda, a pediatric HIV specialist at the Joint Clinical Research Center in Kampala, Uganda says she ..., Headline: Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies, source:Yahoo, summary: Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation., Headline: Gilead Sciences Inc. stock falls Thursday, underperforms market, source:MarketWatch, summary: No summary",GILD
291,2023-08-17,"Headline: Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD) and CVS Health (CVS), source:TipRanks, summary: No summary, Headline: Morgan Dempsey Capital Management LLC Reduces Stake in Polished.com Inc, source:GuruFocus, summary: No summary, Headline: Analysts Have Conflicting Sentiments on These Healthcare Companies: Paycor HCM (PYCR), Legend Biotech (LEGN) and Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Gilead Sciences (GILD) Gets a Buy from Jefferies, source:TipRanks, summary: No summary, Headline: Undervalued Biotech Gems: Two Stocks Combining Dividends with Healthy Returns, source:Yahoo, summary: Distinguishing genuine value from market noise is essential for successful investments, Headline: Undervalued Biotech Gems: 2Stocks Combining Dividends With Healthy Returns, source:GuruFocus, summary: No summary, Headline: Undervalued Biotech Gems: 2 Stocks Combining Dividends With Healthy Returns, source:GuruFocus, summary: No summary, Headline: Autolus Therapeutics' Obe-Cel's Shows Compelling Safety Over Gilead's Drug For Acute Lymphoblastic Leukemia, source:Benzinga, summary: No summary, Headline: 10 Health Care Stocks With Whale Alerts In Today's Session, source:Benzinga, summary: No summary, Headline: Biotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & More, source:Yahoo, summary: Regulatory updates from Galecto (GLTO) and Sonnet BioTherapeutics Holdings (SONN) are in focus in the biotech sector., Headline: Gilead Sciences Inc. stock outperforms competitors despite losses on the day, source:MarketWatch, summary: No summary",GILD
292,2023-08-18,"Headline: Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States, source:Yahoo, summary: FOSTER CITY, Calif. & NASHVILLE, Tenn., August 18, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) and Meharry Medical College, one of the nation’s oldest and largest historically Black academic health science centers, today announced the publication of a new supplemental issue of Meharry Medical College’s Journal of Health Care for the Poor and Underserved. It details the impact of the Gilead COMPASS Initiative® – the company’s 10-year, more than $100 million collaborative initiative that seeks to e",GILD
293,2023-08-20,"Headline: A Closer Look At Gilead Sciences, Inc.'s (NASDAQ:GILD) Impressive ROE, source:Yahoo, summary: While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...",GILD
294,2023-08-21,"Headline: IN BRIEF: Guild Esports to launch Counter-Strike men's team, source:Alliance News, summary: No summary, Headline: Gilead announces partial clinical hold on magrolimab studies, source:Thefly.com, summary: No summary, Headline: Gilead announces FDA partial hold on leukemia trial, source:Seeking Alpha, summary: No summary, Headline: US FDA puts Gilead Sciences blood cancer drug studies on hold, source:Finnhub, summary: Gilead Sciences said onMonday the U.S. Food and Drug Administration had placed apartial clinical hold on initiating new patients in the U.S.studies for drug to treat a type of blood..., Headline: Gilead says FDA hits pause on study of leukemia treatment, source:MarketWatch, summary: Gilead Sciences Inc. said Monday that the U.S. Food and Drug Administration has put a partial clinical hold on U.S. studies evaluating a treatment for acute..., Headline: Gilead Sciences Magrolimab Studies Enrollment Paused by FDA Request, source:Finnhub, summary: By Adriano Marchese Gilead Sciences will pause the enrollment of new participants for its investigational drug study in treating acute myeloid leukemia. The pharmaceutical company said..., Headline: Gilead Sciences announces another magrolimab setback via US FDA action, source:Alliance News, summary: No summary, Headline: Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative on HIV in the Southern United States, source:Finnhub, summary: FOSTER CITY - Gilead Sciences, Inc. and Meharry Medical College, one of the nation's oldest and largest historically Black academic health science centers, today announced the publication of a new..., Headline: 5 Safe Stocks Under $40 to Buy Immediately, source:InvestorPlace, summary: No summary, Headline: Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner, source:TalkMarkets, summary: No summary, Headline: Gilead Announces Partial Clinical Hold for Magrolimab Studies in AML, source:Yahoo, summary: FOSTER CITY, Calif., August 21, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the initiation of new patients in U.S. studies evaluating magrolimab to treat acute myeloid leukemia (AML)., Headline: UPDATE 1-US FDA puts Gilead Sciences blood cancer drug studies on hold, source:Yahoo, summary: Gilead Sciences said on Monday the U.S. health regulator placed a clinical hold on studies of its blood cancer drug, just a month after the company scrapped a late-stage trial due to efficacy concerns.  The company gained access to the drug, magrolimab, with its $4.9 billion buyout of Forty Seven Inc in March 2020.  The company said the U.S. Food and Drug Administration (FDA) had paused screening and enrollment of new study participants, while the patients already under the studies may continue to receive treatment., Headline: Vaccine makers light up as COVID hospitalizations rise, source:Seeking Alpha, summary: No summary, Headline: Gilead Sciences Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.08% higher to $75.94 Monday, on what proved to be an all-around mixed trading session for the stock market, with the..., Headline: Legend Biotech: Working On Supply Issues, source:SeekingAlpha, summary: Carvykti's successful manufacturing ramp-up and clinical de-risking in earlier lines of multiple myeloma put Legend Biotech in a strong position. Learn more on LEGN stock here.",GILD
295,2023-08-22,"Headline: Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Regeneron (REGN) and Syndax Pharmaceuticals (SNDX), source:TipRanks, summary: No summary, Headline: Gilead's (GILD) Leukemia Study Progress Put on Clinical Hold, source:Yahoo, summary: Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States., Headline: Gilead Sciences Inc. stock rises Tuesday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.54% higher to $76.35 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the...",GILD
296,2023-08-23,"Headline: Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Zimmer Biomet Holdings (ZBH) and Premier (PINC), source:TipRanks, summary: No summary, Headline: Arcus to 'trade with strength' after leaked Roche data looked 'good,' says BofA, source:Thefly.com, summary: No summary, Headline: BMO Capital Remains a Buy on Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Gilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial data, source:MarketWatch, summary: Shares of biopharmaceutical companies developing anti-TIGIT cancer therapies, including Gilead Sciences Inc. Arcus Biosciences Inc. and iTeos Therapeutics..., Headline: How Gilead’s Pharmaceutical Development and Manufacturing Team Delivers Transformative Medicines, source:Yahoo, summary: NORTHAMPTON, MA / ACCESSWIRE / August 23, 2023 / Gilead Sciences When Stacey Ma was a little girl, her dream was to work with patients as a doctor. ""As it turns out, I became an engineer who makes medicine to help patients,"" says Stacey, who joined ..., Headline: Gilead Sciences Inc. stock rises Wednesday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.90% higher to $77.04 Wednesday, on what proved to be an all-around positive trading session for the stock market,..., Headline: Gilead Sciences to Present at Upcoming Investor Conferences, source:Yahoo, summary: FOSTER CITY, Calif., August 23, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:, Headline: Bristol-Myers Squibb: Top Defensive Pick During Recessions With A Value Proposition, source:SeekingAlpha, summary: Discover why Bristol-Myers is a strong investment, undervalued with a promising dividend yield. After a slow start, expect a bullish turnaround., Headline: GILD Stock Alert: FDA Expands Indications for Gilead Sciences’ Veklury Covid-19 Treatment, source:InvestorPlace, summary: No summary",GILD
297,2023-08-24,"Headline: FDA approves Gilead's Veklury for COVID-19 in people with hepatic impairment, source:Thefly.com, summary: No summary, Headline: Gilead wins FDA nod to use Veklury for COVID-19 in liver disease, source:Seeking Alpha, summary: No summary, Headline: Drugs picked for Medicare price negotiations to be announced on Tuesday – Politico, source:Seeking Alpha, summary: No summary, Headline: Gilead Covid-19 Drug Cleared by FDA for Patients with Liver Disease, source:Finnhub, summary: By Dean Seal Gilead Sciences said regulators have approved its antiviral remdesivir, sold under the name brand Veklury, for Covid-19 patients with hepatic impairment, or liver failure. The..., Headline: Gilead Sciences' Veklury wins FDA approval as Covid treatment option, source:Alliance News, summary: No summary, Headline: Galapagos cut to Neutral at Citi on lack of catalysts, source:Seeking Alpha, summary: No summary, Headline: GILD Stock Alert: FDA Approves Gilead Sciences’ Veklury Covid-19 Treatment, source:InvestorPlace, summary: No summary, Headline: FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment, source:Yahoo, summary: FOSTER CITY, Calif., August 24, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) for the use of Veklury® (remdesivir) with no dose adjustments to treat COVID-19 in people with mild, moderate and severe hepatic impairment. This approval further supports the safety profile of Veklury as the first and only approved antiviral COVID-19 treatment that can be used across all stages of liver di, Headline: Gilead Sciences Inc. stock outperforms market despite losses on the day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slipped 0.92% to $76.33 Thursday, on what proved to be an all-around rough trading session for the stock market, with the S&P...",GILD
298,2023-08-25,"Headline: Robert W. Baird Sticks to Their Hold Rating for Gilead Sciences (GILD), source:TipRanks, summary: No summary, Headline: Guild Esports shares jump on launch of new Street Fighter team, source:Alliance News, summary: No summary, Headline: Galapagos: Good To Have An Approval, Bad To Have No Major Catalysts, source:SeekingAlpha, summary: Galapagos has an approved drug, filgotinib, for rheumatoid arthritis and ulcerative colitis. Read more to see why I'm rating GLBG stock as a soft sell., Headline: Gilead Sciences, Inc. - FDA Approves Veklury to Treat COVID-19 in People with Mild to Severe Hepatic Impairment with no Dose Adjustment, source:Finnhub, summary: FOSTER CITY - Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration approved a supplemental new drug application for the use of Veklury with no dose adjustments to..., Headline: The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics, source:Yahoo, summary: Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog., Headline: Gilead (GILD) Gets FDA Nod for Veklury for Hepatic Impairment, source:Yahoo, summary: Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment., Headline: Gilead Sciences Inc. stock rises Friday, outperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.69% higher to $76.86 Friday, on what proved to be an all-around favorable trading session for the stock market, with...",GILD
299,2023-08-27,"Headline: AlloVir: An Intriguing $3 Biotech Concern, source:Seeking Alpha, summary: No summary, Headline: Here's Why We Think Gilead Sciences (NASDAQ:GILD) Is Well Worth Watching, source:Yahoo, summary: It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...",GILD
300,2023-08-28,"Headline: Gilead Sciences: Searching For A Catalyst, source:SeekingAlpha, summary: Over the long run, Gilead Sciences' pipeline and its oncology segment could lead to higher sales. Click here to read why GILD stock is a Buy., Headline: 10 Health Care Stocks Whale Activity In Today's Session, source:Benzinga, summary: No summary, Headline: 12 Undervalued Wide Moat Stocks To Invest In, source:Yahoo, summary: In this piece, we will take a look at 12 undervalued wide moat stocks to invest in. If you want to skip our primer on wide moat investing, then check out 5 Undervalued Wide Moat Stocks To Invest In. The strategy of wide moat investing has gained a lot of traction over the past few […], Headline: Gilead Sciences Inc. stock rises Monday, still underperforms market, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.23% higher to $77.04 Monday, on what proved to be an all-around positive trading session for the stock market, with...",GILD
301,2023-08-29,"Headline: Nearing Retirement? These Stocks Will Pay You For Life, source:Yahoo, summary: One place to look is the stock market.  Investing in reliable dividend stocks can be a great source of steady passive income, but only if the stocks in question have the tools to distribute growing payouts for a while.  Let's look at two companies that can do that: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD)., Headline: Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data, source:SeekingAlpha, summary: Arcus Biosciences, Inc. stock has dropped 40% since its high in 2022, making it an attractive investment opportunity. Click here for more on RCUS stock., Headline: Gilead Sciences Inc. stock outperforms competitors on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. rallied 1.52% to $78.21 Tuesday, on what proved to be an all-around great trading session for the stock market, with the S&P...",GILD
302,2023-08-30,"Headline: Upcoming Dividend Run For GILD?, source:Dividend Channel, summary: No summary, Headline: Gilead Sciences: Fifth Anniversary of COMPASS: Helping Address the HIV Epidemic in the U.S. South, source:Yahoo, summary: This year marks the fifth anniversary of the Gilead COMPASS Initiative®, a 10-year, more than $100 million commitment to addressing the HIV epidemic in the Southern United States., Headline: Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 0.70% to $77.66 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the...",GILD
303,2023-08-31,"Headline: The Highest Quality Dividend Challenger Summary, source:SeekingAlpha, summary: Discover the top 20 highest-quality Dividend Challengers, along with stocks offering favorable valuations and compelling metrics for various investor types., Headline: With 86% institutional ownership, Gilead Sciences, Inc. (NASDAQ:GILD) is a favorite amongst the big guns, source:Yahoo, summary: Key Insights Institutions' substantial holdings in Gilead Sciences implies that they have significant influence over..., Headline: Gilead Sciences Inc. stock underperforms Thursday when compared to competitors, source:MarketWatch, summary: Shares of Gilead Sciences Inc. slid 1.52% to $76.48 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500...",GILD
304,2023-09-01,"Headline: Gilead Sciences Inc. stock outperforms market on strong trading day, source:MarketWatch, summary: Shares of Gilead Sciences Inc. inched 0.22% higher to $76.65 Friday, on what proved to be an all-around favorable trading session for the stock market, with..., Headline: Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know, source:Yahoo, summary: In the latest trading session, Gilead Sciences (GILD) closed at $76.65, marking a +0.22% move from the previous day.",GILD
